{"data":[{"public_id":"zatD5AFL","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-11-08","title":"The condition for self-accelerating AI research","summary":"Adam Marblestone's model describes how AI research could accelerate on fixed hardware if research productivity grows faster than the effort required for further software efficiency gains.","cta_url":"https://eternalsearch.net/organizations/aQrAI2Yd","source_refs":{"ukhvat_news":{"id":"de045450-e565-41f7-b0bb-49d93b042d1c","api_slug":"marblestone-ai-research-feedback-exponents","keywords":["ai-self-improvement","software-efficiency","compute-scaling","research-productivity","algorithmic-progress"],"title_en":"AI development could accelerate with each software improvement even on existing computers: Adam Marblestone’s model","short_slug":"261108009","api_title_ru":"Разработка ИИ может ускоряться с каждым улучшением программ даже на прежних компьютерах — модель Адама Марблстоуна","published_at":"2026-11-08 16:00:00+00","category_slugs":["scientific-computing","science-research"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/aQrAI2Yd","name":"Convergent Research","type":"organization","route":"/organizations/aQrAI2Yd","match_score":14.9},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-11-08 16:17:51.671254+00","updated_at":"2026-11-08 16:17:51.671254+00","public_url":"https://eternalsearch.net/journal/zatD5AFL","api_url":"https://eternalsearch.net/api/v1/content/journal/zatD5AFL"},{"public_id":"mTBT1D15","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-11-08","title":"Sebastiano’s inventorship on a cellular reprogramming patent publication","summary":"The patent publication identifies Vittorio Sebastiano as an inventor, but the supplied excerpt contains no methods or experimental results to assess its cellular aging claim.","cta_url":"https://eternalsearch.net/investors/epTdGswn","source_refs":{"dossier":"THE EDGE: Vittorio Sebastiano (investor) —[person_authored_article, confidence 0.99]→ Transient cellular reprogramming for reversal of cell aging (publication)\n\nStored evidence excerpt: Inventor Vittorio SEBASTIANO\n\nFROM ENDPOINT —\nINVESTOR/PERSON: Vittorio Sebastiano\n\nTO ENDPOINT —\nPUBLICATION: Transient cellular reprogramming for reversal of cell aging\nURL: https://patents.google.com/patent/WO2019178296A1/en\nText: WO2019178296A1 - Transient cellular reprogramming for reversal of cell aging - Google Patents WO2019178296A1 - Transient cellular reprogramming for reversal of cell aging - Google Patents Transient cellular reprogramming for reversal of cell aging Download PDF Info Publication number WO2019178296A1 WO2019178296A1 PCT/US2019/022149 US2019022149W WO2019178296A1 WO 2019178296 A1 WO2019178296 A1 WO 2019178296A1 US 2019022149 W US2019022149 W US 2019022149W WO 2019178296 A1 WO2019178296 A1 WO 2019178296A1 Authority WO WIPO (PCT) Prior art keywords cells rejuvenated cell subject expression Prior art date 2018-03-13 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/US2019/022149 Other languages French ( fr ) Inventor Vittorio SEBASTIANO Tapash Jay SARKAR Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Leland Stanford Junior University Original Assignee Leland Stanford Junior University Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2018-03-13 Filing date 2019-03-13 Publication date 2019-09-19 2019-03-13 Priority to JP2020548709A priority Critical patent/JP2021518331A/en 2019-03-13 Priority to MX2020009491A priority patent/MX2020009491A/en 2019-03-13 Priority to SG11202008839WA priority patent/SG11202008839WA/en 2019-03-13 Priority to CR20200462A priority patent/CR20200462A/en 2019-03-13 Priority to AU2019235861A priority patent/AU2019235861B2/en 2019-03-13 Priority to US16/979,842 priority patent/US20210010034A1/en 2019-03-13 Priority to KR1020207029373A priority patent/KR20200131301A/en 2019-03-13 Priority to CN201980031919.8A priority patent/CN112154210A/en 2019-03-13 Priority to EP19768132.3A priority patent/EP3764795A4/en 2019-03-13 Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University 2019-03-13 Priority to BR112020018602-3A priority patent/BR112020018602A2/en 2019-03-13 Priority to CA3093823A priority patent/CA3093823C/en 2019-03-13 Priority to RU2020133377A priority patent/RU2801316C2/en 2019-09-19 Publication of WO2019178296A1 publication Critical patent/WO2019178296A1/en 2020-09-10 Priority to IL277265A priority patent/IL277265A/en 2020-09-13 Anticipated expiration legal-status Critical 2023-10-04 Priority to JP2023172587A priority patent/JP7696406B2/en 2025-06-09 Priority to JP2025095345A priority patent/JP2025131775A/en Status Ceased legal-status Critical Current Links Espacenet Global Dossier PatentScope Discuss Classifications A — HUMAN NECESSITIES A01 — AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING A01N — PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS A01N1/00 — Preservation of bodies of humans or animals, or parts thereof A01N1/10 — Preservation of living parts A01N1/12 — Chemical aspects of preservation A01N1/122 — Preservation or perfusion media A01N1/126 — Physiologically active agents, e.g. antioxidants or nutrients C — CHEMISTRY; METALLURGY C12 — BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING C12N — MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA C12N15/00 — Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor C12N15/09 &mdash\n…[publication text continues — 308216 more chars in the linked source]\n\nEVIDENCE DOCUMENT: Transient cellular reprogramming for reversal of cell aging\nURL: https://patents.google.com/patent/WO2019178296A1/en\nFull text: WO2019178296A1 - Transient cellular reprogramming for reversal of cell aging - Google Patents WO2019178296A1 - Transient cellular reprogramming for reversal of cell aging - Google Patents Transient cellular reprogramming for reversal of cell aging Download PDF Info Publication number WO2019178296A1 WO2019178296A1 PCT/US2019/022149 US2019022149W WO2019178296A1 WO 2019178296 A1 WO2019178296 A1 WO 2019178296A1 US 2019022149 W US2019022149 W US 2019022149W WO 2019178296 A1 WO2019178296 A1 WO 2019178296A1 Authority WO WIPO (PCT) Prior art keywords cells rejuvenated cell subject expression Prior art date 2018-03-13 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/US2019/022149 Other languages French ( fr ) Inventor Vittorio SEBASTIANO Tapash Jay SARKAR Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Leland Stanford Junior University Original Assignee Leland Stanford Junior University Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2018-03-13 Filing date 2019-03-13 Publication date 2019-09-19 2019-03-13 Priority to JP2020548709A priority Critical patent/JP2021518331A/en 2019-03-13 Priority to MX2020009491A priority patent/MX2020009491A/en 2019-03-13 Priority to SG11202008839WA priority patent/SG11202008839WA/en 2019-03-13 Priority to CR20200462A priority patent/CR20200462A/en 2019-03-13 Priority to AU2019235861A priority patent/AU2019235861B2/en 2019-03-13 Priority to US16/979,842 priority patent/US20210010034A1/en 2019-03-13 Priority to KR1020207029373A priority patent/KR20200131301A/en 2019-03-13 Priority to CN201980031919.8A priority patent/CN112154210A/en 2019-03-13 Priority to EP19768132.3A priority patent/EP3764795A4/en 2019-03-13 Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University 2019-03-13 Priority to BR112020018602-3A priority patent/BR112020018602A2/en 2019-03-13 Priority to CA3093823A priority patent/CA3093823C/en 2019-03-13 Priority to RU2020133377A priority patent/RU2801316C2/en 2019-09-19 Publication of WO2019178296A1 publication Critical patent/WO2019178296A1/en 2020-09-10 Priority to IL277265A priority patent/IL277265A/en 2020-09-13 Anticipated expiration legal-status Critical 2023-10-04 Priority to JP2023172587A priority patent/JP7696406B2/en 2025-06-09 Priority to JP2025095345A priority patent/JP2025131775A/en Status Ceased legal-status Critical Current Links Espacenet Global Dossier PatentScope Discuss Classifications A — HUMAN NECESSITIES A01 — AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING A01N — PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS A01N1/00 — Preservation of bodies of humans or animals, or parts thereof A01N1/10 — Preservation of living parts A01N1/12 — Chemical aspects of preservation A01N1/122 — Preservation or perfusion media A01N1/126 — Physiologically active agents, e.g. antioxidants or nutrients C — CHEMISTRY; METALLURGY C12 — BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING C12N — MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA C12N15/00 — Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor C12N15/09 &mdash\n…[evidence text continues — 308216 more chars in the linked source]\n\nNEIGHBOURS of this investor (other public links it participates in):\n- person_authored_article: Validation of biomarkers of aging (publication)\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Cellular Reprogramming (term)\n- article_references_term: Epigenetic Rejuvenation (term)\n- article_references_term: Gene Therapy (term)\n- article_references_term: Cell Therapy (term)\n- article_references_term: Autophagy (term)\n- article_references_term: Sirtuin Signaling (term)\n- article_references_term: NF-kB Signaling (term)\n\nEVIDENCE DOCUMENT: Transient cellular reprogramming for reversal of cell aging\nURL: https://patents.google.com/patent/WO2019178296A1/en\nFull text: WO2019178296A1 - Transient cellular reprogramming for reversal of cell aging - Google Patents WO2019178296A1 - Transient cellular reprogramming for reversal of cell aging - Google Patents Transient cellular reprogramming for reversal of cell aging Download PDF Info Publication number WO2019178296A1 WO2019178296A1 PCT/US2019/022149 US2019022149W WO2019178296A1 WO 2019178296 A1 WO2019178296 A1 WO 2019178296A1 US 2019022149 W US2019022149 W US 2019022149W WO 2019178296 A1 WO2019178296 A1 WO 2019178296A1 Authority WO WIPO (PCT) Prior art keywords cells rejuvenated cell subject expression Prior art date 2018-03-13 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/US2019/022149 Other languages French ( fr ) Inventor Vittorio SEBASTIANO Tapash Jay SARKAR Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Leland Stanford Junior University Original Assignee Leland Stanford Junior University Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2018-03-13 Filing date 2019-03-13 Publication date 2019-09-19 2019-03-13 Priority to JP2020548709A priority Critical patent/JP2021518331A/en 2019-03-13 Priority to MX2020009491A priority patent/MX2020009491A/en 2019-03-13 Priority to SG11202008839WA priority patent/SG11202008839WA/en 2019-03-13 Priority to CR20200462A priority patent/CR20200462A/en 2019-03-13 Priority to AU2019235861A priority patent/AU2019235861B2/en 2019-03-13 Priority to US16/979,842 priority patent/US20210010034A1/en 2019-03-13 Priority to KR1020207029373A priority patent/KR20200131301A/en 2019-03-13 Priority to CN201980031919.8A priority patent/CN112154210A/en 2019-03-13 Priority to EP19768132.3A priority patent/EP3764795A4/en 2019-03-13 Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University 2019-03-13 Priority to BR112020018602-3A priority patent/BR112020018602A2/en 2019-03-13 Priority to CA3093823A priority patent/CA3093823C/en 2019-03-13 Priority to RU2020133377A priority patent/RU2801316C2/en 2019-09-19 Publication of WO2019178296A1 publication Critical patent/WO2019178296A1/en 2020-09-10 Priority to IL277265A priority patent/IL277265A/en 2020-09-13 Anticipated expiration legal-status Critical 2023-10-04 Priority to JP2023172587A priority patent/JP7696406B2/en 2025-06-09 Priority to JP2025095345A priority patent/JP2025131775A/en Status Ceased legal-status Critical Current Links Espacenet Global Dossier PatentScope Discuss Classifications A — HUMAN NECESSITIES A01 — AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING A01N — PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS A01N1/00 — Preservation of bodies of humans or animals, or parts thereof A01N1/10 — Preservation of living parts A01N1/12 — Chemical aspects of preservation A01N1/122 — Preservation or perfusion media A01N1/126 — Physiologically active agents, e.g. antioxidants or nutrients C — CHEMISTRY; METALLURGY C12 — BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING C12N — MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA C12N15/00 — Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor C12N15/09 &mdash\n…[evidence text continues — 308216 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe source identifies Vittorio Sebastiano and Tapash Jay Sarkar as inventors on patent publication WO2019178296A1, titled “Transient cellular reprogramming for reversal of cell aging,” published on September 19, 2019, with Stanford listed as the original assignee. This supports an inventorship connection, rather than the article-authorship relationship assigned to the edge. The supplied excerpt contains bibliographic information but stops before the scientific description or experimental evidence.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The invention may concern using a limited period of cellular reprogramming to reverse features of cellular aging; the methods and results must be read before developing this interpretation.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- What intervention, delivery method, treatment duration and cell types the patent actually describes.\n- Which aging-related outcomes were measured, with what controls and results, and whether cellular identity was preserved.\n- Whether the document reports experiments supporting its proposed applications or primarily describes claims.\n- The dossier does not establish Sebastiano’s investment activity or any licensing or commercial relationship.\n- The displayed legal-status label does not establish the current legal status of individual national patent-family members.","endpoints":{"to":{"id":"0245fad6-2bf5-4cfb-b511-8c1bfb8ee8cc","name":"Transient cellular reprogramming for reversal of cell aging","type":"publication","route":"https://patents.google.com/patent/WO2019178296A1/en","isPublic":true},"from":{"id":"64ad7fc8-2745-4165-972f-7707ebc3b6e1","name":"Vittorio Sebastiano","type":"investor","route":"/investors/epTdGswn","isPublic":true}},"connection":{"id":"761957f6-ab3e-48e7-92e6-4808b4b6cfd1","kind":"person_authored_article","to_id":"0245fad6-2bf5-4cfb-b511-8c1bfb8ee8cc","from_id":"64ad7fc8-2745-4165-972f-7707ebc3b6e1","to_type":"publication","from_type":"investor","confidence":0.99,"created_at":"2026-05-30 14:23:19.384782+00","evidence_excerpt":"Inventor Vittorio SEBASTIANO","evidence_source_id":"0245fad6-2bf5-4cfb-b511-8c1bfb8ee8cc","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The invention may concern using a limited period of cellular reprogramming to reverse features of cellular aging; the methods and results must be read before developing this interpretation."],"unresolved":["What intervention, delivery method, treatment duration and cell types the patent actually describes.","Which aging-related outcomes were measured, with what controls and results, and whether cellular identity was preserved.","Whether the document reports experiments supporting its proposed applications or primarily describes claims.","The dossier does not establish Sebastiano’s investment activity or any licensing or commercial relationship.","The displayed legal-status label does not establish the current legal status of individual national patent-family members."],"understanding":"The source identifies Vittorio Sebastiano and Tapash Jay Sarkar as inventors on patent publication WO2019178296A1, titled “Transient cellular reprogramming for reversal of cell aging,” published on September 19, 2019, with Stanford listed as the original assignee. This supports an inventorship connection, rather than the article-authorship relationship assigned to the edge. The supplied excerpt contains bibliographic information but stops before the scientific description or experimental evidence.","instrument_calls":[{"hit":true,"args":{"source_id":"0245fad6-2bf5-4cfb-b511-8c1bfb8ee8cc","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-11-08 15:13:53.814115+00","updated_at":"2026-11-08 15:13:53.814115+00","public_url":"https://eternalsearch.net/journal/mTBT1D15","api_url":"https://eternalsearch.net/api/v1/content/journal/mTBT1D15"},{"public_id":"IYZt6TgR","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-11-07","title":"Selectivity of Senolytics","summary":"Patent application US20200121620A1 defines senolytic compounds by selective killing of senescent cells, but the available excerpt does not show the experiments supporting that selectivity.","cta_url":"https://eternalsearch.net/glossary/senolytics","source_refs":{"dossier":"THE EDGE: US20200121620A1 - Senolytic compounds - Google Patents (publication) —[article_references_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: \"compounds that are capable of selectively killing senescent cells over non-senescent cells, i.e. senolytic compounds\"\n\nFROM ENDPOINT —\nPUBLICATION: US20200121620A1 - Senolytic compounds - Google Patents\nURL: https://patents.google.com/patent/US20200121620A1/en\nText: US20200121620A1 - Senolytic compounds - Google Patents US20200121620A1 - Senolytic compounds - Google Patents Senolytic compounds Download PDF Info Publication number US20200121620A1 US20200121620A1 US16/616,251 US201816616251A US2020121620A1 US 20200121620 A1 US20200121620 A1 US 20200121620A1 US 201816616251 A US201816616251 A US 201816616251A US 2020121620 A1 US2020121620 A1 US 2020121620A1 Authority US United States Prior art keywords disease disorder senescence compound fibrosis Prior art date 2017-05-26 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US16/616,251 Inventor Jesus Gil Ana GUERRERO Nicolas HARRANZ Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) United Kingdom Research and Innovation Original Assignee United Kingdom Research and Innovation Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-05-26 Filing date 2018-05-25 Publication date 2020-04-23 2018-05-25 Application filed by United Kingdom Research and Innovation filed Critical United Kingdom Research and Innovation 2020-02-25 Assigned to UNITED KINGDOM RESEARCH AND INNOVATION reassignment UNITED KINGDOM RESEARCH AND INNOVATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GIL, Jesus, GUERRERO, Ana, HARRANZ, Nicolas 2020-04-23 Publication of US20200121620A1 publication Critical patent/US20200121620A1/en Status Abandoned legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss DEZFNHCVIZBHBI-ZHACJKMWSA-N CC(=O)C1=C(O)C(CC2=C(O)C3=C(OC(C)(C)C=C3)C(C(=O)/C=C/C3=CC=CC=C3)=C2O)=C(O)C(C)=C1O Chemical compound CC(=O)C1=C(O)C(CC2=C(O)C3=C(OC(C)(C)C=C3)C(C(=O)/C=C/C3=CC=CC=C3)=C2O)=C(O)C(C)=C1O DEZFNHCVIZBHBI-ZHACJKMWSA-N 0.000 description 2 XRZYELWZLNAXGE-KPKJPENVSA-N CC(C)(C)C1=CC(/C=C(\\C#N)C(N)=S)=CC(C(C)(C)C)=C1O Chemical compound CC(C)(C)C1=CC(/C=C(\\C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 2 ZEGDFCCYTFPECB-UHFFFAOYSA-N COC1=C(OC)C(=O)C2=C(C=CC=C2)C1=O Chemical compound COC1=C(OC)C(=O)C2=C(C=CC=C2)C1=O ZEGDFCCYTFPECB-UHFFFAOYSA-N 0.000 description 2 DHZBEENLJMYSHQ-OBDNUKKESA-N C[C@]12C(=O)OC(=O)[C@@]1(C)C1CCC2O1 Chemical compound C[C@]12C(=O)OC(=O)[C@@]1(C)C1CCC2O1 DHZBEENLJMYSHQ-OBDNUKKESA-N 0.000 description 2 UUJHFIBEJJLZBF-UHFFFAOYSA-N O=C1C2=C(C=CC=C2)C(=O)C2=C1C(NCCC1=CC=C(O)C=C1)=CC=C2NCCC1=CC=C(O)C=C1 Chemical compound O=C1C2=C(C=CC=C2)C(=O)C2=C1C(NCCC1=CC=C(O)C=C1)=CC=C2NCCC1=CC=C(O)C=C1 UUJHFIBEJJLZBF-UHFFFAOYSA-N 0.000 description 2 ODJLBQGVINUMMR-HZXDTFASSA-N [H][C@]12CC[C@]3(C)[C@@H](C4=CC(=O)OC4)CC[C@]3(O)[C@]1([H])CC[C@]1(O)C[C@@H](O)CC[C@@]12C=O Chemical compound [H][C@]12CC[C@]3(C)[C@@H](C4=CC(=O)OC4)CC[C@]3(O)[C@]1([H])CC[C@]1(O)C[C@@H](O)CC[C@@]12C=O ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 2 PEWVMQDYYUSPRM-UHFFFAOYSA-N C1=CC2=C(C=C1)C1=C(/C=C\\C=C/1)[IH]2.[Cl-] Chemical compound C1=CC2=C(C=C1)C1=C(/C=C\\C=C/1)[IH]2.[Cl-] PEWVMQDYYUSPRM-UHFFFAOYSA-N 0.000 description 1 YQNQNVDNTFHQSW-UHFFFAOYSA-N CC(=O)OC1=C(C(=O)NC2=NC=C([N+](=O)[O-])S2)C=CC=C1 Chemical compound CC(=O)OC1=C(C(=O)NC2=NC=C([N+](=O)[O-])S2)C=CC=C1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1 WIXPPVOBTMLYGR-GEGGRIHQSA-N CC(=O)[C@]1(O)CC2=C(O)C3=C(C(=O)C4=CC=CC=C4C3=O)C(O)=C2[C@@](C)(OC2CC(N)C(O)C(C)O2)C1 Chemical compound CC(=O)[C@]1(O)CC2=C(O)C3=C(C(=O)C4=CC=CC=C4C3=O)C(O)=C2[C@@](C)(OC2CC(N)C(O)C(C)O2)C1 WIXPPVOBTMLYGR-GEGGRIHQSA-N 0.000 description 1 XUKUURHRXDUEBC-KAYWLYCHSA-N CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O Chemical compound CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=C\n…[publication text continues — 281938 more chars in the linked source]\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nEVIDENCE DOCUMENT: US20200121620A1 - Senolytic compounds - Google Patents\nURL: https://patents.google.com/patent/US20200121620A1/en\nFull text: US20200121620A1 - Senolytic compounds - Google Patents US20200121620A1 - Senolytic compounds - Google Patents Senolytic compounds Download PDF Info Publication number US20200121620A1 US20200121620A1 US16/616,251 US201816616251A US2020121620A1 US 20200121620 A1 US20200121620 A1 US 20200121620A1 US 201816616251 A US201816616251 A US 201816616251A US 2020121620 A1 US2020121620 A1 US 2020121620A1 Authority US United States Prior art keywords disease disorder senescence compound fibrosis Prior art date 2017-05-26 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US16/616,251 Inventor Jesus Gil Ana GUERRERO Nicolas HARRANZ Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) United Kingdom Research and Innovation Original Assignee United Kingdom Research and Innovation Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-05-26 Filing date 2018-05-25 Publication date 2020-04-23 2018-05-25 Application filed by United Kingdom Research and Innovation filed Critical United Kingdom Research and Innovation 2020-02-25 Assigned to UNITED KINGDOM RESEARCH AND INNOVATION reassignment UNITED KINGDOM RESEARCH AND INNOVATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GIL, Jesus, GUERRERO, Ana, HARRANZ, Nicolas 2020-04-23 Publication of US20200121620A1 publication Critical patent/US20200121620A1/en Status Abandoned legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss DEZFNHCVIZBHBI-ZHACJKMWSA-N CC(=O)C1=C(O)C(CC2=C(O)C3=C(OC(C)(C)C=C3)C(C(=O)/C=C/C3=CC=CC=C3)=C2O)=C(O)C(C)=C1O Chemical compound CC(=O)C1=C(O)C(CC2=C(O)C3=C(OC(C)(C)C=C3)C(C(=O)/C=C/C3=CC=CC=C3)=C2O)=C(O)C(C)=C1O DEZFNHCVIZBHBI-ZHACJKMWSA-N 0.000 description 2 XRZYELWZLNAXGE-KPKJPENVSA-N CC(C)(C)C1=CC(/C=C(\\C#N)C(N)=S)=CC(C(C)(C)C)=C1O Chemical compound CC(C)(C)C1=CC(/C=C(\\C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 2 ZEGDFCCYTFPECB-UHFFFAOYSA-N COC1=C(OC)C(=O)C2=C(C=CC=C2)C1=O Chemical compound COC1=C(OC)C(=O)C2=C(C=CC=C2)C1=O ZEGDFCCYTFPECB-UHFFFAOYSA-N 0.000 description 2 DHZBEENLJMYSHQ-OBDNUKKESA-N C[C@]12C(=O)OC(=O)[C@@]1(C)C1CCC2O1 Chemical compound C[C@]12C(=O)OC(=O)[C@@]1(C)C1CCC2O1 DHZBEENLJMYSHQ-OBDNUKKESA-N 0.000 description 2 UUJHFIBEJJLZBF-UHFFFAOYSA-N O=C1C2=C(C=CC=C2)C(=O)C2=C1C(NCCC1=CC=C(O)C=C1)=CC=C2NCCC1=CC=C(O)C=C1 Chemical compound O=C1C2=C(C=CC=C2)C(=O)C2=C1C(NCCC1=CC=C(O)C=C1)=CC=C2NCCC1=CC=C(O)C=C1 UUJHFIBEJJLZBF-UHFFFAOYSA-N 0.000 description 2 ODJLBQGVINUMMR-HZXDTFASSA-N [H][C@]12CC[C@]3(C)[C@@H](C4=CC(=O)OC4)CC[C@]3(O)[C@]1([H])CC[C@]1(O)C[C@@H](O)CC[C@@]12C=O Chemical compound [H][C@]12CC[C@]3(C)[C@@H](C4=CC(=O)OC4)CC[C@]3(O)[C@]1([H])CC[C@]1(O)C[C@@H](O)CC[C@@]12C=O ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 2 PEWVMQDYYUSPRM-UHFFFAOYSA-N C1=CC2=C(C=C1)C1=C(/C=C\\C=C/1)[IH]2.[Cl-] Chemical compound C1=CC2=C(C=C1)C1=C(/C=C\\C=C/1)[IH]2.[Cl-] PEWVMQDYYUSPRM-UHFFFAOYSA-N 0.000 description 1 YQNQNVDNTFHQSW-UHFFFAOYSA-N CC(=O)OC1=C(C(=O)NC2=NC=C([N+](=O)[O-])S2)C=CC=C1 Chemical compound CC(=O)OC1=C(C(=O)NC2=NC=C([N+](=O)[O-])S2)C=CC=C1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1 WIXPPVOBTMLYGR-GEGGRIHQSA-N CC(=O)[C@]1(O)CC2=C(O)C3=C(C(=O)C4=CC=CC=C4C3=O)C(O)=C2[C@@](C)(OC2CC(N)C(O)C(C)O2)C1 Chemical compound CC(=O)[C@]1(O)CC2=C(O)C3=C(C(=O)C4=CC=CC=C4C3=O)C(O)=C2[C@@](C)(OC2CC(N)C(O)C(C)O2)C1 WIXPPVOBTMLYGR-GEGGRIHQSA-N 0.000 description 1 XUKUURHRXDUEBC-KAYWLYCHSA-N CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O Chemical compound CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=C\n…[evidence text continues — 281938 more chars in the linked source]\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Navitoclax (term)\n- article_references_term: Dasatinib (term)\n- article_references_term: Quercetin (term)\n- article_references_term: Apoptosis (term)\n- article_references_term: Senomorphics (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nEVIDENCE DOCUMENT: US20200121620A1 - Senolytic compounds - Google Patents\nURL: https://patents.google.com/patent/US20200121620A1/en\nFull text: US20200121620A1 - Senolytic compounds - Google Patents US20200121620A1 - Senolytic compounds - Google Patents Senolytic compounds Download PDF Info Publication number US20200121620A1 US20200121620A1 US16/616,251 US201816616251A US2020121620A1 US 20200121620 A1 US20200121620 A1 US 20200121620A1 US 201816616251 A US201816616251 A US 201816616251A US 2020121620 A1 US2020121620 A1 US 2020121620A1 Authority US United States Prior art keywords disease disorder senescence compound fibrosis Prior art date 2017-05-26 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US16/616,251 Inventor Jesus Gil Ana GUERRERO Nicolas HARRANZ Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) United Kingdom Research and Innovation Original Assignee United Kingdom Research and Innovation Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-05-26 Filing date 2018-05-25 Publication date 2020-04-23 2018-05-25 Application filed by United Kingdom Research and Innovation filed Critical United Kingdom Research and Innovation 2020-02-25 Assigned to UNITED KINGDOM RESEARCH AND INNOVATION reassignment UNITED KINGDOM RESEARCH AND INNOVATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GIL, Jesus, GUERRERO, Ana, HARRANZ, Nicolas 2020-04-23 Publication of US20200121620A1 publication Critical patent/US20200121620A1/en Status Abandoned legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss DEZFNHCVIZBHBI-ZHACJKMWSA-N CC(=O)C1=C(O)C(CC2=C(O)C3=C(OC(C)(C)C=C3)C(C(=O)/C=C/C3=CC=CC=C3)=C2O)=C(O)C(C)=C1O Chemical compound CC(=O)C1=C(O)C(CC2=C(O)C3=C(OC(C)(C)C=C3)C(C(=O)/C=C/C3=CC=CC=C3)=C2O)=C(O)C(C)=C1O DEZFNHCVIZBHBI-ZHACJKMWSA-N 0.000 description 2 XRZYELWZLNAXGE-KPKJPENVSA-N CC(C)(C)C1=CC(/C=C(\\C#N)C(N)=S)=CC(C(C)(C)C)=C1O Chemical compound CC(C)(C)C1=CC(/C=C(\\C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 2 ZEGDFCCYTFPECB-UHFFFAOYSA-N COC1=C(OC)C(=O)C2=C(C=CC=C2)C1=O Chemical compound COC1=C(OC)C(=O)C2=C(C=CC=C2)C1=O ZEGDFCCYTFPECB-UHFFFAOYSA-N 0.000 description 2 DHZBEENLJMYSHQ-OBDNUKKESA-N C[C@]12C(=O)OC(=O)[C@@]1(C)C1CCC2O1 Chemical compound C[C@]12C(=O)OC(=O)[C@@]1(C)C1CCC2O1 DHZBEENLJMYSHQ-OBDNUKKESA-N 0.000 description 2 UUJHFIBEJJLZBF-UHFFFAOYSA-N O=C1C2=C(C=CC=C2)C(=O)C2=C1C(NCCC1=CC=C(O)C=C1)=CC=C2NCCC1=CC=C(O)C=C1 Chemical compound O=C1C2=C(C=CC=C2)C(=O)C2=C1C(NCCC1=CC=C(O)C=C1)=CC=C2NCCC1=CC=C(O)C=C1 UUJHFIBEJJLZBF-UHFFFAOYSA-N 0.000 description 2 ODJLBQGVINUMMR-HZXDTFASSA-N [H][C@]12CC[C@]3(C)[C@@H](C4=CC(=O)OC4)CC[C@]3(O)[C@]1([H])CC[C@]1(O)C[C@@H](O)CC[C@@]12C=O Chemical compound [H][C@]12CC[C@]3(C)[C@@H](C4=CC(=O)OC4)CC[C@]3(O)[C@]1([H])CC[C@]1(O)C[C@@H](O)CC[C@@]12C=O ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 2 PEWVMQDYYUSPRM-UHFFFAOYSA-N C1=CC2=C(C=C1)C1=C(/C=C\\C=C/1)[IH]2.[Cl-] Chemical compound C1=CC2=C(C=C1)C1=C(/C=C\\C=C/1)[IH]2.[Cl-] PEWVMQDYYUSPRM-UHFFFAOYSA-N 0.000 description 1 YQNQNVDNTFHQSW-UHFFFAOYSA-N CC(=O)OC1=C(C(=O)NC2=NC=C([N+](=O)[O-])S2)C=CC=C1 Chemical compound CC(=O)OC1=C(C(=O)NC2=NC=C([N+](=O)[O-])S2)C=CC=C1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1 WIXPPVOBTMLYGR-GEGGRIHQSA-N CC(=O)[C@]1(O)CC2=C(O)C3=C(C(=O)C4=CC=CC=C4C3=O)C(O)=C2[C@@](C)(OC2CC(N)C(O)C(C)O2)C1 Chemical compound CC(=O)[C@]1(O)CC2=C(O)C3=C(C(=O)C4=CC=CC=C4C3=O)C(O)=C2[C@@](C)(OC2CC(N)C(O)C(C)O2)C1 WIXPPVOBTMLYGR-GEGGRIHQSA-N 0.000 description 1 XUKUURHRXDUEBC-KAYWLYCHSA-N CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O Chemical compound CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=C\n…[evidence text continues — 281938 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe patent application explicitly defines senolytic compounds by their ability to kill senescent cells selectively over non-senescent cells, directly supporting its connection to Senolytics. The visible text supplies publication metadata and chemical indexing but does not establish which compounds were tested, how selectivity was measured, or what results support the invention. The primate findings in the glossary definition are separate context and cannot be attributed to this patent.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The patent's substantive contribution may involve compounds with experimentally demonstrated selectivity for senescent cells; its examples and results would be needed to establish this.\n- References to navitoclax, dasatinib, quercetin, apoptosis and senomorphics may help explain the invention's relationship to existing approaches, but the links alone do not establish their roles.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which compounds are the invention's principal candidates, and which appear only as background or comparators?\n- What cell models, senescence induction methods, doses and non-senescent controls were used?\n- What quantitative evidence demonstrates selective cell killing, and is apoptosis experimentally established?\n- Does the patent report animal experiments or only cell experiments and proposed therapeutic uses?\n- The displayed abandoned status does not establish the status of related applications or explain why this application was abandoned.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"d2d0dfa0-ed40-4312-9e6d-b499c6277796","name":"US20200121620A1 - Senolytic compounds - Google Patents","type":"publication","route":"https://patents.google.com/patent/US20200121620A1/en","isPublic":true}},"connection":{"id":"1bbe5019-da4c-41b8-a21c-02b231c87c52","kind":"article_references_term","to_id":"senolytics","from_id":"d2d0dfa0-ed40-4312-9e6d-b499c6277796","to_type":"term","from_type":"publication","confidence":0.99,"created_at":"2026-05-30 14:27:58.662611+00","evidence_excerpt":"\"compounds that are capable of selectively killing senescent cells over non-senescent cells, i.e. senolytic compounds\"","evidence_source_id":"d2d0dfa0-ed40-4312-9e6d-b499c6277796","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The patent's substantive contribution may involve compounds with experimentally demonstrated selectivity for senescent cells; its examples and results would be needed to establish this.","References to navitoclax, dasatinib, quercetin, apoptosis and senomorphics may help explain the invention's relationship to existing approaches, but the links alone do not establish their roles."],"unresolved":["Which compounds are the invention's principal candidates, and which appear only as background or comparators?","What cell models, senescence induction methods, doses and non-senescent controls were used?","What quantitative evidence demonstrates selective cell killing, and is apoptosis experimentally established?","Does the patent report animal experiments or only cell experiments and proposed therapeutic uses?","The displayed abandoned status does not establish the status of related applications or explain why this application was abandoned."],"understanding":"The patent application explicitly defines senolytic compounds by their ability to kill senescent cells selectively over non-senescent cells, directly supporting its connection to Senolytics. The visible text supplies publication metadata and chemical indexing but does not establish which compounds were tested, how selectivity was measured, or what results support the invention. The primate findings in the glossary definition are separate context and cannot be attributed to this patent.","instrument_calls":[{"hit":true,"args":{"source_id":"d2d0dfa0-ed40-4312-9e6d-b499c6277796","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-11-07 15:13:24.871016+00","updated_at":"2026-11-07 15:13:24.871016+00","public_url":"https://eternalsearch.net/journal/IYZt6TgR","api_url":"https://eternalsearch.net/api/v1/content/journal/IYZt6TgR"},{"public_id":"06PMOzFZ","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-11-07","title":"How controls shape a mouse lifespan gain","summary":"Bone loading increased median mouse lifespan by 79.5 days, but control lifespans and comparisons with other studies complicate interpreting the gain as slower aging.","cta_url":"https://eternalsearch.net/organizations/gqgncSKf","source_refs":{"ukhvat_news":{"id":"8a3d57c1-6758-4521-931c-0f56be82ba5a","api_slug":"lustgarten-bone-loading-short-control-critique","keywords":["bone-loading","mouse-lifespan","900-day-rule","c57bl-6","control-lifespan"],"title_en":"Physiologist Mike Lustgarten says the 9% increase in median mouse lifespan from bone loading is overstated: control mice had a median lifespan of 846 days, compared with about 900 days for healthy mice under the “900-day rule”","short_slug":"261107004","api_title_ru":"Прибавка в 9% к медиане жизни мышей от нагрузки на кость завышена, говорит физиолог Майк Лустгартен: у контрольных мышей медиана 846 дней, а по «правилу 900 дней» у здоровых около 900 дней","published_at":"2026-11-07 10:00:00+00","category_slugs":["longevity-research"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/gqgncSKf","name":"Harvard Medical School","type":"organization","route":"/organizations/gqgncSKf","match_score":15.2},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-11-07 11:18:59.685614+00","updated_at":"2026-11-07 11:18:59.685614+00","public_url":"https://eternalsearch.net/journal/06PMOzFZ","api_url":"https://eternalsearch.net/api/v1/content/journal/06PMOzFZ"},{"public_id":"7rwA2mPi","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-11-06","title":"FOXO4-DRI as a senolytic peptide","summary":"FOXO4-DRI disrupts the interaction between FOXO4 and p53 to trigger apoptosis in senescent cells, with reported benefits in mice but no established human efficacy or safety in the supplied material.","cta_url":"https://eternalsearch.net/glossary/foxo4_dri","source_refs":{"dossier":"THE EDGE: FOXO4-DRI (term) —[term_related_to_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: is a senolytic peptide: “FOXO4-DRI” is described as a compound that selectively targets senescent cells.\n\nFROM ENDPOINT —\nTERM: FOXO4-DRI (category: compound)\nDefinition: FOXO4-DRI is a cell-penetrating senolytic peptide derived from FOXO4 that disrupts the FOXO4-p53 interaction. In senescent cells, it drives p53 nuclear exclusion and cell-intrinsic apoptosis. In mouse studies cited here, treatment restored tissue homeostasis after chemotoxicity and improved fitness, fur density, and renal function in naturally aged and accelerated-aging mice.\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Peter de Keizer (hero)\n- article_references_term: WO2016118014A2 - Anti-senescence compounds and uses thereof (publication)\n- article_references_term: 老化細胞除去薬 - Wikipedia (publication)\n- project_investigates_term: Lono Jaeyak (project)\n- article_references_term: US20200255489A1 - Novel Senolytic Peptides - Google Patents (publication)\n- article_references_term: EP3970150A1 - Deep proteome markers of human biological aging ... (publication)\n- project_investigates_term: CHANGS (project)\n- article_references_term: WO2019069070A1 - Novel senolytic peptides - Google Patents (publication)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nANALYST READING (orientation — the post still asserts only facts above):\nFOXO4-DRI belongs to the senolytic intervention class because it is described as selectively eliminating senescent cells by disrupting the FOXO4–p53 interaction, promoting p53 nuclear exclusion and apoptosis. Its definition reports improvements in tissue homeostasis and several functional outcomes in mouse studies. The nonhuman-primate findings in the Senolytics definition concern dasatinib plus quercetin, not FOXO4-DRI.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- Disrupting the FOXO4–p53 interaction may exploit a survival dependency of senescent cells, providing a concrete mechanistic angle for explaining this senolytic peptide.\n- The reported mouse outcomes may reflect benefits of eliminating senescent cells, although the dossier does not establish the causal contribution of cell clearance to each outcome.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The underlying mouse studies, doses, sample sizes, controls, effect sizes and adverse effects are not provided.\n- The extent of selectivity across cell types and the effects on non-senescent cells cannot be assessed from these definitions.\n- Human efficacy, safety and clinical development status for FOXO4-DRI are not established.\n- The source is identified as hero_text, which the fuller_evidence instrument does not support; the listed neighbours lack identifiers usable for further retrieval.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"foxo4_dri","name":"FOXO4-DRI","type":"term","route":"/glossary/foxo4_dri","isPublic":true}},"connection":{"id":"c3a151d3-fe84-4140-8250-19746d46091e","kind":"term_related_to_term","to_id":"senolytics","from_id":"foxo4_dri","to_type":"term","from_type":"term","confidence":0.99,"created_at":"2026-05-30 14:29:21.873694+00","evidence_excerpt":"is a senolytic peptide: “FOXO4-DRI” is described as a compound that selectively targets senescent cells.","evidence_source_id":"aad37a50-f5fa-42e6-bb5e-cac8329582e3","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["Disrupting the FOXO4–p53 interaction may exploit a survival dependency of senescent cells, providing a concrete mechanistic angle for explaining this senolytic peptide.","The reported mouse outcomes may reflect benefits of eliminating senescent cells, although the dossier does not establish the causal contribution of cell clearance to each outcome."],"unresolved":["The underlying mouse studies, doses, sample sizes, controls, effect sizes and adverse effects are not provided.","The extent of selectivity across cell types and the effects on non-senescent cells cannot be assessed from these definitions.","Human efficacy, safety and clinical development status for FOXO4-DRI are not established.","The source is identified as hero_text, which the fuller_evidence instrument does not support; the listed neighbours lack identifiers usable for further retrieval."],"understanding":"FOXO4-DRI belongs to the senolytic intervention class because it is described as selectively eliminating senescent cells by disrupting the FOXO4–p53 interaction, promoting p53 nuclear exclusion and apoptosis. Its definition reports improvements in tissue homeostasis and several functional outcomes in mouse studies. The nonhuman-primate findings in the Senolytics definition concern dasatinib plus quercetin, not FOXO4-DRI.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-11-06 18:18:42.424065+00","updated_at":"2026-11-06 18:18:42.424065+00","public_url":"https://eternalsearch.net/journal/7rwA2mPi","api_url":"https://eternalsearch.net/api/v1/content/journal/7rwA2mPi"},{"public_id":"uiSE3Slz","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-11-06","title":"Lean Checked the Proofs; Most Statements Await Human Review","summary":"Axiom Math reports a Lean library of 15.75 million nonempty lines, with about 30,000 lines checked by humans against the Stacks Project textbook and human review of the rest still pending.","cta_url":"https://eternalsearch.net/investors/Koy9hnS8","source_refs":{"ukhvat_news":{"id":"24a89ed1-e3c7-41f2-ae0a-5ea358907b33","api_slug":"axiom-stacks-project-lean-16m-lines","keywords":["lean","formal-verification","algebraic-geometry","ai-agents","stacks-project"],"title_en":"Axiom Math has formalized almost all definitions and theorems in the Stacks Project algebraic geometry textbook in Lean, which checks every step of a proof: AI agents wrote most of the 15,75 million nonempty lines of code, while humans checked about 30 thousand against the textbook","short_slug":"261106010","api_title_ru":"Стартап Axiom Math записал почти все определения и теоремы учебника «Проект Stacks» по алгебраической геометрии на языке Lean, где программа проверяет каждый шаг доказательств: 15,75 млн непустых строк кода в основном написали ИИ-агенты, а люди сверили с учебником около 30 тысяч из них","published_at":"2026-11-06 18:00:00+00","category_slugs":["scientific-computing"]},"linked_entity":{"url":"https://eternalsearch.net/investors/Koy9hnS8","name":"About Reason Reason","type":"investor","route":"/investors/Koy9hnS8","match_score":5},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-11-06 18:14:51.661794+00","updated_at":"2026-11-06 18:14:51.661794+00","public_url":"https://eternalsearch.net/journal/uiSE3Slz","api_url":"https://eternalsearch.net/api/v1/content/journal/uiSE3Slz"},{"public_id":"dkorKCpY","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-11-05","title":"Senolytic Peptides and the Selectivity Test","summary":"A patent application claims that its peptides induce apoptosis in senescent cells, while the available excerpt leaves their selectivity unresolved.","cta_url":"https://eternalsearch.net/glossary/senolytics","source_refs":{"dossier":"THE EDGE: US20200255489A1 - Novel Senolytic Peptides - Google Patents (publication) —[article_references_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: \"Novel Senolytic Peptides\"; peptides are \"effective to induce apoptosis of senescent cells\"\n\nFROM ENDPOINT —\nPUBLICATION: US20200255489A1 - Novel Senolytic Peptides - Google Patents\nURL: https://patents.google.com/patent/US20200255489A1/en\nText: US20200255489A1 - Novel Senolytic Peptides - Google Patents US20200255489A1 - Novel Senolytic Peptides - Google Patents Novel Senolytic Peptides Download PDF Info Publication number US20200255489A1 US20200255489A1 US16/652,815 US201816652815A US2020255489A1 US 20200255489 A1 US20200255489 A1 US 20200255489A1 US 201816652815 A US201816652815 A US 201816652815A US 2020255489 A1 US2020255489 A1 US 2020255489A1 Authority US United States Prior art keywords seq senolytic peptide foxo4 rrrrrrrprk Prior art date 2017-10-02 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US16/652,815 Inventor Emel Timucin Ugur Sezerman Gunseli Bayram Akcapinar Yavuz Ahiska Süleyman Selim Çinarouglu Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Eternans Ltd Original Assignee Eternans Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-10-02 Filing date 2018-10-02 Publication date 2020-08-13 2018-10-02 Application filed by Eternans Ltd filed Critical Eternans Ltd 2018-10-02 Priority to US16/652,815 priority Critical patent/US20200255489A1/en 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AHISKA, YAVUZ, DR., AKCAPINAR, GUNSELI BAYRAM, DR., CINAROGLU, SÜLEYMAN SELIM, SEZERMAN, Ugur, TIMUCIN, EMEL, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-08-13 Publication of US20200255489A1 publication Critical patent/US20200255489A1/en Status Abandoned legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C07K14/435 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans C07K14/46 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates C07K14/47 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals C07K14/4701 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used C07K14/4702 — Regulators; Modulating activity A — HUMAN N\n…[publication text continues — 379313 more chars in the linked source]\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nEVIDENCE DOCUMENT: US20200255489A1 - Novel Senolytic Peptides - Google Patents\nURL: https://patents.google.com/patent/US20200255489A1/en\nFull text: US20200255489A1 - Novel Senolytic Peptides - Google Patents US20200255489A1 - Novel Senolytic Peptides - Google Patents Novel Senolytic Peptides Download PDF Info Publication number US20200255489A1 US20200255489A1 US16/652,815 US201816652815A US2020255489A1 US 20200255489 A1 US20200255489 A1 US 20200255489A1 US 201816652815 A US201816652815 A US 201816652815A US 2020255489 A1 US2020255489 A1 US 2020255489A1 Authority US United States Prior art keywords seq senolytic peptide foxo4 rrrrrrrprk Prior art date 2017-10-02 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US16/652,815 Inventor Emel Timucin Ugur Sezerman Gunseli Bayram Akcapinar Yavuz Ahiska Süleyman Selim Çinarouglu Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Eternans Ltd Original Assignee Eternans Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-10-02 Filing date 2018-10-02 Publication date 2020-08-13 2018-10-02 Application filed by Eternans Ltd filed Critical Eternans Ltd 2018-10-02 Priority to US16/652,815 priority Critical patent/US20200255489A1/en 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AHISKA, YAVUZ, DR., AKCAPINAR, GUNSELI BAYRAM, DR., CINAROGLU, SÜLEYMAN SELIM, SEZERMAN, Ugur, TIMUCIN, EMEL, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-08-13 Publication of US20200255489A1 publication Critical patent/US20200255489A1/en Status Abandoned legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C07K14/435 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans C07K14/46 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates C07K14/47 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals C07K14/4701 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used C07K14/4702 — Regulators; Modulating activity A — HUMAN N\n…[evidence text continues — 379313 more chars in the linked source]\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Apoptosis (term)\n- article_references_term: FOXO4-DRI (term)\n- article_references_term: Dasatinib (term)\n- article_references_term: Quercetin (term)\n- article_references_term: Fisetin (term)\n- article_references_term: Navitoclax (term)\n- article_references_term: FOXO Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nEVIDENCE DOCUMENT: US20200255489A1 - Novel Senolytic Peptides - Google Patents\nURL: https://patents.google.com/patent/US20200255489A1/en\nFull text: US20200255489A1 - Novel Senolytic Peptides - Google Patents US20200255489A1 - Novel Senolytic Peptides - Google Patents Novel Senolytic Peptides Download PDF Info Publication number US20200255489A1 US20200255489A1 US16/652,815 US201816652815A US2020255489A1 US 20200255489 A1 US20200255489 A1 US 20200255489A1 US 201816652815 A US201816652815 A US 201816652815A US 2020255489 A1 US2020255489 A1 US 2020255489A1 Authority US United States Prior art keywords seq senolytic peptide foxo4 rrrrrrrprk Prior art date 2017-10-02 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US16/652,815 Inventor Emel Timucin Ugur Sezerman Gunseli Bayram Akcapinar Yavuz Ahiska Süleyman Selim Çinarouglu Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Eternans Ltd Original Assignee Eternans Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-10-02 Filing date 2018-10-02 Publication date 2020-08-13 2018-10-02 Application filed by Eternans Ltd filed Critical Eternans Ltd 2018-10-02 Priority to US16/652,815 priority Critical patent/US20200255489A1/en 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AHISKA, YAVUZ, DR., AKCAPINAR, GUNSELI BAYRAM, DR., CINAROGLU, SÜLEYMAN SELIM, SEZERMAN, Ugur, TIMUCIN, EMEL, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-06-07 Assigned to ETERNANS LTD reassignment ETERNANS LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKCAPINAR, GUNSELI BAYRAM, DR., SEZERMAN, Ugur, TIMUCIN, EMEL, DR., AHISKA, YAVUZ, DR. 2020-08-13 Publication of US20200255489A1 publication Critical patent/US20200255489A1/en Status Abandoned legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C07K14/435 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans C07K14/46 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates C07K14/47 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals C07K14/4701 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used C07K14/4702 — Regulators; Modulating activity A — HUMAN N\n…[evidence text continues — 379313 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe patent application describes peptides claimed to induce apoptosis in senescent cells, which gives a substantive basis for its connection to senolytics. The glossary defines senolytics by selective elimination of senescent cells while sparing non-senescent cells, but the visible patent excerpt does not establish that selectivity experimentally. Links to FOXO4-DRI and FOXO signaling suggest relevant mechanistic context without establishing how these particular peptides work.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The peptides may pursue a FOXO4-related route to senescent-cell elimination; the patent's mechanism and experimental sections are needed to establish this.\n- A useful angle may be whether these peptides improve on an existing senolytic approach in selectivity or potency, if the patent contains comparative experiments.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which peptide sequences or modifications constitute the proposed invention, and what mechanism is claimed?\n- Does the patent report original experiments demonstrating selective killing of senescent cells relative to non-senescent controls?\n- What models, doses, comparators and quantitative results support the claims?\n- Are FOXO4-DRI and the linked small-molecule senolytics experimental comparators or background references?\n- The glossary's dasatinib-plus-quercetin primate findings do not establish efficacy or safety of these peptides.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"359ca6e7-a30a-40cb-9de6-7d480f2c35d3","name":"US20200255489A1 - Novel Senolytic Peptides - Google Patents","type":"publication","route":"https://patents.google.com/patent/US20200255489A1/en","isPublic":true}},"connection":{"id":"0108b433-8765-4e5e-aa4e-80fbbe6069e5","kind":"article_references_term","to_id":"senolytics","from_id":"359ca6e7-a30a-40cb-9de6-7d480f2c35d3","to_type":"term","from_type":"publication","confidence":0.99,"created_at":"2026-05-30 14:29:21.873694+00","evidence_excerpt":"\"Novel Senolytic Peptides\"; peptides are \"effective to induce apoptosis of senescent cells\"","evidence_source_id":"359ca6e7-a30a-40cb-9de6-7d480f2c35d3","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The peptides may pursue a FOXO4-related route to senescent-cell elimination; the patent's mechanism and experimental sections are needed to establish this.","A useful angle may be whether these peptides improve on an existing senolytic approach in selectivity or potency, if the patent contains comparative experiments."],"unresolved":["Which peptide sequences or modifications constitute the proposed invention, and what mechanism is claimed?","Does the patent report original experiments demonstrating selective killing of senescent cells relative to non-senescent controls?","What models, doses, comparators and quantitative results support the claims?","Are FOXO4-DRI and the linked small-molecule senolytics experimental comparators or background references?","The glossary's dasatinib-plus-quercetin primate findings do not establish efficacy or safety of these peptides."],"understanding":"The patent application describes peptides claimed to induce apoptosis in senescent cells, which gives a substantive basis for its connection to senolytics. The glossary defines senolytics by selective elimination of senescent cells while sparing non-senescent cells, but the visible patent excerpt does not establish that selectivity experimentally. Links to FOXO4-DRI and FOXO signaling suggest relevant mechanistic context without establishing how these particular peptides work.","instrument_calls":[{"hit":true,"args":{"source_id":"359ca6e7-a30a-40cb-9de6-7d480f2c35d3","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-11-05 19:12:09.496858+00","updated_at":"2026-11-05 19:12:09.496858+00","public_url":"https://eternalsearch.net/journal/dkorKCpY","api_url":"https://eternalsearch.net/api/v1/content/journal/dkorKCpY"},{"public_id":"Yq20KbB3","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-11-05","title":"Insilico's dual-purpose drug strategy","summary":"Insilico is entitled to $115 million upfront under its Lilly agreement, while the supplied material provides no evidence that the licensed candidates affect aging or lifespan.","cta_url":"https://eternalsearch.net/heroes/alex-zhavoronkov","source_refs":{"ukhvat_news":{"id":"7a0d33c2-c367-49e5-8d68-9fd45b13e5c5","api_slug":"economist-quest-for-immortality-serious-business","keywords":["longevity-clinics","aging-drugs","whole-body-mri","glp-1","epigenetic-reprogramming","fda"],"title_en":"Life extension has spawned two industries: clinics sell scans and procedures of sometimes questionable benefit to patients paying out of pocket, while biotech and pharmaceutical companies pursue drugs to treat aging, The Economist reports","short_slug":"261105006","api_title_ru":"Вокруг продления жизни выросли две отрасли: клиники продают за наличные сканирования и процедуры порой сомнительной пользы, а биотехи с фармой ищут лекарства от старения, — пишет The Economist","published_at":"2026-11-05 11:00:00+00","category_slugs":["therapeutics","biotech-funding","industry-policy"]},"linked_entity":{"url":"https://eternalsearch.net/heroes/alex-zhavoronkov","name":"Alex Zhavoronkov","type":"hero","route":"/heroes/alex-zhavoronkov","match_score":14.6},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-11-05 11:17:32.102812+00","updated_at":"2026-11-05 11:17:32.102812+00","public_url":"https://eternalsearch.net/journal/Yq20KbB3","api_url":"https://eternalsearch.net/api/v1/content/journal/Yq20KbB3"},{"public_id":"bdWiAGQi","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-11-04","title":"Senolytic selectivity needs testing","summary":"Patent application US20230330058A1 describes compounds intended to selectively kill senescent cells, but the supplied excerpt provides no quantitative selectivity data or experimental conditions.","cta_url":"https://eternalsearch.net/glossary/senolytics","source_refs":{"dossier":"THE EDGE: US20230330058A1 - Senolytic compounds and compositions (publication) —[article_references_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: compounds that exhibit selective senolytic activity... selectively killing senescent cells over non-senescent cells\n\nFROM ENDPOINT —\nPUBLICATION: US20230330058A1 - Senolytic compounds and compositions\nURL: https://patents.google.com/patent/US20230330058A1/en\nText: US20230330058A1 - Senolytic compounds and compositions - Google Patents US20230330058A1 - Senolytic compounds and compositions - Google Patents Senolytic compounds and compositions Download PDF Info Publication number US20230330058A1 US20230330058A1 US18/025,307 US202118025307A US2023330058A1 US 20230330058 A1 US20230330058 A1 US 20230330058A1 US 202118025307 A US202118025307 A US 202118025307A US 2023330058 A1 US2023330058 A1 US 2023330058A1 Authority US United States Prior art keywords agent senescence composition composition according magnolol Prior art date 2020-09-09 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number US18/025,307 Inventor Nichola Jane Conlon Malcolm Philip Young Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Nuchido Ltd Original Assignee Nuchido Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2020-09-09 Filing date 2021-09-08 Publication date 2023-10-19 2021-09-08 Application filed by Nuchido Ltd filed Critical Nuchido Ltd 2023-10-19 Publication of US20230330058A1 publication Critical patent/US20230330058A1/en Status Pending legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/395 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins A61K31/435 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom A61K31/47 — Quinolines; Isoquinolines A61K31/472 — Non-condensed isoquinolines, e.g. papaverine A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/60 — Salicylic acid; Derivatives thereof A61K31/609 — Amides, e.g. salicylamide A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/335 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin A61K31/35 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom A61K31/352 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/045 — Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates A61K31/05 — Phenols A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/16 — Amides, e.g. hy\n…[publication text continues — 122059 more chars in the linked source]\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nEVIDENCE DOCUMENT: US20230330058A1 - Senolytic compounds and compositions\nURL: https://patents.google.com/patent/US20230330058A1/en\nFull text: US20230330058A1 - Senolytic compounds and compositions - Google Patents US20230330058A1 - Senolytic compounds and compositions - Google Patents Senolytic compounds and compositions Download PDF Info Publication number US20230330058A1 US20230330058A1 US18/025,307 US202118025307A US2023330058A1 US 20230330058 A1 US20230330058 A1 US 20230330058A1 US 202118025307 A US202118025307 A US 202118025307A US 2023330058 A1 US2023330058 A1 US 2023330058A1 Authority US United States Prior art keywords agent senescence composition composition according magnolol Prior art date 2020-09-09 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number US18/025,307 Inventor Nichola Jane Conlon Malcolm Philip Young Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Nuchido Ltd Original Assignee Nuchido Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2020-09-09 Filing date 2021-09-08 Publication date 2023-10-19 2021-09-08 Application filed by Nuchido Ltd filed Critical Nuchido Ltd 2023-10-19 Publication of US20230330058A1 publication Critical patent/US20230330058A1/en Status Pending legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/395 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins A61K31/435 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom A61K31/47 — Quinolines; Isoquinolines A61K31/472 — Non-condensed isoquinolines, e.g. papaverine A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/60 — Salicylic acid; Derivatives thereof A61K31/609 — Amides, e.g. salicylamide A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/335 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin A61K31/35 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom A61K31/352 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/045 — Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates A61K31/05 — Phenols A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/16 — Amides, e.g. hy\n…[evidence text continues — 122059 more chars in the linked source]\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Navitoclax (term)\n- article_references_term: Metformin (term)\n- article_references_term: Quercetin (term)\n- article_references_term: Resveratrol (term)\n- article_references_term: Apoptosis (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nEVIDENCE DOCUMENT: US20230330058A1 - Senolytic compounds and compositions\nURL: https://patents.google.com/patent/US20230330058A1/en\nFull text: US20230330058A1 - Senolytic compounds and compositions - Google Patents US20230330058A1 - Senolytic compounds and compositions - Google Patents Senolytic compounds and compositions Download PDF Info Publication number US20230330058A1 US20230330058A1 US18/025,307 US202118025307A US2023330058A1 US 20230330058 A1 US20230330058 A1 US 20230330058A1 US 202118025307 A US202118025307 A US 202118025307A US 2023330058 A1 US2023330058 A1 US 2023330058A1 Authority US United States Prior art keywords agent senescence composition composition according magnolol Prior art date 2020-09-09 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number US18/025,307 Inventor Nichola Jane Conlon Malcolm Philip Young Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Nuchido Ltd Original Assignee Nuchido Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2020-09-09 Filing date 2021-09-08 Publication date 2023-10-19 2021-09-08 Application filed by Nuchido Ltd filed Critical Nuchido Ltd 2023-10-19 Publication of US20230330058A1 publication Critical patent/US20230330058A1/en Status Pending legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/395 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins A61K31/435 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom A61K31/47 — Quinolines; Isoquinolines A61K31/472 — Non-condensed isoquinolines, e.g. papaverine A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/60 — Salicylic acid; Derivatives thereof A61K31/609 — Amides, e.g. salicylamide A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/335 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin A61K31/35 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom A61K31/352 — Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/045 — Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates A61K31/05 — Phenols A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/16 — Amides, e.g. hy\n…[evidence text continues — 122059 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe October 19, 2023 patent application names Nuchido Ltd as assignee and describes compounds intended to kill senescent cells selectively, directly matching the supplied definition of senolytics. The visible evidence establishes the subject of the application, but does not establish which compounds demonstrate selectivity or under what experimental conditions. The primate study mentioned in the glossary is separate context and cannot substantiate this application's compounds.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The application's experimental examples may provide a concrete story about selective cell killing, if they compare senescent and non-senescent cells under matched conditions.\n- Magnolol may be relevant to the proposed compositions because it appears among the patent's keywords; its precise role remains unestablished.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which compounds and combinations are proposed, and which are only cited as background or comparators?\n- What cell models, senescence-induction methods, doses, exposure periods and controls were used?\n- Does the application report quantitative evidence of selective killing, and how was cell death distinguished from changes in senescence markers?\n- Are any animal or human results reported for the proposed compositions?","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"2076fe97-74cd-4422-babe-c99d59337546","name":"US20230330058A1 - Senolytic compounds and compositions","type":"publication","route":"https://patents.google.com/patent/US20230330058A1/en","isPublic":true}},"connection":{"id":"b2434700-60ce-4857-9fc2-521dc6dc4405","kind":"article_references_term","to_id":"senolytics","from_id":"2076fe97-74cd-4422-babe-c99d59337546","to_type":"term","from_type":"publication","confidence":0.99,"created_at":"2026-05-30 14:30:07.820053+00","evidence_excerpt":"compounds that exhibit selective senolytic activity... selectively killing senescent cells over non-senescent cells","evidence_source_id":"2076fe97-74cd-4422-babe-c99d59337546","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The application's experimental examples may provide a concrete story about selective cell killing, if they compare senescent and non-senescent cells under matched conditions.","Magnolol may be relevant to the proposed compositions because it appears among the patent's keywords; its precise role remains unestablished."],"unresolved":["Which compounds and combinations are proposed, and which are only cited as background or comparators?","What cell models, senescence-induction methods, doses, exposure periods and controls were used?","Does the application report quantitative evidence of selective killing, and how was cell death distinguished from changes in senescence markers?","Are any animal or human results reported for the proposed compositions?"],"understanding":"The October 19, 2023 patent application names Nuchido Ltd as assignee and describes compounds intended to kill senescent cells selectively, directly matching the supplied definition of senolytics. The visible evidence establishes the subject of the application, but does not establish which compounds demonstrate selectivity or under what experimental conditions. The primate study mentioned in the glossary is separate context and cannot substantiate this application's compounds.","instrument_calls":[{"hit":true,"args":{"source_id":"2076fe97-74cd-4422-babe-c99d59337546","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-11-04 15:14:43.368417+00","updated_at":"2026-11-04 15:14:43.368417+00","public_url":"https://eternalsearch.net/journal/bdWiAGQi","api_url":"https://eternalsearch.net/api/v1/content/journal/bdWiAGQi"},{"public_id":"rhzfPghp","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-11-04","title":"Strength measurements did not explain longer survival after adult castration","summary":"Male mice castrated in adulthood had the longest median lifespan, but grip strength and frailty measurements did not support the hypothesis that they had built a reserve of physical strength.","cta_url":"https://eternalsearch.net/glossary/grip_strength","source_refs":{"ukhvat_news":{"id":"7575d424-40ef-4da2-a377-33129ccfe054","api_slug":"castration-adult-mice-umhet3-lifespan-testicular-factors","keywords":["castration","male-longevity","testicular-factors","um-het3-mice","sex-differences","lifespan-extension"],"title_en":"Castration extended lifespan more in adult male mice than in males castrated before puberty (preprint)","short_slug":"261104006","api_title_ru":"Кастрация взрослых самцов мышей продлила жизнь сильнее, чем кастрация до полового созревания (препринт)","published_at":"2026-11-04 10:00:00+00","category_slugs":["longevity-research"]},"linked_entity":{"url":"https://eternalsearch.net/glossary/grip_strength","name":"Grip Strength","type":"term","route":"/glossary/grip_strength","match_score":14.3},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-11-04 11:15:13.157953+00","updated_at":"2026-11-04 11:15:13.157953+00","public_url":"https://eternalsearch.net/journal/rhzfPghp","api_url":"https://eternalsearch.net/api/v1/content/journal/rhzfPghp"},{"public_id":"HGOjpg0i","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-11-01","title":"A Patent Application Proposes Senolytic Compounds","summary":"WO2025186418A1 proposes compounds as senolytics, but the supplied excerpt lacks the experimental details and results needed to assess their claimed selectivity.","cta_url":"https://eternalsearch.net/glossary/senolytics","source_refs":{"dossier":"THE EDGE: WO2025186418A1 - Senolytic compounds - Google Patents (publication) —[article_references_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: \"the present invention relates to the novel use of compounds as senolytic\" and \"selectively kills senescent cells without harming non-senescent cells\"\n\nFROM ENDPOINT —\nPUBLICATION: WO2025186418A1 - Senolytic compounds - Google Patents\nURL: https://patents.google.com/patent/WO2025186418A1/en\nText: WO2025186418A1 - Senolytic compounds - Google Patents WO2025186418A1 - Senolytic compounds - Google Patents Senolytic compounds Info Publication number WO2025186418A1 WO2025186418A1 PCT/EP2025/056210 EP2025056210W WO2025186418A1 WO 2025186418 A1 WO2025186418 A1 WO 2025186418A1 EP 2025056210 W EP2025056210 W EP 2025056210W WO 2025186418 A1 WO2025186418 A1 WO 2025186418A1 Authority WO WIPO (PCT) Prior art keywords optionally substituted compound derivative aryl cycloalkyl Prior art date 2024-03-06 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number PCT/EP2025/056210 Other languages French ( fr ) Other versions WO2025186418A8 ( en Inventor Jörg Rademann Damian KLEMCZAK Markus Tiemann Clemens Schmitt Maurice REIMANN Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Charite Universitaetsmedizin Berlin Freie Universitaet Berlin Original Assignee Charite Universitaetsmedizin Berlin Freie Universitaet Berlin Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2024-03-06 Filing date 2025-03-06 Publication date 2025-09-12 2025-03-06 Application filed by Charite Universitaetsmedizin Berlin, Freie Universitaet Berlin filed Critical Charite Universitaetsmedizin Berlin 2025-09-12 Publication of WO2025186418A1 publication Critical patent/WO2025186418A1/en 2025-10-02 Publication of WO2025186418A8 publication Critical patent/WO2025186418A8/en Status Pending legal-status Critical Current 2026-09-06 Anticipated expiration legal-status Critical Links Espacenet Global Dossier PatentScope Discuss Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/395 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins A61K31/53 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61P — SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS A61P35/00 — Antineoplastic agents Definitions the present invention relates to the novel use of compounds as senolytic according to the preambles of claims 1 and 26, to novel compounds according to the preamble of claim 28, as well as to a medicament according to claim 32. Yoneda et al. (1971), Yoneda et al. (1973), and Yoneda et al. (1975) describe some of the toxoflavins, their synthesis method, and their reactivity. JP H09255681 A describes an antitumor agent comprising a 7-azapteridine derivative of a pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-dione. WO 2010/014798 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as anti-cancer drug. DE 103 01 788 A1 describes various pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones, their manufacturing method and their use as drug for treating diabetes. WO 2012/006104 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as drug for treating tuberculosis. WO 2018/140762 A1 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as drug for treating human immunodeficiency virus (HIV) infections, in particular for inhibiting HIV- 1 integrase multimerization. HIV human immunodeficiency virus WO 2010/072807 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their\n…[publication text continues — 304635 more chars in the linked source]\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nEVIDENCE DOCUMENT: WO2025186418A1 - Senolytic compounds - Google Patents\nURL: https://patents.google.com/patent/WO2025186418A1/en\nFull text: WO2025186418A1 - Senolytic compounds - Google Patents WO2025186418A1 - Senolytic compounds - Google Patents Senolytic compounds Info Publication number WO2025186418A1 WO2025186418A1 PCT/EP2025/056210 EP2025056210W WO2025186418A1 WO 2025186418 A1 WO2025186418 A1 WO 2025186418A1 EP 2025056210 W EP2025056210 W EP 2025056210W WO 2025186418 A1 WO2025186418 A1 WO 2025186418A1 Authority WO WIPO (PCT) Prior art keywords optionally substituted compound derivative aryl cycloalkyl Prior art date 2024-03-06 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number PCT/EP2025/056210 Other languages French ( fr ) Other versions WO2025186418A8 ( en Inventor Jörg Rademann Damian KLEMCZAK Markus Tiemann Clemens Schmitt Maurice REIMANN Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Charite Universitaetsmedizin Berlin Freie Universitaet Berlin Original Assignee Charite Universitaetsmedizin Berlin Freie Universitaet Berlin Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2024-03-06 Filing date 2025-03-06 Publication date 2025-09-12 2025-03-06 Application filed by Charite Universitaetsmedizin Berlin, Freie Universitaet Berlin filed Critical Charite Universitaetsmedizin Berlin 2025-09-12 Publication of WO2025186418A1 publication Critical patent/WO2025186418A1/en 2025-10-02 Publication of WO2025186418A8 publication Critical patent/WO2025186418A8/en Status Pending legal-status Critical Current 2026-09-06 Anticipated expiration legal-status Critical Links Espacenet Global Dossier PatentScope Discuss Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/395 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins A61K31/53 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61P — SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS A61P35/00 — Antineoplastic agents Definitions the present invention relates to the novel use of compounds as senolytic according to the preambles of claims 1 and 26, to novel compounds according to the preamble of claim 28, as well as to a medicament according to claim 32. Yoneda et al. (1971), Yoneda et al. (1973), and Yoneda et al. (1975) describe some of the toxoflavins, their synthesis method, and their reactivity. JP H09255681 A describes an antitumor agent comprising a 7-azapteridine derivative of a pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-dione. WO 2010/014798 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as anti-cancer drug. DE 103 01 788 A1 describes various pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones, their manufacturing method and their use as drug for treating diabetes. WO 2012/006104 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as drug for treating tuberculosis. WO 2018/140762 A1 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as drug for treating human immunodeficiency virus (HIV) infections, in particular for inhibiting HIV- 1 integrase multimerization. HIV human immunodeficiency virus WO 2010/072807 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their\n…[evidence text continues — 304635 more chars in the linked source]\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Navitoclax (term)\n- article_references_term: Cell Therapy (term)\n- article_references_term: Apoptosis (term)\n- article_references_term: DNA Damage Response (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nEVIDENCE DOCUMENT: WO2025186418A1 - Senolytic compounds - Google Patents\nURL: https://patents.google.com/patent/WO2025186418A1/en\nFull text: WO2025186418A1 - Senolytic compounds - Google Patents WO2025186418A1 - Senolytic compounds - Google Patents Senolytic compounds Info Publication number WO2025186418A1 WO2025186418A1 PCT/EP2025/056210 EP2025056210W WO2025186418A1 WO 2025186418 A1 WO2025186418 A1 WO 2025186418A1 EP 2025056210 W EP2025056210 W EP 2025056210W WO 2025186418 A1 WO2025186418 A1 WO 2025186418A1 Authority WO WIPO (PCT) Prior art keywords optionally substituted compound derivative aryl cycloalkyl Prior art date 2024-03-06 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number PCT/EP2025/056210 Other languages French ( fr ) Other versions WO2025186418A8 ( en Inventor Jörg Rademann Damian KLEMCZAK Markus Tiemann Clemens Schmitt Maurice REIMANN Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Charite Universitaetsmedizin Berlin Freie Universitaet Berlin Original Assignee Charite Universitaetsmedizin Berlin Freie Universitaet Berlin Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2024-03-06 Filing date 2025-03-06 Publication date 2025-09-12 2025-03-06 Application filed by Charite Universitaetsmedizin Berlin, Freie Universitaet Berlin filed Critical Charite Universitaetsmedizin Berlin 2025-09-12 Publication of WO2025186418A1 publication Critical patent/WO2025186418A1/en 2025-10-02 Publication of WO2025186418A8 publication Critical patent/WO2025186418A8/en Status Pending legal-status Critical Current 2026-09-06 Anticipated expiration legal-status Critical Links Espacenet Global Dossier PatentScope Discuss Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K31/00 — Medicinal preparations containing organic active ingredients A61K31/33 — Heterocyclic compounds A61K31/395 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins A61K31/53 — Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61P — SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS A61P35/00 — Antineoplastic agents Definitions the present invention relates to the novel use of compounds as senolytic according to the preambles of claims 1 and 26, to novel compounds according to the preamble of claim 28, as well as to a medicament according to claim 32. Yoneda et al. (1971), Yoneda et al. (1973), and Yoneda et al. (1975) describe some of the toxoflavins, their synthesis method, and their reactivity. JP H09255681 A describes an antitumor agent comprising a 7-azapteridine derivative of a pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-dione. WO 2010/014798 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as anti-cancer drug. DE 103 01 788 A1 describes various pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones, their manufacturing method and their use as drug for treating diabetes. WO 2012/006104 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as drug for treating tuberculosis. WO 2018/140762 A1 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their use as drug for treating human immunodeficiency virus (HIV) infections, in particular for inhibiting HIV- 1 integrase multimerization. HIV human immunodeficiency virus WO 2010/072807 A2 describes pyrimido-[5,6-e]-1 , 2, 4-triazine-5, 7-diones and their\n…[evidence text continues — 304635 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nWO2025186418A1 is a patent publication that explicitly proposes using compounds as senolytics, making its connection to the term substantive. The supplied excerpt describes selective killing of senescent cells and discusses prior work on toxoflavins and related compounds, but does not show the experiments supporting selectivity. The primate study in the glossary concerns dasatinib plus quercetin and provides no evidence for this patent's compounds.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The invention may extend a previously studied chemical family into senolytic applications; the claims and experimental examples are needed to establish what is new.\n- The publication's connection to navitoclax may indicate a senolytic comparator, but could also reflect background discussion.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which specific compounds are claimed and which were experimentally tested?\n- What cell types, senescence-induction methods, controls, concentrations and quantitative results support selective killing?\n- Does the document establish a mechanism of action or only describe senolytic activity?\n- Are there animal or human results, or is the evidence limited to cell experiments?\n- What role does navitoclax play in the document?","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"b99d3268-c296-4ba8-8694-810e0bc379e6","name":"WO2025186418A1 - Senolytic compounds - Google Patents","type":"publication","route":"https://patents.google.com/patent/WO2025186418A1/en","isPublic":true}},"connection":{"id":"ce629b10-cd15-4a14-ab6b-9252a9d2a179","kind":"article_references_term","to_id":"senolytics","from_id":"b99d3268-c296-4ba8-8694-810e0bc379e6","to_type":"term","from_type":"publication","confidence":0.99,"created_at":"2026-05-30 14:31:36.086554+00","evidence_excerpt":"\"the present invention relates to the novel use of compounds as senolytic\" and \"selectively kills senescent cells without harming non-senescent cells\"","evidence_source_id":"b99d3268-c296-4ba8-8694-810e0bc379e6","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The invention may extend a previously studied chemical family into senolytic applications; the claims and experimental examples are needed to establish what is new.","The publication's connection to navitoclax may indicate a senolytic comparator, but could also reflect background discussion."],"unresolved":["Which specific compounds are claimed and which were experimentally tested?","What cell types, senescence-induction methods, controls, concentrations and quantitative results support selective killing?","Does the document establish a mechanism of action or only describe senolytic activity?","Are there animal or human results, or is the evidence limited to cell experiments?","What role does navitoclax play in the document?"],"understanding":"WO2025186418A1 is a patent publication that explicitly proposes using compounds as senolytics, making its connection to the term substantive. The supplied excerpt describes selective killing of senescent cells and discusses prior work on toxoflavins and related compounds, but does not show the experiments supporting selectivity. The primate study in the glossary concerns dasatinib plus quercetin and provides no evidence for this patent's compounds.","instrument_calls":[{"hit":true,"args":{"source_id":"b99d3268-c296-4ba8-8694-810e0bc379e6","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-11-01 15:13:48.074819+00","updated_at":"2026-11-01 15:13:48.074819+00","public_url":"https://eternalsearch.net/journal/HGOjpg0i","api_url":"https://eternalsearch.net/api/v1/content/journal/HGOjpg0i"},{"public_id":"STB45CeF","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-11-01","title":"Montana’s treatment board grants first approval with conditions","summary":"Montana’s treatment board required consent changes in its first approval, while the combination of clemastine and audio remains under placebo-controlled testing.","cta_url":"https://eternalsearch.net/heroes/matt-kaeberlein","source_refs":{"ukhvat_news":{"id":"031a80bd-b9f2-4b27-9378-d22b7223c7bc","api_slug":"kaeberlein-montana-etrb-chair-response-seoh-not-longevity-law","keywords":["right-to-try","phase-1","montana-sb-535","experimental-drugs","treatment-review"],"title_en":"Matt Kaeberlein, chair of Montana’s experimental treatment board, responds to criticism of a law allowing unapproved drugs to be sold after Phase 1 trials: an independent board reviews every treatment protocol","short_slug":"261101007","api_title_ru":"Председатель совета по экспериментальному лечению Монтаны Мэтт Кэберлейн ответил на критику закона, разрешающего продавать неодобренные препараты после первой фазы испытаний: каждый протокол лечения рассматривает независимый совет","published_at":"2026-11-01 11:00:00+00","category_slugs":["industry-policy","clinical-trials"]},"linked_entity":{"url":"https://eternalsearch.net/heroes/matt-kaeberlein","name":"Matt Kaeberlein","type":"hero","route":"/heroes/matt-kaeberlein","match_score":14.5},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-11-01 11:16:34.18244+00","updated_at":"2026-11-01 11:16:34.18244+00","public_url":"https://eternalsearch.net/journal/STB45CeF","api_url":"https://eternalsearch.net/api/v1/content/journal/STB45CeF"},{"public_id":"4ANAopfA","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-31","title":"uPAR-Targeted T Cells as Senolytics","summary":"A patent application describes uPAR-targeted T cells as senolytics, but the available excerpt does not show the evidence needed to assess their selectivity.","cta_url":"https://eternalsearch.net/glossary/senolytics","source_refs":{"dossier":"THE EDGE: US20220098320A1 - Senolytic car-t cells targeting upar, a cell ... (publication) —[article_references_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: \"Senolytic car-t cells targeting upar\"; \"senolytic CAR T cells are bona fide in vivo senolytics\"\n\nFROM ENDPOINT —\nPUBLICATION: US20220098320A1 - Senolytic car-t cells targeting upar, a cell ...\nURL: https://patents.google.com/patent/US20220098320A1/en\nText: US20220098320A1 - Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker - Google Patents US20220098320A1 - Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker - Google Patents Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker Download PDF Info Publication number US20220098320A1 US20220098320A1 US17/426,728 US202017426728A US2022098320A1 US 20220098320 A1 US20220098320 A1 US 20220098320A1 US 202017426728 A US202017426728 A US 202017426728A US 2022098320 A1 US2022098320 A1 US 2022098320A1 Authority US United States Prior art keywords cell cells seq upar cancer Prior art date 2019-02-01 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number US17/426,728 Inventor Michel Sadelain Scott Lowe Josef LEIBOLD Corina AMOR Judith Feucht Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Memorial Sloan Kettering Cancer Center Original Assignee Memorial Sloan Kettering Cancer Center Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2019-02-01 Filing date 2020-01-31 Publication date 2022-03-31 2020-01-31 Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center 2020-01-31 Priority to US17/426,728 priority Critical patent/US20220098320A1/en 2022-03-31 Publication of US20220098320A1 publication Critical patent/US20220098320A1/en Status Pending legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K16/00 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies C07K16/18 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans C07K16/28 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants C07K16/2896 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K35/00 — Medicinal preparations containing materials or reaction products thereof with undetermined constitution A61K35/12 — Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells A61K35/14 — Blood; Artificial blood A61K35/17 — Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00 — Medicinal preparations containing peptides A61K38/16 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof A61K38/17 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans A61K38/177 — Receptors; Cell surface antigens; Cell surface determinants A61K38/1774 — Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molec\n…[publication text continues — 579775 more chars in the linked source]\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nEVIDENCE DOCUMENT: US20220098320A1 - Senolytic car-t cells targeting upar, a cell ...\nURL: https://patents.google.com/patent/US20220098320A1/en\nFull text: US20220098320A1 - Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker - Google Patents US20220098320A1 - Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker - Google Patents Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker Download PDF Info Publication number US20220098320A1 US20220098320A1 US17/426,728 US202017426728A US2022098320A1 US 20220098320 A1 US20220098320 A1 US 20220098320A1 US 202017426728 A US202017426728 A US 202017426728A US 2022098320 A1 US2022098320 A1 US 2022098320A1 Authority US United States Prior art keywords cell cells seq upar cancer Prior art date 2019-02-01 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number US17/426,728 Inventor Michel Sadelain Scott Lowe Josef LEIBOLD Corina AMOR Judith Feucht Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Memorial Sloan Kettering Cancer Center Original Assignee Memorial Sloan Kettering Cancer Center Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2019-02-01 Filing date 2020-01-31 Publication date 2022-03-31 2020-01-31 Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center 2020-01-31 Priority to US17/426,728 priority Critical patent/US20220098320A1/en 2022-03-31 Publication of US20220098320A1 publication Critical patent/US20220098320A1/en Status Pending legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K16/00 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies C07K16/18 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans C07K16/28 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants C07K16/2896 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K35/00 — Medicinal preparations containing materials or reaction products thereof with undetermined constitution A61K35/12 — Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells A61K35/14 — Blood; Artificial blood A61K35/17 — Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00 — Medicinal preparations containing peptides A61K38/16 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof A61K38/17 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans A61K38/177 — Receptors; Cell surface antigens; Cell surface determinants A61K38/1774 — Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molec\n…[evidence text continues — 579775 more chars in the linked source]\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Cell Therapy (term)\n- article_references_term: Rapamycin (term)\n- article_references_term: Gene Therapy (term)\n- article_references_term: mTOR Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nEVIDENCE DOCUMENT: US20220098320A1 - Senolytic car-t cells targeting upar, a cell ...\nURL: https://patents.google.com/patent/US20220098320A1/en\nFull text: US20220098320A1 - Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker - Google Patents US20220098320A1 - Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker - Google Patents Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker Download PDF Info Publication number US20220098320A1 US20220098320A1 US17/426,728 US202017426728A US2022098320A1 US 20220098320 A1 US20220098320 A1 US 20220098320A1 US 202017426728 A US202017426728 A US 202017426728A US 2022098320 A1 US2022098320 A1 US 2022098320A1 Authority US United States Prior art keywords cell cells seq upar cancer Prior art date 2019-02-01 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Pending Application number US17/426,728 Inventor Michel Sadelain Scott Lowe Josef LEIBOLD Corina AMOR Judith Feucht Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Memorial Sloan Kettering Cancer Center Original Assignee Memorial Sloan Kettering Cancer Center Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2019-02-01 Filing date 2020-01-31 Publication date 2022-03-31 2020-01-31 Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center 2020-01-31 Priority to US17/426,728 priority Critical patent/US20220098320A1/en 2022-03-31 Publication of US20220098320A1 publication Critical patent/US20220098320A1/en Status Pending legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K16/00 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies C07K16/18 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans C07K16/28 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants C07K16/2896 — Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K35/00 — Medicinal preparations containing materials or reaction products thereof with undetermined constitution A61K35/12 — Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells A61K35/14 — Blood; Artificial blood A61K35/17 — Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00 — Medicinal preparations containing peptides A61K38/16 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof A61K38/17 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans A61K38/177 — Receptors; Cell surface antigens; Cell surface determinants A61K38/1774 — Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molec\n…[evidence text continues — 579775 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe publication is a patent application describing senolytic CAR T cells targeting uPAR, which its title identifies as a cell-surface and secreted senescence biomarker. Its connection to Senolytics is explicit in the quoted claim that these cells act as in vivo senolytics, but the visible document text does not expose the experiments supporting that claim. The nonhuman-primate results in the glossary concern dasatinib plus quercetin and cannot establish efficacy or safety for these CAR T cells.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The potentially useful story is a cellular approach to senolysis: engineered T cells may recognize uPAR on target cells and eliminate them.\n- Whether uPAR targeting sufficiently distinguishes senescent cells from non-senescent cells may be central to evaluating this approach.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which experimental models, controls, doses and outcomes support the claim of in vivo senolytic activity?\n- What evidence demonstrates selective elimination of senescent cells and assesses effects on non-senescent uPAR-expressing cells?\n- Does the document report human treatment data, or only preclinical experiments and proposed therapeutic uses?\n- What adverse effects, persistence of activity and functional benefits were measured?","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"ef704d19-4205-4d8d-b2e6-7c2afa52c66b","name":"US20220098320A1 - Senolytic car-t cells targeting upar, a cell ...","type":"publication","route":"https://patents.google.com/patent/US20220098320A1/en","isPublic":true}},"connection":{"id":"512bc4fc-66fe-4ca9-822e-c0824500dd88","kind":"article_references_term","to_id":"senolytics","from_id":"ef704d19-4205-4d8d-b2e6-7c2afa52c66b","to_type":"term","from_type":"publication","confidence":0.99,"created_at":"2026-05-30 14:36:03.830425+00","evidence_excerpt":"\"Senolytic car-t cells targeting upar\"; \"senolytic CAR T cells are bona fide in vivo senolytics\"","evidence_source_id":"ef704d19-4205-4d8d-b2e6-7c2afa52c66b","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The potentially useful story is a cellular approach to senolysis: engineered T cells may recognize uPAR on target cells and eliminate them.","Whether uPAR targeting sufficiently distinguishes senescent cells from non-senescent cells may be central to evaluating this approach."],"unresolved":["Which experimental models, controls, doses and outcomes support the claim of in vivo senolytic activity?","What evidence demonstrates selective elimination of senescent cells and assesses effects on non-senescent uPAR-expressing cells?","Does the document report human treatment data, or only preclinical experiments and proposed therapeutic uses?","What adverse effects, persistence of activity and functional benefits were measured?"],"understanding":"The publication is a patent application describing senolytic CAR T cells targeting uPAR, which its title identifies as a cell-surface and secreted senescence biomarker. Its connection to Senolytics is explicit in the quoted claim that these cells act as in vivo senolytics, but the visible document text does not expose the experiments supporting that claim. The nonhuman-primate results in the glossary concern dasatinib plus quercetin and cannot establish efficacy or safety for these CAR T cells.","instrument_calls":[{"hit":true,"args":{"source_id":"ef704d19-4205-4d8d-b2e6-7c2afa52c66b","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-31 15:13:48.888659+00","updated_at":"2026-10-31 15:13:48.888659+00","public_url":"https://eternalsearch.net/journal/4ANAopfA","api_url":"https://eternalsearch.net/api/v1/content/journal/4ANAopfA"},{"public_id":"BgsMoPBd","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-31","title":"In-house Experiments in AI Drug Development","summary":"David Shaywitz suggests that in-house experiments could help drug developers select new targets as AI becomes widely available, though a competitive advantage remains unproven in the supplied material.","cta_url":"https://eternalsearch.net/organizations/uudYoX2y","source_refs":{"ukhvat_news":{"id":"a21fb5e3-3d4d-4043-98fb-3862b60154cf","api_slug":"crawler-zohar-ai-drug-development-differentiation","keywords":["ai-drug-discovery","in-house-experiments","causal-biology","drug-targets","proprietary-data","insitro"],"title_en":"In-house experiments could offer an edge in drug development as AI becomes widely available, suggests physician-scientist David Shaywitz","short_slug":"261031005","api_title_ru":"При общем доступе к ИИ преимущество в разработке лекарств могут дать собственные эксперименты — предполагает врач-исследователь Дэвид Шейвиц","published_at":"2026-10-31 11:00:00+00","category_slugs":["ai-and-medicine","therapeutics"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/uudYoX2y","name":"Bristol Myers Squibb","type":"organization","route":"/organizations/uudYoX2y","match_score":15},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-31 11:15:45.057835+00","updated_at":"2026-10-31 11:15:45.057835+00","public_url":"https://eternalsearch.net/journal/BgsMoPBd","api_url":"https://eternalsearch.net/api/v1/content/journal/BgsMoPBd"},{"public_id":"eXDGpufh","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-30","title":"Dasatinib and Quercetin in Senolytic Research","summary":"Monthly dasatinib plus quercetin treatment reduced senescence-associated gene expression in primate adipose tissue, while each compound's contribution remains unknown.","cta_url":"https://eternalsearch.net/glossary/dasatinib","source_refs":{"dossier":"THE EDGE: Dasatinib (term) —[term_related_to_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: used as a senolytic: The study calls D+Q a “senolytic combination.”\n\nFROM ENDPOINT —\nTERM: Dasatinib (category: compound)\nDefinition: An anticancer Src-family/BCR-ABL tyrosine kinase inhibitor that has been repurposed in senolytic studies. In this source, dasatinib is named as a senolytic compound candidate for treating headache disorders and chronic pain, including in lists alongside navitoclax, venetoclax, and PROTAC BCL2-family degraders.\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: James L. Kirkland (hero)\n- article_references_term: Drug conjugates of sugar derivatives and uses thereof as senolytic ... (publication)\n- article_references_term: US20200316066A1 - Killing senescent cells and treating ... (publication)\n- article_references_term: Methods and combinations for killing senescent cells and for treating ... (publication)\n- article_references_term: Senolíticos - Wikipedia, la enciclopedia libre (publication)\n- article_references_term: محلل الشيخوخة - ويكيبيديا (publication)\n- article_references_term: Senolytika - Wikipedia (publication)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier connects dasatinib, an anticancer kinase inhibitor, to senolytics through its use with quercetin as the D+Q combination. The senolytics definition describes a six-month, monthly-treatment study in middle-aged nonhuman primates that reported reduced senescence-associated biomarkers and several inflammatory and physiological changes; these findings concern the combination, not dasatinib alone.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The writer could explore dasatinib’s repurposing from cancer treatment to a combination intended to target senescent cells.\n- The reported biomarker changes could be consistent with senolytic activity, but the dossier does not establish selective elimination of senescent cells.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The underlying study’s identity, sample size, doses, control groups, and effect sizes are unavailable.\n- The respective contributions of dasatinib and quercetin cannot be established.\n- The dossier does not establish clinical benefit in humans, lifespan extension, or safety beyond the reported exposure period.\n- The stored evidence uses a hero_text source, which the fuller_evidence instrument does not support; no usable endpoint IDs or term slugs are supplied for further retrieval.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"dasatinib","name":"Dasatinib","type":"term","route":"/glossary/dasatinib","isPublic":true}},"connection":{"id":"2cd142f7-2465-4837-99ec-e7a775a70b6d","kind":"term_related_to_term","to_id":"senolytics","from_id":"dasatinib","to_type":"term","from_type":"term","confidence":0.99,"created_at":"2026-05-30 14:37:32.37642+00","evidence_excerpt":"used as a senolytic: The study calls D+Q a “senolytic combination.”","evidence_source_id":"bb1ce0d2-7a92-457c-b9f6-5cb602e29c42","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The writer could explore dasatinib’s repurposing from cancer treatment to a combination intended to target senescent cells.","The reported biomarker changes could be consistent with senolytic activity, but the dossier does not establish selective elimination of senescent cells."],"unresolved":["The underlying study’s identity, sample size, doses, control groups, and effect sizes are unavailable.","The respective contributions of dasatinib and quercetin cannot be established.","The dossier does not establish clinical benefit in humans, lifespan extension, or safety beyond the reported exposure period.","The stored evidence uses a hero_text source, which the fuller_evidence instrument does not support; no usable endpoint IDs or term slugs are supplied for further retrieval."],"understanding":"The dossier connects dasatinib, an anticancer kinase inhibitor, to senolytics through its use with quercetin as the D+Q combination. The senolytics definition describes a six-month, monthly-treatment study in middle-aged nonhuman primates that reported reduced senescence-associated biomarkers and several inflammatory and physiological changes; these findings concern the combination, not dasatinib alone.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-30 15:14:54.123469+00","updated_at":"2026-10-30 15:14:54.123469+00","public_url":"https://eternalsearch.net/journal/eXDGpufh","api_url":"https://eternalsearch.net/api/v1/content/journal/eXDGpufh"},{"public_id":"6hIoHGmz","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-30","title":"Finding affordable measures of immune aging","summary":"A Nature commentary proposes identifying affordable measures of immune health through repeated assessments, independent validation, and tests of whether their use improves clinical outcomes.","cta_url":"https://eternalsearch.net/organizations/gqgncSKf","source_refs":{"ukhvat_news":{"id":"6b684503-8f03-4900-a3ff-3640b05af5cb","api_slug":"nature-immunome-ai-immune-aging-measurement-roadmap","keywords":["immune-aging","immunome","immune-health","biomarkers","clinical-ai","vaccination-response"],"title_en":"A Nature commentary proposes using a detailed map of the immune system to identify a few inexpensive tests of immune health and aging","short_slug":"261030007","api_title_ru":"В Nature предложили из подробного описания иммунной системы выбрать несколько недорогих анализов её состояния и старения","published_at":"2026-10-30 11:00:00+00","category_slugs":["longevity-research","ai-and-medicine"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/gqgncSKf","name":"Harvard Medical School","type":"organization","route":"/organizations/gqgncSKf","match_score":15.2},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-30 11:16:56.132249+00","updated_at":"2026-10-30 11:16:56.132249+00","public_url":"https://eternalsearch.net/journal/6hIoHGmz","api_url":"https://eternalsearch.net/api/v1/content/journal/6hIoHGmz"},{"public_id":"EkloIsuS","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-29","title":"Senolytic Peptides and the Selectivity Test","summary":"A patent describes peptides intended to induce apoptosis in senescent cells, but the available excerpt does not establish whether experiments demonstrated selective killing.","cta_url":"https://eternalsearch.net/glossary/senolytics","source_refs":{"dossier":"THE EDGE: WO2019069070A1 - Novel senolytic peptides - Google Patents (publication) —[article_references_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: \"Novel senolytic peptides\" and peptides \"effective to induce apoptosis of senescent cells\"\n\nFROM ENDPOINT —\nPUBLICATION: WO2019069070A1 - Novel senolytic peptides - Google Patents\nURL: https://patents.google.com/patent/WO2019069070A1/en\nText: WO2019069070A1 - Novel senolytic peptides - Google Patents WO2019069070A1 - Novel senolytic peptides - Google Patents Novel senolytic peptides Download PDF Info Publication number WO2019069070A1 WO2019069070A1 PCT/GB2018/052812 GB2018052812W WO2019069070A1 WO 2019069070 A1 WO2019069070 A1 WO 2019069070A1 GB 2018052812 W GB2018052812 W GB 2018052812W WO 2019069070 A1 WO2019069070 A1 WO 2019069070A1 Authority WO WIPO (PCT) Prior art keywords seq senolytic peptide rrrrrrrprk prkggrrrra Prior art date 2017-10-02 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/GB2018/052812 Other languages French ( fr ) Inventor Emel TIMUCIN Yavuz Ahiska Ugur SEZERMAN Gunseli BAYRAM AKCAPINAR Selim ÇINAROUGLU Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Eternans Ltd Original Assignee Eternans Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-10-02 Filing date 2018-10-02 Publication date 2019-04-11 2018-10-02 Application filed by Eternans Ltd filed Critical Eternans Ltd 2018-10-02 Priority to US16/652,815 priority Critical patent/US20200255489A1/en 2018-10-02 Priority to CN201880077189.0A priority patent/CN111417647A/en 2019-04-11 Publication of WO2019069070A1 publication Critical patent/WO2019069070A1/en 2020-04-02 Anticipated expiration legal-status Critical Status Ceased legal-status Critical Current Links Espacenet Global Dossier PatentScope Discuss Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C07K14/435 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans C07K14/46 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates C07K14/47 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals C07K14/4701 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used C07K14/4702 — Regulators; Modulating activity A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00 — Medicinal preparations containing peptides A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K45/00 — Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 A61K45/06 — Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K2317/00 — Immunoglobulins specific features C07K2317/70 — Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen C07K2317/73 — Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation Definitions Senescence and apoptosis are among mechanisms that, when activated, restrict tumor gro\n…[publication text continues — 378429 more chars in the linked source]\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nEVIDENCE DOCUMENT: WO2019069070A1 - Novel senolytic peptides - Google Patents\nURL: https://patents.google.com/patent/WO2019069070A1/en\nFull text: WO2019069070A1 - Novel senolytic peptides - Google Patents WO2019069070A1 - Novel senolytic peptides - Google Patents Novel senolytic peptides Download PDF Info Publication number WO2019069070A1 WO2019069070A1 PCT/GB2018/052812 GB2018052812W WO2019069070A1 WO 2019069070 A1 WO2019069070 A1 WO 2019069070A1 GB 2018052812 W GB2018052812 W GB 2018052812W WO 2019069070 A1 WO2019069070 A1 WO 2019069070A1 Authority WO WIPO (PCT) Prior art keywords seq senolytic peptide rrrrrrrprk prkggrrrra Prior art date 2017-10-02 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/GB2018/052812 Other languages French ( fr ) Inventor Emel TIMUCIN Yavuz Ahiska Ugur SEZERMAN Gunseli BAYRAM AKCAPINAR Selim ÇINAROUGLU Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Eternans Ltd Original Assignee Eternans Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-10-02 Filing date 2018-10-02 Publication date 2019-04-11 2018-10-02 Application filed by Eternans Ltd filed Critical Eternans Ltd 2018-10-02 Priority to US16/652,815 priority Critical patent/US20200255489A1/en 2018-10-02 Priority to CN201880077189.0A priority patent/CN111417647A/en 2019-04-11 Publication of WO2019069070A1 publication Critical patent/WO2019069070A1/en 2020-04-02 Anticipated expiration legal-status Critical Status Ceased legal-status Critical Current Links Espacenet Global Dossier PatentScope Discuss Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C07K14/435 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans C07K14/46 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates C07K14/47 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals C07K14/4701 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used C07K14/4702 — Regulators; Modulating activity A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00 — Medicinal preparations containing peptides A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K45/00 — Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 A61K45/06 — Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K2317/00 — Immunoglobulins specific features C07K2317/70 — Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen C07K2317/73 — Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation Definitions Senescence and apoptosis are among mechanisms that, when activated, restrict tumor gro\n…[evidence text continues — 378429 more chars in the linked source]\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Apoptosis (term)\n- article_references_term: FOXO4-DRI (term)\n- article_references_term: Dasatinib (term)\n- article_references_term: Quercetin (term)\n- article_references_term: Navitoclax (term)\n- article_references_term: Fisetin (term)\n- article_references_term: FOXO Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n\nEVIDENCE DOCUMENT: WO2019069070A1 - Novel senolytic peptides - Google Patents\nURL: https://patents.google.com/patent/WO2019069070A1/en\nFull text: WO2019069070A1 - Novel senolytic peptides - Google Patents WO2019069070A1 - Novel senolytic peptides - Google Patents Novel senolytic peptides Download PDF Info Publication number WO2019069070A1 WO2019069070A1 PCT/GB2018/052812 GB2018052812W WO2019069070A1 WO 2019069070 A1 WO2019069070 A1 WO 2019069070A1 GB 2018052812 W GB2018052812 W GB 2018052812W WO 2019069070 A1 WO2019069070 A1 WO 2019069070A1 Authority WO WIPO (PCT) Prior art keywords seq senolytic peptide rrrrrrrprk prkggrrrra Prior art date 2017-10-02 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/GB2018/052812 Other languages French ( fr ) Inventor Emel TIMUCIN Yavuz Ahiska Ugur SEZERMAN Gunseli BAYRAM AKCAPINAR Selim ÇINAROUGLU Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Eternans Ltd Original Assignee Eternans Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2017-10-02 Filing date 2018-10-02 Publication date 2019-04-11 2018-10-02 Application filed by Eternans Ltd filed Critical Eternans Ltd 2018-10-02 Priority to US16/652,815 priority Critical patent/US20200255489A1/en 2018-10-02 Priority to CN201880077189.0A priority patent/CN111417647A/en 2019-04-11 Publication of WO2019069070A1 publication Critical patent/WO2019069070A1/en 2020-04-02 Anticipated expiration legal-status Critical Status Ceased legal-status Critical Current Links Espacenet Global Dossier PatentScope Discuss Classifications C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C07K14/435 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans C07K14/46 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates C07K14/47 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals C07K14/4701 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used C07K14/4702 — Regulators; Modulating activity A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00 — Medicinal preparations containing peptides A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K45/00 — Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 A61K45/06 — Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K2317/00 — Immunoglobulins specific features C07K2317/70 — Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen C07K2317/73 — Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation Definitions Senescence and apoptosis are among mechanisms that, when activated, restrict tumor gro\n…[evidence text continues — 378429 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nWO2019069070A1, published on 11 April 2019 with Eternans Ltd listed as assignee, describes peptides intended to induce apoptosis of senescent cells. This connects it substantively to senolytics, whose defining aim is selective elimination of senescent cells while sparing non-senescent cells; the visible excerpt does not establish that selectivity experimentally. Links to FOXO4-DRI and FOXO signaling suggest relevant context but do not establish the peptides' mechanism.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The patent may describe a peptide approach related to FOXO4-DRI, but the mechanism and any claimed improvements require examination of the document.\n- A useful reader-facing angle could be how these peptides attempt to distinguish senescent cells from non-senescent cells, if the patent provides comparative experiments.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which peptides are proposed, what molecular interaction they target, and how they relate to FOXO4-DRI.\n- Whether experiments demonstrate selective killing with non-senescent controls, and at what concentrations.\n- Which cell types or animal models were tested, with what quantitative results.\n- Which statements are patent claims, which are experimental findings, and whether any human evidence is presented.\n- The glossary's dasatinib-plus-quercetin trial description does not establish efficacy or safety of these peptides.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"044d8a6f-e8e6-4ef0-860f-dc9c1fd2b53d","name":"WO2019069070A1 - Novel senolytic peptides - Google Patents","type":"publication","route":"https://patents.google.com/patent/WO2019069070A1/en","isPublic":true}},"connection":{"id":"b52d0520-e59f-4a9e-b42b-68afce76cf3f","kind":"article_references_term","to_id":"senolytics","from_id":"044d8a6f-e8e6-4ef0-860f-dc9c1fd2b53d","to_type":"term","from_type":"publication","confidence":0.99,"created_at":"2026-05-30 14:37:32.37642+00","evidence_excerpt":"\"Novel senolytic peptides\" and peptides \"effective to induce apoptosis of senescent cells\"","evidence_source_id":"044d8a6f-e8e6-4ef0-860f-dc9c1fd2b53d","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The patent may describe a peptide approach related to FOXO4-DRI, but the mechanism and any claimed improvements require examination of the document.","A useful reader-facing angle could be how these peptides attempt to distinguish senescent cells from non-senescent cells, if the patent provides comparative experiments."],"unresolved":["Which peptides are proposed, what molecular interaction they target, and how they relate to FOXO4-DRI.","Whether experiments demonstrate selective killing with non-senescent controls, and at what concentrations.","Which cell types or animal models were tested, with what quantitative results.","Which statements are patent claims, which are experimental findings, and whether any human evidence is presented.","The glossary's dasatinib-plus-quercetin trial description does not establish efficacy or safety of these peptides."],"understanding":"WO2019069070A1, published on 11 April 2019 with Eternans Ltd listed as assignee, describes peptides intended to induce apoptosis of senescent cells. This connects it substantively to senolytics, whose defining aim is selective elimination of senescent cells while sparing non-senescent cells; the visible excerpt does not establish that selectivity experimentally. Links to FOXO4-DRI and FOXO signaling suggest relevant context but do not establish the peptides' mechanism.","instrument_calls":[{"hit":true,"args":{"source_id":"044d8a6f-e8e6-4ef0-860f-dc9c1fd2b53d","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-29 15:14:35.97681+00","updated_at":"2026-10-29 15:14:35.97681+00","public_url":"https://eternalsearch.net/journal/EkloIsuS","api_url":"https://eternalsearch.net/api/v1/content/journal/EkloIsuS"},{"public_id":"rj003UY2","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-29","title":"Joe Betts-LaCroix proposes confidential FDA evaluation of AI trial predictions","summary":"Retro CEO Joe Betts-LaCroix proposes FDA evaluation of AI predictions against confidential trial outcomes, hoping sustained accuracy could eventually support drug approvals without human trials.","cta_url":"https://eternalsearch.net/heroes/joe-betts-lacroix","source_refs":{"ukhvat_news":{"id":"f6cc4cc8-6628-4181-94a1-9a8ef82b1107","api_slug":"retro-betts-lacroix-ardd2026-fda-blind-trial-prediction-ai-proteins","keywords":["fda","clinical-trial-prediction","drug-approval","blinded-evaluation","retro-biosciences","rtr242"],"title_en":"FDA could confidentially test AI models on their predictions of clinical trial outcomes, then approve drugs without trials after a series of accurate predictions, says Retro CEO Joe Betts-LaCroix","short_slug":"261029006","api_title_ru":"FDA могла бы конфиденциально проверять ИИ-модели на прогнозах исходов клинических испытаний, а после череды точных прогнозов одобрять лекарства без испытаний, считает глава компании Retro Джо Беттс-Лакруа","published_at":"2026-10-29 10:00:00+00","category_slugs":["ai-and-medicine","clinical-trials","industry-policy"]},"linked_entity":{"url":"https://eternalsearch.net/heroes/joe-betts-lacroix","name":"Joe Betts-LaCroix","type":"hero","route":"/heroes/joe-betts-lacroix","match_score":14.7},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-29 11:17:49.362538+00","updated_at":"2026-10-29 11:17:49.362538+00","public_url":"https://eternalsearch.net/journal/rj003UY2","api_url":"https://eternalsearch.net/api/v1/content/journal/rj003UY2"},{"public_id":"M1veo988","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-28","title":"Marco Quarta’s senolytic patent credit","summary":"US patent US11026963B2 names Marco Quarta as one of three inventors and records an assignment of rights to Rubedo Life Sciences Inc.","cta_url":"https://eternalsearch.net/investors/7KhuGEib","source_refs":{"dossier":"THE EDGE: Marco Quarta (investor) —[person_authored_article, confidence 0.99]→ US11026963B2 - Senolytic compositions and uses thereof (publication)\n\nStored evidence excerpt: Inventor Mark A. Gallop Julian Klein Marco Quarta\n\nFROM ENDPOINT —\nINVESTOR/PERSON: Marco Quarta\n\nTO ENDPOINT —\nPUBLICATION: US11026963B2 - Senolytic compositions and uses thereof\nURL: https://patents.google.com/patent/US11026963B2/en\nText: US11026963B2 - Senolytic compositions and uses thereof - Google Patents US11026963B2 - Senolytic compositions and uses thereof - Google Patents Senolytic compositions and uses thereof Download PDF Info Publication number US11026963B2 US11026963B2 US16/508,477 US201916508477A US11026963B2 US 11026963 B2 US11026963 B2 US 11026963B2 US 201916508477 A US201916508477 A US 201916508477A US 11026963 B2 US11026963 B2 US 11026963B2 Authority US United States Prior art keywords disease diseases compounds senolytic disorders Prior art date 2018-07-11 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number US16/508,477 Other versions US20200016185A1 ( en Inventor Mark A. Gallop Julian Klein Marco Quarta Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Rubedo Life Sciences Inc Original Assignee Rubedo Life Sciences Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2018-07-11 Filing date 2019-07-11 Publication date 2021-06-08 2019-07-11 Application filed by Rubedo Life Sciences Inc filed Critical Rubedo Life Sciences Inc 2019-07-11 Priority to US16/508,477 priority Critical patent/US11026963B2/en 2019-08-02 Assigned to Rubedo Life Sciences, Inc. reassignment Rubedo Life Sciences, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GALLOP, MARK A., KLEIN, JULIAN, QUARTA, MARCO 2020-01-16 Publication of US20200016185A1 publication Critical patent/US20200016185A1/en 2021-05-04 Priority to US17/307,047 priority patent/US20210299154A1/en 2021-06-08 Application granted granted Critical 2021-06-08 Publication of US11026963B2 publication Critical patent/US11026963B2/en 2023-04-17 Priority to US18/301,874 priority patent/US20230321130A1/en Status Active legal-status Critical Current 2039-07-11 Anticipated expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss 0 **.C#CC1=CC=CC(NC2=NC=NC3=C2C=C(OCCCCCCC(=O)CO)C(OC)=C3)=C1.CC(C)[C@H](C(=O)CC1=CC=C(C(=O)CO)C=C1)C1=CC=CC=C1.CN(C)CC1=C(C(=O)NCCOC2=CC=C(C(=O)CO)C=C2)OC2=C1C=CC=C2.CN1/C=C(/CNCC2CCN(C3=NC=C(C(=O)CO)C=N3)CC2)C2=C1C=CC=C2.O=C(/C=C/C1=CC=C(CN(CCO)CC2=CNC3=C2C=CC=C3)C=C1)CO.O=C(CO)CCCCCCCC(=O)C1=CN=C(N(C2=CC=CC=C2)C2=CC=CC=C2)N=C1 Chemical compound **.C#CC1=CC=CC(NC2=NC=NC3=C2C=C(OCCCCCCC(=O)CO)C(OC)=C3)=C1.CC(C)[C@H](C(=O)CC1=CC=C(C(=O)CO)C=C1)C1=CC=CC=C1.CN(C)CC1=C(C(=O)NCCOC2=CC=C(C(=O)CO)C=C2)OC2=C1C=CC=C2.CN1/C=C(/CNCC2CCN(C3=NC=C(C(=O)CO)C=N3)CC2)C2=C1C=CC=C2.O=C(/C=C/C1=CC=C(CN(CCO)CC2=CNC3=C2C=CC=C3)C=C1)CO.O=C(CO)CCCCCCCC(=O)C1=CN=C(N(C2=CC=CC=C2)C2=CC=CC=C2)N=C1 0.000 description 3 BDBAGJDYRIFXMF-COIKBYTDSA-N CC(C)C1=C(O)C=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1.CC(C)C1=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C=C(O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1 Chemical compound CC(C)C1=C(O)C=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1.CC(C)C1=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C=C(O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1 BDBAGJDYRIFXMF-COIKBYTDSA-N 0.000 description 2 NAIXRDYLZBGFKB-XOFDEKEJSA-N CCNC(=O)C1=NOC(C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1.CCNC(=O)C1=NOC(C2=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C=C(O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1 Chemical compound CCNC(=O)C1=NOC(C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1.CCNC(=O)C1=NOC(C2=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C=C(O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1 NAIXRDYLZBGFKB-XOFDEKEJSA-N 0.000 description 2\n…[publication text continues — 550651 more chars in the linked source]\n\nEVIDENCE DOCUMENT: US11026963B2 - Senolytic compositions and uses thereof\nURL: https://patents.google.com/patent/US11026963B2/en\nFull text: US11026963B2 - Senolytic compositions and uses thereof - Google Patents US11026963B2 - Senolytic compositions and uses thereof - Google Patents Senolytic compositions and uses thereof Download PDF Info Publication number US11026963B2 US11026963B2 US16/508,477 US201916508477A US11026963B2 US 11026963 B2 US11026963 B2 US 11026963B2 US 201916508477 A US201916508477 A US 201916508477A US 11026963 B2 US11026963 B2 US 11026963B2 Authority US United States Prior art keywords disease diseases compounds senolytic disorders Prior art date 2018-07-11 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number US16/508,477 Other versions US20200016185A1 ( en Inventor Mark A. Gallop Julian Klein Marco Quarta Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Rubedo Life Sciences Inc Original Assignee Rubedo Life Sciences Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2018-07-11 Filing date 2019-07-11 Publication date 2021-06-08 2019-07-11 Application filed by Rubedo Life Sciences Inc filed Critical Rubedo Life Sciences Inc 2019-07-11 Priority to US16/508,477 priority Critical patent/US11026963B2/en 2019-08-02 Assigned to Rubedo Life Sciences, Inc. reassignment Rubedo Life Sciences, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GALLOP, MARK A., KLEIN, JULIAN, QUARTA, MARCO 2020-01-16 Publication of US20200016185A1 publication Critical patent/US20200016185A1/en 2021-05-04 Priority to US17/307,047 priority patent/US20210299154A1/en 2021-06-08 Application granted granted Critical 2021-06-08 Publication of US11026963B2 publication Critical patent/US11026963B2/en 2023-04-17 Priority to US18/301,874 priority patent/US20230321130A1/en Status Active legal-status Critical Current 2039-07-11 Anticipated expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss 0 **.C#CC1=CC=CC(NC2=NC=NC3=C2C=C(OCCCCCCC(=O)CO)C(OC)=C3)=C1.CC(C)[C@H](C(=O)CC1=CC=C(C(=O)CO)C=C1)C1=CC=CC=C1.CN(C)CC1=C(C(=O)NCCOC2=CC=C(C(=O)CO)C=C2)OC2=C1C=CC=C2.CN1/C=C(/CNCC2CCN(C3=NC=C(C(=O)CO)C=N3)CC2)C2=C1C=CC=C2.O=C(/C=C/C1=CC=C(CN(CCO)CC2=CNC3=C2C=CC=C3)C=C1)CO.O=C(CO)CCCCCCCC(=O)C1=CN=C(N(C2=CC=CC=C2)C2=CC=CC=C2)N=C1 Chemical compound **.C#CC1=CC=CC(NC2=NC=NC3=C2C=C(OCCCCCCC(=O)CO)C(OC)=C3)=C1.CC(C)[C@H](C(=O)CC1=CC=C(C(=O)CO)C=C1)C1=CC=CC=C1.CN(C)CC1=C(C(=O)NCCOC2=CC=C(C(=O)CO)C=C2)OC2=C1C=CC=C2.CN1/C=C(/CNCC2CCN(C3=NC=C(C(=O)CO)C=N3)CC2)C2=C1C=CC=C2.O=C(/C=C/C1=CC=C(CN(CCO)CC2=CNC3=C2C=CC=C3)C=C1)CO.O=C(CO)CCCCCCCC(=O)C1=CN=C(N(C2=CC=CC=C2)C2=CC=CC=C2)N=C1 0.000 description 3 BDBAGJDYRIFXMF-COIKBYTDSA-N CC(C)C1=C(O)C=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1.CC(C)C1=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C=C(O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1 Chemical compound CC(C)C1=C(O)C=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1.CC(C)C1=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C=C(O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1 BDBAGJDYRIFXMF-COIKBYTDSA-N 0.000 description 2 NAIXRDYLZBGFKB-XOFDEKEJSA-N CCNC(=O)C1=NOC(C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1.CCNC(=O)C1=NOC(C2=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C=C(O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1 Chemical compound CCNC(=O)C1=NOC(C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1.CCNC(=O)C1=NOC(C2=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C=C(O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1 NAIXRDYLZBGFKB-XOFDEKEJSA-N 0.000 description 2\n…[evidence text continues — 550651 more chars in the linked source]\n\nNEIGHBOURS of this investor (other public links it participates in):\n- person_authored_article: Speakers - Hevolution Foundation (publication)\n- person_authored_article: US11026963B2 - Senolytic compositions and uses thereof (publication)\n- person_authored_article: WO2020014409A1 - Senolytic compositions and uses thereof (publication)\n- person_authored_article: Drug conjugates of sugar derivatives and uses thereof as senolytic ... (publication)\n\nNEIGHBOURS of this publication (other public links it participates in):\n- article_references_term: Senolytics (term)\n\nEVIDENCE DOCUMENT: US11026963B2 - Senolytic compositions and uses thereof\nURL: https://patents.google.com/patent/US11026963B2/en\nFull text: US11026963B2 - Senolytic compositions and uses thereof - Google Patents US11026963B2 - Senolytic compositions and uses thereof - Google Patents Senolytic compositions and uses thereof Download PDF Info Publication number US11026963B2 US11026963B2 US16/508,477 US201916508477A US11026963B2 US 11026963 B2 US11026963 B2 US 11026963B2 US 201916508477 A US201916508477 A US 201916508477A US 11026963 B2 US11026963 B2 US 11026963B2 Authority US United States Prior art keywords disease diseases compounds senolytic disorders Prior art date 2018-07-11 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number US16/508,477 Other versions US20200016185A1 ( en Inventor Mark A. Gallop Julian Klein Marco Quarta Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Rubedo Life Sciences Inc Original Assignee Rubedo Life Sciences Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2018-07-11 Filing date 2019-07-11 Publication date 2021-06-08 2019-07-11 Application filed by Rubedo Life Sciences Inc filed Critical Rubedo Life Sciences Inc 2019-07-11 Priority to US16/508,477 priority Critical patent/US11026963B2/en 2019-08-02 Assigned to Rubedo Life Sciences, Inc. reassignment Rubedo Life Sciences, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GALLOP, MARK A., KLEIN, JULIAN, QUARTA, MARCO 2020-01-16 Publication of US20200016185A1 publication Critical patent/US20200016185A1/en 2021-05-04 Priority to US17/307,047 priority patent/US20210299154A1/en 2021-06-08 Application granted granted Critical 2021-06-08 Publication of US11026963B2 publication Critical patent/US11026963B2/en 2023-04-17 Priority to US18/301,874 priority patent/US20230321130A1/en Status Active legal-status Critical Current 2039-07-11 Anticipated expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss 0 **.C#CC1=CC=CC(NC2=NC=NC3=C2C=C(OCCCCCCC(=O)CO)C(OC)=C3)=C1.CC(C)[C@H](C(=O)CC1=CC=C(C(=O)CO)C=C1)C1=CC=CC=C1.CN(C)CC1=C(C(=O)NCCOC2=CC=C(C(=O)CO)C=C2)OC2=C1C=CC=C2.CN1/C=C(/CNCC2CCN(C3=NC=C(C(=O)CO)C=N3)CC2)C2=C1C=CC=C2.O=C(/C=C/C1=CC=C(CN(CCO)CC2=CNC3=C2C=CC=C3)C=C1)CO.O=C(CO)CCCCCCCC(=O)C1=CN=C(N(C2=CC=CC=C2)C2=CC=CC=C2)N=C1 Chemical compound **.C#CC1=CC=CC(NC2=NC=NC3=C2C=C(OCCCCCCC(=O)CO)C(OC)=C3)=C1.CC(C)[C@H](C(=O)CC1=CC=C(C(=O)CO)C=C1)C1=CC=CC=C1.CN(C)CC1=C(C(=O)NCCOC2=CC=C(C(=O)CO)C=C2)OC2=C1C=CC=C2.CN1/C=C(/CNCC2CCN(C3=NC=C(C(=O)CO)C=N3)CC2)C2=C1C=CC=C2.O=C(/C=C/C1=CC=C(CN(CCO)CC2=CNC3=C2C=CC=C3)C=C1)CO.O=C(CO)CCCCCCCC(=O)C1=CN=C(N(C2=CC=CC=C2)C2=CC=CC=C2)N=C1 0.000 description 3 BDBAGJDYRIFXMF-COIKBYTDSA-N CC(C)C1=C(O)C=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1.CC(C)C1=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C=C(O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1 Chemical compound CC(C)C1=C(O)C=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1.CC(C)C1=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C=C(O)C(C(=O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2)=C1 BDBAGJDYRIFXMF-COIKBYTDSA-N 0.000 description 2 NAIXRDYLZBGFKB-XOFDEKEJSA-N CCNC(=O)C1=NOC(C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1.CCNC(=O)C1=NOC(C2=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C=C(O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1 Chemical compound CCNC(=O)C1=NOC(C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1.CCNC(=O)C1=NOC(C2=C(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)C=C(O)C(C(C)C)=C2)=C1C1=CC=C(CN2CCOCC2)C=C1 NAIXRDYLZBGFKB-XOFDEKEJSA-N 0.000 description 2\n…[evidence text continues — 550651 more chars in the linked source]\n\nANALYST READING (orientation — the post still asserts only facts above):\nMarco Quarta is listed alongside Mark A. Gallop and Julian Klein as an inventor on US11026963B2, “Senolytic compositions and uses thereof,” granted on June 8, 2021. The supplied patent record names Rubedo Life Sciences Inc as the original assignee and records an assignment from the three inventors in August 2019. This supports a concrete connection to senolytic intellectual property; the edge label “person_authored_article” obscures that the documented role is patent inventor.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- Quarta’s inventor credit may offer a useful angle on his involvement in developing senolytic technology, beyond his classification as an investor.\n- The neighbouring patent publications may reveal a broader programme of senolytic inventions, although their relationship and distinctness remain unestablished.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The supplied excerpt does not explain the invention’s mechanism, claimed scope, experimental results or distinction from earlier senolytic approaches.\n- Inventor credit does not establish Quarta’s individual technical contribution, employment role or financial investment in Rubedo.\n- The neighbouring publications could represent related patent-family documents rather than independent inventions.\n- The displayed legal status and assignee information carry source caveats and do not establish a verified current legal position.","endpoints":{"to":{"id":"3b84f6c7-0143-4947-baf2-6a907991bd31","name":"US11026963B2 - Senolytic compositions and uses thereof","type":"publication","route":"https://patents.google.com/patent/US11026963B2/en","isPublic":true},"from":{"id":"83e7cfc8-0686-434d-aea7-c1494c5a78dc","name":"Marco Quarta","type":"investor","route":"/investors/7KhuGEib","isPublic":true}},"connection":{"id":"47334ae7-0c1b-4bb6-8106-d82a26248449","kind":"person_authored_article","to_id":"3b84f6c7-0143-4947-baf2-6a907991bd31","from_id":"83e7cfc8-0686-434d-aea7-c1494c5a78dc","to_type":"publication","from_type":"investor","confidence":0.99,"created_at":"2026-05-30 14:38:03.56892+00","evidence_excerpt":"Inventor Mark A. Gallop Julian Klein Marco Quarta","evidence_source_id":"3b84f6c7-0143-4947-baf2-6a907991bd31","evidence_source_kind":"project_publication"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["Quarta’s inventor credit may offer a useful angle on his involvement in developing senolytic technology, beyond his classification as an investor.","The neighbouring patent publications may reveal a broader programme of senolytic inventions, although their relationship and distinctness remain unestablished."],"unresolved":["The supplied excerpt does not explain the invention’s mechanism, claimed scope, experimental results or distinction from earlier senolytic approaches.","Inventor credit does not establish Quarta’s individual technical contribution, employment role or financial investment in Rubedo.","The neighbouring publications could represent related patent-family documents rather than independent inventions.","The displayed legal status and assignee information carry source caveats and do not establish a verified current legal position."],"understanding":"Marco Quarta is listed alongside Mark A. Gallop and Julian Klein as an inventor on US11026963B2, “Senolytic compositions and uses thereof,” granted on June 8, 2021. The supplied patent record names Rubedo Life Sciences Inc as the original assignee and records an assignment from the three inventors in August 2019. This supports a concrete connection to senolytic intellectual property; the edge label “person_authored_article” obscures that the documented role is patent inventor.","instrument_calls":[{"hit":true,"args":{"source_id":"3b84f6c7-0143-4947-baf2-6a907991bd31","source_kind":"project_publication"},"name":"fuller_evidence","round":1}]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-28 17:14:32.63766+00","updated_at":"2026-10-28 17:14:32.63766+00","public_url":"https://eternalsearch.net/journal/M1veo988","api_url":"https://eternalsearch.net/api/v1/content/journal/M1veo988"},{"public_id":"CSOLMeii","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-28","title":"Claude's Claimed 3-SAT Refutation Needs Human Review","summary":"Anthropic reports a formally verified refutation of the Exponential Time Hypothesis, with an enormous threshold for beating exhaustive search and human review of the formal statements still needed.","cta_url":"https://eternalsearch.net/organizations/6v7jD1ps","source_refs":{"ukhvat_news":{"id":"0b15efc0-7ea4-404e-9877-0460500acffd","api_slug":"anthropic-independent-eth-refutation-claude-lean","keywords":["claude","3-sat","exponential-time-hypothesis","lean-4","algorithmic-complexity","formal-proof"],"title_en":"Hours after OpenAI, Anthropic announced that its Claude model had also disproved the exponential time hypothesis (the claim that every algorithm for 3-SAT requires an exponentially growing number of steps)","short_slug":"261028006","api_title_ru":"Через несколько часов после OpenAI Anthropic заявила, что её модель Claude тоже опровергла гипотезу об экспоненциальном времени (для задачи 3-SAT любому алгоритму нужно экспоненциально растущее число шагов)","published_at":"2026-10-28 10:00:00+00","category_slugs":["scientific-computing","science-research"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/6v7jD1ps","name":"Anthropic","type":"organization","route":"/organizations/6v7jD1ps","match_score":13.9},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-28 11:19:02.103056+00","updated_at":"2026-10-28 11:19:02.103056+00","public_url":"https://eternalsearch.net/journal/CSOLMeii","api_url":"https://eternalsearch.net/api/v1/content/journal/CSOLMeii"},{"public_id":"PviUDI1x","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-27","title":"Kirkland, Quercetin and Kidney Injury in Mice","summary":"Eternal Search links Kirkland to quercetin through a finding that dasatinib plus quercetin reduced kidney injury in diabetic mice, while his role in the experiment and quercetin's separate contribution remain unknown.","cta_url":"https://eternalsearch.net/heroes/james-l-kirkland","source_refs":{"dossier":"THE EDGE: James L. Kirkland (hero) —[person_holds_term, confidence 0.99]→ Quercetin (term)\n\nStored evidence excerpt: Dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice.\n\nFROM ENDPOINT —\nPERSON (hero): James L. Kirkland\nBio: Physician-scientist and former director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic whose research helped establish cellular senescence as a therapeutic target for age-related disease.\nImpact score: 40.3\n\nTO ENDPOINT —\nTERM: Quercetin (category: compound)\nDefinition: Quercetin is a natural flavonoid senolytic compound. In this source, it is cited together with dasatinib as an established example of a senolytic used as prior art motivating the search for additional compounds with improved safety profiles.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Fisetin (term)\n- person_holds_term: Senolytics (term)\n- person_holds_term: Dasatinib (term)\n- person_holds_term: Integrated Stress Response (term)\n- person_holds_term: Senomorphics (term)\n- person_holds_term: NF-kB Signaling (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: NAD Metabolism (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- project_investigates_term: First Approval (project)\n- article_references_term: Prenetics' IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging (publication)\n- term_related_to_term: Senolytics (term)\n- article_references_term: US20200316066A1 - Killing senescent cells and treating ... (publication)\n- article_references_term: Methods and combinations for killing senescent cells and for treating ... (publication)\n- article_references_term: EP3870164A2 - Compositions for the elimination of senescent cells (publication)\n- article_references_term: US20210379087A1 - Compositions for the elimination of senescent ... (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier links James L. Kirkland, whose research helped establish cellular senescence as a therapeutic target, to quercetin through a report that dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice. This supports a concrete research connection to a combination treatment in an animal model; it does not establish an effect of quercetin alone or a benefit in humans.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The writer could explore the hypothesis that targeting senescent cells may alleviate diabetes-associated kidney injury, using the reported mouse findings as a limited example.\n- Kirkland's additional links to dasatinib, fisetin, and senolytics suggest that the quercetin connection belongs to a broader research interest in interventions targeting cellular senescence.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The underlying study's identity, publication date, methods, sample size, effect sizes, and treatment schedule are not provided.\n- Kirkland's specific role in the reported mouse study is not established.\n- The dossier does not isolate quercetin's contribution from dasatinib's or establish that senescent-cell reduction caused the kidney improvements.\n- Human efficacy and safety for this indication are not established.\n- No eligible retrieval arguments are available: neighbours have names but no supplied IDs or slugs, and the evidence source is hero_text, which fuller_evidence does not support.","endpoints":{"to":{"id":"quercetin","name":"Quercetin","type":"term","route":"/glossary/quercetin","isPublic":true},"from":{"id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","name":"James L. Kirkland","type":"hero","route":"/heroes/james-l-kirkland","isPublic":true}},"connection":{"id":"c0d62776-732f-4ebb-8ff6-40ad24969421","kind":"person_holds_term","to_id":"quercetin","from_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:31:38.571859+00","evidence_excerpt":"Dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice.","evidence_source_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The writer could explore the hypothesis that targeting senescent cells may alleviate diabetes-associated kidney injury, using the reported mouse findings as a limited example.","Kirkland's additional links to dasatinib, fisetin, and senolytics suggest that the quercetin connection belongs to a broader research interest in interventions targeting cellular senescence."],"unresolved":["The underlying study's identity, publication date, methods, sample size, effect sizes, and treatment schedule are not provided.","Kirkland's specific role in the reported mouse study is not established.","The dossier does not isolate quercetin's contribution from dasatinib's or establish that senescent-cell reduction caused the kidney improvements.","Human efficacy and safety for this indication are not established.","No eligible retrieval arguments are available: neighbours have names but no supplied IDs or slugs, and the evidence source is hero_text, which fuller_evidence does not support."],"understanding":"The dossier links James L. Kirkland, whose research helped establish cellular senescence as a therapeutic target, to quercetin through a report that dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice. This supports a concrete research connection to a combination treatment in an animal model; it does not establish an effect of quercetin alone or a benefit in humans.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-27 15:14:09.705633+00","updated_at":"2026-10-27 15:14:09.705633+00","public_url":"https://eternalsearch.net/journal/PviUDI1x","api_url":"https://eternalsearch.net/api/v1/content/journal/PviUDI1x"},{"public_id":"VX5NXZQu","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-27","title":"AEP inhibitor increased mean mouse lifespan and reduced frailty","summary":"Compound #11a increased mean lifespan from 24 to 28 months in normally aging mice and lowered frailty scores in a blinded assessment covering 29 signs of aging.","cta_url":"https://eternalsearch.net/glossary/frailty_index","source_refs":{"ukhvat_news":{"id":"5cd75d06-4780-4b11-b8d6-c331fcd94ddc","api_slug":"aep-inhibitor-11a-lifespan-aged-mice","keywords":["aep-inhibitor","mouse-lifespan","nampt","nad-plus","sirt1","frailty"],"title_en":"Mice given the AEP enzyme inhibitor in their food from 18 months of age lived an average of 28 months, compared with 24 months for mice without the inhibitor","short_slug":"261027005","api_title_ru":"Мыши, которым с 18 месяцев добавляли в корм блокатор фермента AEP, прожили в среднем 28 месяцев против 24 у мышей без блокатора","published_at":"2026-10-27 10:00:00+00","category_slugs":["longevity-research","therapeutics"]},"linked_entity":{"url":"https://eternalsearch.net/glossary/frailty_index","name":"Frailty Index","type":"term","route":"/glossary/frailty_index","match_score":14.3},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-27 11:14:29.218982+00","updated_at":"2026-10-27 11:14:29.218982+00","public_url":"https://eternalsearch.net/journal/VX5NXZQu","api_url":"https://eternalsearch.net/api/v1/content/journal/VX5NXZQu"},{"public_id":"csMS9jaf","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-26","title":"James L. Kirkland and Senolytics","summary":"James L. Kirkland helped establish senolytics as a longevity research field focused on selectively eliminating senescent cells.","cta_url":"https://eternalsearch.net/heroes/james-l-kirkland","source_refs":{"dossier":"THE EDGE: James L. Kirkland (hero) —[person_holds_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: Kirkland helped establish senolytics as a longevity research field; senolytic drugs eliminate senescent cells.\n\nFROM ENDPOINT —\nPERSON (hero): James L. Kirkland\nBio: Physician-scientist and former director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic whose research helped establish cellular senescence as a therapeutic target for age-related disease.\nImpact score: 40.3\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Fisetin (term)\n- person_holds_term: Dasatinib (term)\n- person_holds_term: Quercetin (term)\n- person_holds_term: Integrated Stress Response (term)\n- person_holds_term: Senomorphics (term)\n- person_holds_term: NF-kB Signaling (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: NAD Metabolism (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n- article_references_term: WO2018215795A2 - Senolytic compounds - Google Patents (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nJames L. Kirkland is a physician-scientist whose research helped establish cellular senescence as a therapeutic target; the stored evidence credits him with helping establish senolytics as a longevity research field. Senolytics aim to selectively eliminate senescent cells, and his listed connections include dasatinib, quercetin and fisetin. The glossary describes a six-month dasatinib-plus-quercetin study in nonhuman primates, but the dossier does not establish Kirkland's involvement in that study.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- Kirkland's connections to senolytics, dasatinib and quercetin suggest a possible narrative linking the therapeutic concept of senescent-cell removal to specific candidate interventions.\n- His connections to both senolytics and senomorphics could support an explanation of different approaches to targeting cellular senescence, if the latter term and his contributions were documented.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which specific discoveries, experiments or publications establish Kirkland's contribution to founding the senolytics field?\n- What were the sample size, controls and publication details of the nonhuman-primate study summarized in the glossary?\n- Whether the reported biomarker changes translate into clinical benefit or longer lifespan is not established.\n- The neighbours have no supplied identifiers or explicit slugs for valid retrieval requests, and fuller_evidence does not support the supplied hero_text source.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","name":"James L. Kirkland","type":"hero","route":"/heroes/james-l-kirkland","isPublic":true}},"connection":{"id":"c8c52db3-f3fc-4dfc-a17e-8f5cbc2ddc4c","kind":"person_holds_term","to_id":"senolytics","from_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:31:38.571859+00","evidence_excerpt":"Kirkland helped establish senolytics as a longevity research field; senolytic drugs eliminate senescent cells.","evidence_source_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["Kirkland's connections to senolytics, dasatinib and quercetin suggest a possible narrative linking the therapeutic concept of senescent-cell removal to specific candidate interventions.","His connections to both senolytics and senomorphics could support an explanation of different approaches to targeting cellular senescence, if the latter term and his contributions were documented."],"unresolved":["Which specific discoveries, experiments or publications establish Kirkland's contribution to founding the senolytics field?","What were the sample size, controls and publication details of the nonhuman-primate study summarized in the glossary?","Whether the reported biomarker changes translate into clinical benefit or longer lifespan is not established.","The neighbours have no supplied identifiers or explicit slugs for valid retrieval requests, and fuller_evidence does not support the supplied hero_text source."],"understanding":"James L. Kirkland is a physician-scientist whose research helped establish cellular senescence as a therapeutic target; the stored evidence credits him with helping establish senolytics as a longevity research field. Senolytics aim to selectively eliminate senescent cells, and his listed connections include dasatinib, quercetin and fisetin. The glossary describes a six-month dasatinib-plus-quercetin study in nonhuman primates, but the dossier does not establish Kirkland's involvement in that study.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-26 17:20:01.159622+00","updated_at":"2026-10-26 17:20:01.159622+00","public_url":"https://eternalsearch.net/journal/csMS9jaf","api_url":"https://eternalsearch.net/api/v1/content/journal/csMS9jaf"},{"public_id":"LUB31WSb","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-26","title":"EL-PERTURB Tests Virtual Cells on Unfamiliar Responses","summary":"EL-PERTURB finds that random data splits overestimate virtual-cell model performance when similar cellular responses appear in both training and test sets.","cta_url":"https://eternalsearch.net/organizations/FAnZddlr","source_refs":{"ukhvat_news":{"id":"78976668-67b7-4e66-8f9c-8e52ab6b255f","api_slug":"elucidata-el-perturb-perturbation-models-fail-out-of-distribution","keywords":["virtual-cells","gene-silencing","crispri","perturb-seq","model-evaluation","data-splitting"],"title_en":"EL-PERTURB preprint: random data splits overestimate the performance of models that predict cellular responses to gene silencing","short_slug":"261026007","api_title_ru":"Препринт EL-PERTURB: случайное разбиение данных завышает оценки моделей, предсказывающих реакцию клетки на выключение гена","published_at":"2026-10-26 11:00:00+00","category_slugs":["scientific-computing","science-research"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/FAnZddlr","name":"Experiment","type":"organization","route":"/organizations/FAnZddlr","match_score":14},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-26 11:17:40.72978+00","updated_at":"2026-10-26 11:17:40.72978+00","public_url":"https://eternalsearch.net/journal/LUB31WSb","api_url":"https://eternalsearch.net/api/v1/content/journal/LUB31WSb"},{"public_id":"DIbYONlq","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-25","title":"James L. Kirkland and dasatinib","summary":"A mouse kidney finding accompanies the link between Kirkland and dasatinib, but the underlying study, his involvement, and dasatinib's individual contribution remain unknown.","cta_url":"https://eternalsearch.net/heroes/james-l-kirkland","source_refs":{"dossier":"THE EDGE: James L. Kirkland (hero) —[person_holds_term, confidence 0.99]→ Dasatinib (term)\n\nStored evidence excerpt: Dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice.\n\nFROM ENDPOINT —\nPERSON (hero): James L. Kirkland\nBio: Physician-scientist and former director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic whose research helped establish cellular senescence as a therapeutic target for age-related disease.\nImpact score: 40.3\n\nTO ENDPOINT —\nTERM: Dasatinib (category: compound)\nDefinition: An anticancer Src-family/BCR-ABL tyrosine kinase inhibitor that has been repurposed in senolytic studies. In this source, dasatinib is named as a senolytic compound candidate for treating headache disorders and chronic pain, including in lists alongside navitoclax, venetoclax, and PROTAC BCL2-family degraders.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Fisetin (term)\n- person_holds_term: Senolytics (term)\n- person_holds_term: Quercetin (term)\n- person_holds_term: Integrated Stress Response (term)\n- person_holds_term: Senomorphics (term)\n- person_holds_term: NF-kB Signaling (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: NAD Metabolism (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- term_related_to_term: Senolytics (term)\n- article_references_term: Drug conjugates of sugar derivatives and uses thereof as senolytic ... (publication)\n- article_references_term: US20200316066A1 - Killing senescent cells and treating ... (publication)\n- article_references_term: Methods and combinations for killing senescent cells and for treating ... (publication)\n- article_references_term: Senolíticos - Wikipedia, la enciclopedia libre (publication)\n- article_references_term: محلل الشيخوخة - ويكيبيديا (publication)\n- article_references_term: Senolytika - Wikipedia (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier associates James L. Kirkland with dasatinib through an excerpt reporting that dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice. His biography and links to senolytics and quercetin provide relevant research context, but the excerpt does not establish his role in that experiment or isolate dasatinib’s contribution.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The connection may reflect Kirkland’s work on senolytic combinations as interventions for disease associated with cellular senescence.\n- The mouse findings may offer a concrete example of studying senolytics in diabetic kidney injury, provided the underlying study can be identified.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The underlying study’s title, authors, date, and Kirkland’s involvement are not supplied.\n- The mouse model, treatment doses, sample sizes, controls, effect sizes, and statistical results are unavailable.\n- The excerpt cannot establish whether dasatinib alone produced benefits or whether senescent-cell reduction caused the improvements in kidney outcomes.\n- No human kidney outcomes are provided.\n- The glossary definition’s headache and chronic-pain context does not explain the kidney findings.\n- The available evidence identifier is for hero_text, which fuller_evidence does not support; no endpoint IDs or term slugs are supplied for valid additional requests.","endpoints":{"to":{"id":"dasatinib","name":"Dasatinib","type":"term","route":"/glossary/dasatinib","isPublic":true},"from":{"id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","name":"James L. Kirkland","type":"hero","route":"/heroes/james-l-kirkland","isPublic":true}},"connection":{"id":"ce67c5ef-a43e-4c4a-b18d-753aa395a48a","kind":"person_holds_term","to_id":"dasatinib","from_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:31:38.571859+00","evidence_excerpt":"Dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice.","evidence_source_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The connection may reflect Kirkland’s work on senolytic combinations as interventions for disease associated with cellular senescence.","The mouse findings may offer a concrete example of studying senolytics in diabetic kidney injury, provided the underlying study can be identified."],"unresolved":["The underlying study’s title, authors, date, and Kirkland’s involvement are not supplied.","The mouse model, treatment doses, sample sizes, controls, effect sizes, and statistical results are unavailable.","The excerpt cannot establish whether dasatinib alone produced benefits or whether senescent-cell reduction caused the improvements in kidney outcomes.","No human kidney outcomes are provided.","The glossary definition’s headache and chronic-pain context does not explain the kidney findings.","The available evidence identifier is for hero_text, which fuller_evidence does not support; no endpoint IDs or term slugs are supplied for valid additional requests."],"understanding":"The dossier associates James L. Kirkland with dasatinib through an excerpt reporting that dasatinib plus quercetin reduced kidney inflammation, senescent-cell abundance, and injury in diabetic mice. His biography and links to senolytics and quercetin provide relevant research context, but the excerpt does not establish his role in that experiment or isolate dasatinib’s contribution.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-25 15:14:56.30742+00","updated_at":"2026-10-25 15:14:56.30742+00","public_url":"https://eternalsearch.net/journal/DIbYONlq","api_url":"https://eternalsearch.net/api/v1/content/journal/DIbYONlq"},{"public_id":"4EUcof8L","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-25","title":"Five compounds extended lifespan in old mice","summary":"Five of ten selected compounds extended lifespan in old mice, but a less successful second series leaves the reliability of selection by gene activity uncertain.","cta_url":"https://eternalsearch.net/investors/iQYbfAxg","source_refs":{"ukhvat_news":{"id":"13091658-cc13-442a-a7e7-cd3ca612d671","api_slug":"gladyshev-ardd2026-no-diseases-only-aging-biological-state-discovery","keywords":["biological-age","aging-clocks","lifespan-extension","drug-screening","gene-expression-signatures","old-mice"],"title_en":"Harvard professor Vadim Gladyshev proposes screening drugs for aging by their effects on biological age and the state of the organism; in his group’s preprint, five of ten selected compounds extended lifespan in old mice","short_slug":"261025006","api_title_ru":"Профессор Гарварда Вадим Гладышев предлагает искать лекарства от старения по их действию на биологический возраст и состояние организма; в препринте его группы пять из десяти отобранных веществ продлили жизнь старым мышам","published_at":"2026-10-25 10:00:00+00","category_slugs":["longevity-research","therapeutics","ai-and-medicine"]},"linked_entity":{"url":"https://eternalsearch.net/investors/iQYbfAxg","name":"Alexander Tyshkovskiy","type":"investor","route":"/investors/iQYbfAxg","match_score":15.1},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-25 11:17:31.205596+00","updated_at":"2026-10-25 11:17:31.205596+00","public_url":"https://eternalsearch.net/journal/4EUcof8L","api_url":"https://eternalsearch.net/api/v1/content/journal/4EUcof8L"},{"public_id":"gHvo6zqy","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-24","title":"Fisetin and Vascular Cell Senescence","summary":"Fisetin reduced senescent endothelial-cell abundance and improved glucose metabolism in obese mice, but the causal relationship and Kirkland's contribution to the study remain unknown.","cta_url":"https://eternalsearch.net/heroes/james-l-kirkland","source_refs":{"dossier":"THE EDGE: James L. Kirkland (hero) —[person_holds_term, confidence 0.99]→ Fisetin (term)\n\nStored evidence excerpt: Fisetin reduced senescent endothelial-cell abundance and improved glucose metabolism in obese mice.\n\nFROM ENDPOINT —\nPERSON (hero): James L. Kirkland\nBio: Physician-scientist and former director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic whose research helped establish cellular senescence as a therapeutic target for age-related disease.\nImpact score: 40.3\n\nTO ENDPOINT —\nTERM: Fisetin (category: compound)\nDefinition: Fisetin is a flavonoid senotherapeutic and senolytic natural product. In this source, fisetin is shown to reduce vascular cell senescence and SASP-related inflammation in old mice, improve endothelial function through senolysis, increase nitric-oxide bioavailability, reduce cellular- and mitochondrial-related oxidative stress, and lower arterial stiffness, supporting its clinical translation for age-related arterial dysfunction.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Senolytics (term)\n- person_holds_term: Dasatinib (term)\n- person_holds_term: Quercetin (term)\n- person_holds_term: Integrated Stress Response (term)\n- person_holds_term: Senomorphics (term)\n- person_holds_term: NF-kB Signaling (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: NAD Metabolism (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- project_investigates_term: First Approval (project)\n- term_related_to_term: Senolytics (term)\n- article_references_term: Prenetics' IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging (publication)\n- project_investigates_term: Rejuvenate Bio (project)\n- article_references_term: Longevity and DeSci Recap – February 2024 | Lifespan Research ... (publication)\n- project_investigates_term: OpenDrugs (project)\n- article_references_term: Fisetin is a senotherapeutic that extends health and lifespan (publication)\n- project_investigates_term: Lono Jaeyak (project)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe stored evidence links James L. Kirkland to a preclinical finding that fisetin reduced senescent endothelial-cell abundance and improved glucose metabolism in obese mice. The fisetin definition separately describes vascular benefits in old mice, giving the connection a concrete scientific theme: senescent vascular cells as a potential target in metabolic and age-related dysfunction. The dossier does not establish Kirkland's role in either study or whether these findings share a source.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- Reduced endothelial-cell senescence could contribute to the glucose-metabolism improvement reported in obese mice, but the excerpt does not establish causation.\n- The connection may reflect Kirkland's broader work on senolytics, consistent with his listed links to senolytics, dasatinib, and quercetin.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The underlying study's title, authors, date, and Kirkland's specific contribution are unavailable.\n- Mouse characteristics, fisetin dose, treatment duration, sample sizes, effect sizes, and statistical uncertainty are missing.\n- It is unclear whether reduced senescent-cell abundance resulted from selective cell clearance or another mechanism.\n- The obese-mouse evidence and the old-mouse findings in the term definition cannot be attributed to the same experiment.\n- No human efficacy or safety findings are supplied.\n- Further retrieval is unavailable under the menu constraints: neighbours have no visible IDs or slugs, and fuller_evidence does not support the supplied hero_text source.","endpoints":{"to":{"id":"fisetin","name":"Fisetin","type":"term","route":"/glossary/fisetin","isPublic":true},"from":{"id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","name":"James L. Kirkland","type":"hero","route":"/heroes/james-l-kirkland","isPublic":true}},"connection":{"id":"3ba27226-c935-4363-b287-264bdbe45748","kind":"person_holds_term","to_id":"fisetin","from_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:31:38.571859+00","evidence_excerpt":"Fisetin reduced senescent endothelial-cell abundance and improved glucose metabolism in obese mice.","evidence_source_id":"59539e63-b3ec-4b56-9c24-a6d121d6b024","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["Reduced endothelial-cell senescence could contribute to the glucose-metabolism improvement reported in obese mice, but the excerpt does not establish causation.","The connection may reflect Kirkland's broader work on senolytics, consistent with his listed links to senolytics, dasatinib, and quercetin."],"unresolved":["The underlying study's title, authors, date, and Kirkland's specific contribution are unavailable.","Mouse characteristics, fisetin dose, treatment duration, sample sizes, effect sizes, and statistical uncertainty are missing.","It is unclear whether reduced senescent-cell abundance resulted from selective cell clearance or another mechanism.","The obese-mouse evidence and the old-mouse findings in the term definition cannot be attributed to the same experiment.","No human efficacy or safety findings are supplied.","Further retrieval is unavailable under the menu constraints: neighbours have no visible IDs or slugs, and fuller_evidence does not support the supplied hero_text source."],"understanding":"The stored evidence links James L. Kirkland to a preclinical finding that fisetin reduced senescent endothelial-cell abundance and improved glucose metabolism in obese mice. The fisetin definition separately describes vascular benefits in old mice, giving the connection a concrete scientific theme: senescent vascular cells as a potential target in metabolic and age-related dysfunction. The dossier does not establish Kirkland's role in either study or whether these findings share a source.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-24 15:14:15.303035+00","updated_at":"2026-10-24 15:14:15.303035+00","public_url":"https://eternalsearch.net/journal/gHvo6zqy","api_url":"https://eternalsearch.net/api/v1/content/journal/gHvo6zqy"},{"public_id":"LmCjd3Iy","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-24","title":"Funding Biology Before a Product Exists","summary":"Morgan Levine asks what commercial funding model could give AI research in biology time to discover unforeseen applications while preserving incentives to put its findings into practice.","cta_url":"https://eternalsearch.net/heroes/morgan-levine","source_refs":{"ukhvat_news":{"id":"95200fa9-e68e-47b2-9fdd-425dd2bef414","api_slug":"morgan-levine-foundational-ai-biology-funding","keywords":["ai-for-biology","basic-research","self-supervised-learning","venture-capital","research-funding"],"title_en":"Morgan Levine asks what business model would let AI learn general patterns in biology before there is a product","short_slug":"261024007","api_title_ru":"Какая коммерческая модель позволит ИИ изучать общие закономерности биологии до появления продукта, спрашивает Морган Левин","published_at":"2026-10-24 11:00:00+00","category_slugs":["scientific-computing","biotech-funding","investors"]},"linked_entity":{"url":"https://eternalsearch.net/heroes/morgan-levine","name":"Morgan Levine","type":"hero","route":"/heroes/morgan-levine","match_score":14.3},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-24 11:16:17.950259+00","updated_at":"2026-10-24 11:16:17.950259+00","public_url":"https://eternalsearch.net/journal/LmCjd3Iy","api_url":"https://eternalsearch.net/api/v1/content/journal/LmCjd3Iy"},{"public_id":"gqkUsyIx","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-23","title":"Steven Austad and Caloric Restriction","summary":"Material about Steven Austad mentions an evaluation of caloric restriction, but the available excerpt identifies neither the study nor his role.","cta_url":"https://eternalsearch.net/heroes/steven-austad","source_refs":{"dossier":"THE EDGE: Steven Austad (hero) —[person_holds_term, confidence 0.99]→ Caloric Restriction (term)\n\nStored evidence excerpt: Calorie restriction was evaluated as an intervention known to extend health in both sexes.\n\nFROM ENDPOINT —\nPERSON (hero): Steven Austad\nBio: Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research at the University of Alabama at Birmingham, known for comparative studies of aging and the biological determinants of healthspan and lifespan.\nImpact score: 32.4\n\nTO ENDPOINT —\nTERM: Caloric Restriction (category: intervention_class)\nDefinition: Caloric Restriction is reduced calorie intake relative to ad libitum feeding while maintaining adequate nutrition. In an 18-week randomized trial of 58 middle-aged and older adults with obesity and prediabetes, caloric restriction produced mean weight loss of 10.8 kg and altered composite circulating SASP factors. In middle-aged nonhuman primates, a 10% caloric restriction intervention improved body composition and immune-cell profiles.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: 17-alpha-Estradiol (term)\n- person_holds_term: Microbiome Modulation (term)\n- person_holds_term: FOXO Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Gregory Fahy (hero)\n- person_holds_term: Daniel Belsky (hero)\n- person_holds_term: Luigi Ferrucci (hero)\n- article_references_term: Timeline of aging research - Wikipedia (publication)\n- article_references_term: Kalorienrestriktion - Wikipedia (publication)\n- article_references_term: Method for altering the lifespan of eukaryotic organisms (publication)\n- article_references_term: Kalorienrestriktion - Wikipedia (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier links aging researcher Steven Austad to caloric restriction through an excerpt saying it was evaluated as an intervention known to extend health in both sexes. Caloric restriction means reducing calorie intake while maintaining adequate nutrition, but the excerpt does not establish Austad’s role, the study population, or the results of that evaluation. The studies summarized in the term definition provide context but are not shown to involve Austad.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- Caloric restriction may have served as a reference intervention for comparing health effects across sexes, rather than being the study’s principal experimental treatment.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which study or document supplied the excerpt, and what role did Austad have in it?\n- What species, restriction regimen, health outcomes, and sex-specific results were evaluated?\n- Does the connection reflect Austad’s research participation, commentary, or a passing mention?\n- The evidence source is hero_text, which the fuller_evidence instrument does not support; no usable endpoint IDs or term slugs are supplied for other retrievals.","endpoints":{"to":{"id":"caloric_restriction","name":"Caloric Restriction","type":"term","route":"/glossary/caloric_restriction","isPublic":true},"from":{"id":"c2615ea2-92c0-433e-b15f-be7714fe851b","name":"Steven Austad","type":"hero","route":"/heroes/steven-austad","isPublic":true}},"connection":{"id":"b9f37616-d6a6-4103-a86f-04477d2ce107","kind":"person_holds_term","to_id":"caloric_restriction","from_id":"c2615ea2-92c0-433e-b15f-be7714fe851b","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:35:24.423382+00","evidence_excerpt":"Calorie restriction was evaluated as an intervention known to extend health in both sexes.","evidence_source_id":"c2615ea2-92c0-433e-b15f-be7714fe851b","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["Caloric restriction may have served as a reference intervention for comparing health effects across sexes, rather than being the study’s principal experimental treatment."],"unresolved":["Which study or document supplied the excerpt, and what role did Austad have in it?","What species, restriction regimen, health outcomes, and sex-specific results were evaluated?","Does the connection reflect Austad’s research participation, commentary, or a passing mention?","The evidence source is hero_text, which the fuller_evidence instrument does not support; no usable endpoint IDs or term slugs are supplied for other retrievals."],"understanding":"The dossier links aging researcher Steven Austad to caloric restriction through an excerpt saying it was evaluated as an intervention known to extend health in both sexes. Caloric restriction means reducing calorie intake while maintaining adequate nutrition, but the excerpt does not establish Austad’s role, the study population, or the results of that evaluation. The studies summarized in the term definition provide context but are not shown to involve Austad.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-23 17:15:11.078739+00","updated_at":"2026-10-23 17:15:11.078739+00","public_url":"https://eternalsearch.net/journal/gqkUsyIx","api_url":"https://eternalsearch.net/api/v1/content/journal/gqkUsyIx"},{"public_id":"WGcWVBEy","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-23","title":"AFAR’s Blue Zones partnership and the data dispute","summary":"AFAR’s institute with Blue Zones brings researchers involved in the longevity data dispute into a formal partnership, while their disclosures and the accuracy of the demographic records require separate scrutiny.","cta_url":"https://eternalsearch.net/organizations/BglWZEmc","source_refs":{"ukhvat_news":{"id":"f089f708-76f8-443f-97f4-60d6b78c64fe","api_slug":"reddit-iama-saul-newman-morbid-aging-science-grift","keywords":["saul-newman","anti-aging","nad-plus","calorie-restriction","epigenetic-clocks","blue-zones"],"title_en":"Any treatment that slows aging would show an effect in ordinary clinical trials, and no supplement has done so, says Morbid author Saul Newman","short_slug":"261023006","api_title_ru":"Любое средство, замедляющее старение, проявилось бы в обычных клинических испытаниях, а ни одна добавка этого не показала, говорит автор книги «Morbid» Сол Ньюман","published_at":"2026-10-23 10:00:00+00","category_slugs":["longevity-research","clinical-trials"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/BglWZEmc","name":"American Federation for Aging Research (AFAR)","type":"organization","route":"/organizations/BglWZEmc","match_score":17.5},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-23 11:16:53.874333+00","updated_at":"2026-10-23 11:16:53.874333+00","public_url":"https://eternalsearch.net/journal/WGcWVBEy","api_url":"https://eternalsearch.net/api/v1/content/journal/WGcWVBEy"},{"public_id":"mFRYb8Ij","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-22","title":"Rat responses to 17-alpha-estradiol varied by sex and genotype","summary":"Rat responses to 17-alpha-estradiol varied by sex and mitochondrial genotype, but the available material establishes neither lifespan extension nor Steven Austad's role in the study.","cta_url":"https://eternalsearch.net/heroes/steven-austad","source_refs":{"dossier":"THE EDGE: Steven Austad (hero) —[person_holds_term, confidence 0.99]→ 17-alpha-Estradiol (term)\n\nStored evidence excerpt: Female rats on a high-fat diet responded with declines in body mass, adiposity, and liver mass.\n\nFROM ENDPOINT —\nPERSON (hero): Steven Austad\nBio: Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research at the University of Alabama at Birmingham, known for comparative studies of aging and the biological determinants of healthspan and lifespan.\nImpact score: 32.4\n\nTO ENDPOINT —\nTERM: 17-alpha-Estradiol (category: compound)\nDefinition: 17-alpha-Estradiol is an estrogen stereoisomer studied as a longevity intervention. In a genetically heterogeneous rat model, its effects varied by sex and mitochondrial genotype: female rats fed a high-fat diet showed lower body mass, adiposity, and liver mass, while only one male mitochondrial genotype responded. These findings qualify the male-specific effects previously reported in mice.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Caloric Restriction (term)\n- person_holds_term: Microbiome Modulation (term)\n- person_holds_term: FOXO Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- article_references_term: WO2018075641A1 - Methods and compositions for extending lifespan (publication)\n- project_investigates_term: OpenDrugs (project)\n- article_references_term: Methods and compositions for extending lifespan - Google Patents (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier associates Steven Austad with 17-alpha-Estradiol, a compound studied as a longevity intervention, but does not establish his specific role in the cited research. The substantive finding concerns sex- and mitochondrial-genotype-dependent responses in rats: females on a high-fat diet showed reduced body mass, adiposity, and liver mass, while a response was reported for only one male mitochondrial genotype. These outcomes do not establish lifespan extension.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The rat findings may suggest that the previously reported male-specific effects in mice depend on species, diet, or genetic background rather than representing a universal sex difference.\n- Mitochondrial genotype may help explain variation in response to 17-alpha-Estradiol, although the dossier does not establish a mechanism.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Whether Austad authored, supervised, discussed, or merely cited the underlying research.\n- The underlying study's title, authors, publication date, and full text.\n- The treatment dose, duration, sample sizes, control groups, effect sizes, and statistical uncertainty.\n- Which mitochondrial genotypes were tested and which outcomes changed in the responding male genotype.\n- Whether reduced body and tissue mass was accompanied by improved health, adverse effects, or changes in lifespan.\n- No endpoint IDs or term slugs are supplied for further retrieval, and the hero_text evidence source is outside the supported source kinds for fuller_evidence.","endpoints":{"to":{"id":"17_alpha_estradiol","name":"17-alpha-Estradiol","type":"term","route":"/glossary/17_alpha_estradiol","isPublic":true},"from":{"id":"c2615ea2-92c0-433e-b15f-be7714fe851b","name":"Steven Austad","type":"hero","route":"/heroes/steven-austad","isPublic":true}},"connection":{"id":"557c811e-bb3f-4857-8c71-e99bc9613044","kind":"person_holds_term","to_id":"17_alpha_estradiol","from_id":"c2615ea2-92c0-433e-b15f-be7714fe851b","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:35:24.423382+00","evidence_excerpt":"Female rats on a high-fat diet responded with declines in body mass, adiposity, and liver mass.","evidence_source_id":"c2615ea2-92c0-433e-b15f-be7714fe851b","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The rat findings may suggest that the previously reported male-specific effects in mice depend on species, diet, or genetic background rather than representing a universal sex difference.","Mitochondrial genotype may help explain variation in response to 17-alpha-Estradiol, although the dossier does not establish a mechanism."],"unresolved":["Whether Austad authored, supervised, discussed, or merely cited the underlying research.","The underlying study's title, authors, publication date, and full text.","The treatment dose, duration, sample sizes, control groups, effect sizes, and statistical uncertainty.","Which mitochondrial genotypes were tested and which outcomes changed in the responding male genotype.","Whether reduced body and tissue mass was accompanied by improved health, adverse effects, or changes in lifespan.","No endpoint IDs or term slugs are supplied for further retrieval, and the hero_text evidence source is outside the supported source kinds for fuller_evidence."],"understanding":"The dossier associates Steven Austad with 17-alpha-Estradiol, a compound studied as a longevity intervention, but does not establish his specific role in the cited research. The substantive finding concerns sex- and mitochondrial-genotype-dependent responses in rats: females on a high-fat diet showed reduced body mass, adiposity, and liver mass, while a response was reported for only one male mitochondrial genotype. These outcomes do not establish lifespan extension.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-22 15:14:47.768739+00","updated_at":"2026-10-22 15:14:47.768739+00","public_url":"https://eternalsearch.net/journal/mFRYb8Ij","api_url":"https://eternalsearch.net/api/v1/content/journal/mFRYb8Ij"},{"public_id":"oK1xqKaI","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-22","title":"Sottas's aging-signal theory and xLongevity's service","summary":"Sottas proposes that senescent-cell signals amplify mortality risk, while his company's related service still needs evidence of efficacy beyond a model and a cited 14-person infusion program.","cta_url":"https://eternalsearch.net/investors/ZhwqH5OE","source_refs":{"ukhvat_news":{"id":"ee5d144b-e8f7-483c-8bd2-78dfc4c2cb5b","api_slug":"sottas-aging-load-gain-systemic-amplification-late-life-rejuvenation","keywords":["cellular-senescence","senolytics","gompertz-law","regenerative-capacity","partial-reprogramming","mortality-risk"],"title_en":"Self-amplifying signals from senescent cells drive the accelerating rise in mortality risk in old age, proposes the author of a theoretical paper in Aging","short_slug":"261022005","api_title_ru":"Риск смерти в старости растёт всё быстрее из-за самоусиливающихся сигналов стареющих клеток, считает автор теории в журнале Aging","published_at":"2026-10-22 10:00:00+00","category_slugs":["longevity-research","therapeutics"]},"linked_entity":{"url":"https://eternalsearch.net/investors/ZhwqH5OE","name":"Pierre-Edouard Sottas","type":"investor","route":"/investors/ZhwqH5OE","match_score":15.1},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-22 11:17:26.551137+00","updated_at":"2026-10-22 11:17:26.551137+00","public_url":"https://eternalsearch.net/journal/oK1xqKaI","api_url":"https://eternalsearch.net/api/v1/content/journal/oK1xqKaI"},{"public_id":"CZ6Xp4fK","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-21","title":"Paul Robbins and Senomorphic Effects","summary":"Reported reductions in senescence markers and inflammatory secretions are consistent with senomorphic activity, but the excerpt does not establish what happened to the treated cells.","cta_url":"https://eternalsearch.net/heroes/paul-d-robbins","source_refs":{"dossier":"THE EDGE: Paul D. Robbins (hero) —[person_holds_term, confidence 0.99]→ Senomorphics (term)\n\nStored evidence excerpt: XJB-5-131 and stem-cell-derived EVs reduced senescence markers and inflammatory SASP factors.\n\nFROM ENDPOINT —\nPERSON (hero): Paul D. Robbins\nBio: Professor at the University of Minnesota and associate director of its aging institute whose laboratory develops senotherapeutics and other approaches targeting hallmarks of aging.\nImpact score: 35.6\n\nTO ENDPOINT —\nTERM: Senomorphics (category: intervention_class)\nDefinition: Senomorphics are interventions that suppress harmful senescent-cell phenotypes without necessarily eliminating senescent cells, including inflammatory and secretory programs. In this source, fucoidan from Fucus vesiculosus reduced senescence across several senescent-cell types and tissues in aged mice, while increasing SIRT6 activity and DNA-repair-associated gene expression.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Gene Therapy (term)\n- person_holds_term: Senolytics (term)\n- person_holds_term: Quercetin (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: Navitoclax (term)\n- person_holds_term: Dasatinib (term)\n- person_holds_term: Wnt Signaling (term)\n- person_holds_term: Cell Therapy (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Andrei Seluanov (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: Alex Zhavoronkov (hero)\n- article_references_term: Life extension - Wikipedia (publication)\n- project_investigates_term: Omega-Point (project)\n- project_investigates_term: Frontier Bio (project)\n- term_related_to_term: Senescence-Associated Secretory Phenotype (term)\n- term_related_to_term: Senolytics (term)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier connects Paul D. Robbins’s senotherapeutics research to senomorphics through an excerpt reporting that XJB-5-131 and stem-cell-derived extracellular vesicles reduced senescence markers and inflammatory SASP factors. This is consistent with suppressing harmful senescent-cell phenotypes, but the excerpt does not establish whether senescent cells survived treatment. The fucoidan example in the term definition does not independently substantiate Robbins’s work on either intervention.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The writer could explore whether these interventions modify senescent-cell behavior, particularly inflammatory secretion, rather than eliminate the cells.\n- Robbins’s links to both senomorphics and senolytics suggest a possible research interest in complementary approaches to targeting cellular senescence.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Which studies support the excerpt, and what was Robbins’s role in them?\n- What experimental models, doses, controls, and measured outcomes were used for each intervention?\n- Did reduced markers and SASP factors reflect altered cell behavior, fewer senescent cells, or another mechanism?\n- Were functional benefits, safety, or effects in humans demonstrated?\n- The cited hero_text source cannot be retrieved with fuller_evidence, which accepts only project_publication or external_article; no usable endpoint IDs or term slugs are supplied for other requests.","endpoints":{"to":{"id":"senomorphics","name":"Senomorphics","type":"term","route":"/glossary/senomorphics","isPublic":true},"from":{"id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","name":"Paul D. Robbins","type":"hero","route":"/heroes/paul-d-robbins","isPublic":true}},"connection":{"id":"38df10bb-ff9d-4493-a10c-de832c3335c6","kind":"person_holds_term","to_id":"senomorphics","from_id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:50:45.05354+00","evidence_excerpt":"XJB-5-131 and stem-cell-derived EVs reduced senescence markers and inflammatory SASP factors.","evidence_source_id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The writer could explore whether these interventions modify senescent-cell behavior, particularly inflammatory secretion, rather than eliminate the cells.","Robbins’s links to both senomorphics and senolytics suggest a possible research interest in complementary approaches to targeting cellular senescence."],"unresolved":["Which studies support the excerpt, and what was Robbins’s role in them?","What experimental models, doses, controls, and measured outcomes were used for each intervention?","Did reduced markers and SASP factors reflect altered cell behavior, fewer senescent cells, or another mechanism?","Were functional benefits, safety, or effects in humans demonstrated?","The cited hero_text source cannot be retrieved with fuller_evidence, which accepts only project_publication or external_article; no usable endpoint IDs or term slugs are supplied for other requests."],"understanding":"The dossier connects Paul D. Robbins’s senotherapeutics research to senomorphics through an excerpt reporting that XJB-5-131 and stem-cell-derived extracellular vesicles reduced senescence markers and inflammatory SASP factors. This is consistent with suppressing harmful senescent-cell phenotypes, but the excerpt does not establish whether senescent cells survived treatment. The fucoidan example in the term definition does not independently substantiate Robbins’s work on either intervention.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-21 15:14:37.360613+00","updated_at":"2026-10-21 15:14:37.360613+00","public_url":"https://eternalsearch.net/journal/CZ6Xp4fK","api_url":"https://eternalsearch.net/api/v1/content/journal/CZ6Xp4fK"},{"public_id":"xJLhdNLw","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-21","title":"What PhenoAge measures in cancer patients","summary":"In a preprint involving 3,067 surgical cancer patients, PhenoAge acceleration predicted survival no better than a simple blood-test sum and increased with tumor stage in three of four cancer groups.","cta_url":"https://eternalsearch.net/heroes/morgan-levine","source_refs":{"ukhvat_news":{"id":"2d36804f-498c-4a1c-9cfd-12e446dafb06","api_slug":"phenoage-cancer-tumor-burden-not-biological-aging","keywords":["phenoage","biological-age","cancer-survival","aging-biomarkers","tumor-stage","blood-biomarkers"],"title_en":"Preprint: in 3067 patients who underwent cancer surgery, blood-based PhenoAge “biological age” predicted survival as well as a simple sum of the same blood measurements, and its excess over chronological age increased with tumor stage in three of four cancer types","short_slug":"261021006","api_title_ru":"Препринт: у 3067 оперированных больных раком «биологический возраст» PhenoAge по анализам крови предсказывал выживание не лучше простой суммы этих же анализов, а его превышение над паспортным возрастом при трёх видах рака из четырёх росло со стадией опухоли","published_at":"2026-10-21 10:00:00+00","category_slugs":["longevity-research"]},"linked_entity":{"url":"https://eternalsearch.net/heroes/morgan-levine","name":"Morgan Levine","type":"hero","route":"/heroes/morgan-levine","match_score":14.3},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-21 11:16:07.489226+00","updated_at":"2026-10-21 11:16:07.489226+00","public_url":"https://eternalsearch.net/journal/xJLhdNLw","api_url":"https://eternalsearch.net/api/v1/content/journal/xJLhdNLw"},{"public_id":"bPDWzc8k","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-20","title":"Paul D. Robbins and Senolytics","summary":"Robbins's reported coauthorship of navitoclax and fisetin studies connects him to senolytics research, but the available dossier lacks the details needed to assess his specific contribution or potential benefits for humans.","cta_url":"https://eternalsearch.net/heroes/paul-d-robbins","source_refs":{"dossier":"THE EDGE: Paul D. Robbins (hero) —[person_holds_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: Robbins coauthored studies on navitoclax and fisetin; miR-106b-5p selectively eliminated senescent cells.\n\nFROM ENDPOINT —\nPERSON (hero): Paul D. Robbins\nBio: Professor at the University of Minnesota and associate director of its aging institute whose laboratory develops senotherapeutics and other approaches targeting hallmarks of aging.\nImpact score: 35.6\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Gene Therapy (term)\n- person_holds_term: Senomorphics (term)\n- person_holds_term: Quercetin (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: Navitoclax (term)\n- person_holds_term: Dasatinib (term)\n- person_holds_term: Wnt Signaling (term)\n- person_holds_term: Cell Therapy (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Vera Gorbunova (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n- article_references_term: WO2018215795A2 - Senolytic compounds - Google Patents (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier connects Paul D. Robbins to senolytics through reported coauthorship of studies on navitoclax and fisetin, alongside an excerpt stating that miR-106b-5p selectively eliminated senescent cells. His laboratory’s stated focus on senotherapeutics supports the broader connection, but the dossier does not establish his specific contribution to each finding. The nonhuman-primate trial described in the glossary provides context for senolytics, with no demonstrated connection to Robbins.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- Robbins’s work may illustrate exploration of multiple approaches to eliminating senescent cells, spanning small molecules and a microRNA-based approach.\n- His connections to both senolytics and senomorphics may reflect a broader research interest in eliminating senescent cells versus modifying their behavior.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The titles, dates, source publications, experimental models, and outcomes of the navitoclax and fisetin studies are absent.\n- The excerpt does not establish Robbins’s role in the miR-106b-5p finding, its experimental setting, or how selective elimination was measured.\n- No evidence establishes clinical benefit in humans from the Robbins-associated work described here.\n- Further retrieval cannot be validly requested: neighbours have no supplied IDs or explicit slugs, and the identified evidence source is hero_text, which the fuller_evidence instrument does not support.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","name":"Paul D. Robbins","type":"hero","route":"/heroes/paul-d-robbins","isPublic":true}},"connection":{"id":"ce75cdf2-df60-41f7-adf7-8f074cce6b90","kind":"person_holds_term","to_id":"senolytics","from_id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:50:45.05354+00","evidence_excerpt":"Robbins coauthored studies on navitoclax and fisetin; miR-106b-5p selectively eliminated senescent cells.","evidence_source_id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["Robbins’s work may illustrate exploration of multiple approaches to eliminating senescent cells, spanning small molecules and a microRNA-based approach.","His connections to both senolytics and senomorphics may reflect a broader research interest in eliminating senescent cells versus modifying their behavior."],"unresolved":["The titles, dates, source publications, experimental models, and outcomes of the navitoclax and fisetin studies are absent.","The excerpt does not establish Robbins’s role in the miR-106b-5p finding, its experimental setting, or how selective elimination was measured.","No evidence establishes clinical benefit in humans from the Robbins-associated work described here.","Further retrieval cannot be validly requested: neighbours have no supplied IDs or explicit slugs, and the identified evidence source is hero_text, which the fuller_evidence instrument does not support."],"understanding":"The dossier connects Paul D. Robbins to senolytics through reported coauthorship of studies on navitoclax and fisetin, alongside an excerpt stating that miR-106b-5p selectively eliminated senescent cells. His laboratory’s stated focus on senotherapeutics supports the broader connection, but the dossier does not establish his specific contribution to each finding. The nonhuman-primate trial described in the glossary provides context for senolytics, with no demonstrated connection to Robbins.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-20 16:14:20.265027+00","updated_at":"2026-10-20 16:14:20.265027+00","public_url":"https://eternalsearch.net/journal/bPDWzc8k","api_url":"https://eternalsearch.net/api/v1/content/journal/bPDWzc8k"},{"public_id":"5GxlqHyb","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-20","title":"Khosla uses Cellino’s $4,995 immune-cell bank","summary":"Cellino investor Vinod Khosla is an early customer of its immune-cell storage service, whose long-term therapeutic value remains unproven.","cta_url":"https://eternalsearch.net/organizations/jcOxTBks","source_refs":{"ukhvat_news":{"id":"63718dfa-734b-437a-8fcf-9c39d41ff54a","api_slug":"reservoir-cellino-immune-cell-banking","keywords":["immune-cell-banking","cryopreservation","cell-therapy","t-cells","cellino"],"title_en":"Cellino launches Reservoir: for $4995, adults can have blood collected at home and their immune cells frozen and stored in their name for the first year","short_slug":"261020001","api_title_ru":"Компания Cellino запустила сервис Reservoir: за $4995 у взрослого берут кровь на дому, замораживают его иммунные клетки и первый год хранят на его имя","published_at":"2026-10-20 00:00:00+00","category_slugs":["longevity-research","therapeutics"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/jcOxTBks","name":"Khosla Ventures","type":"organization","route":"/organizations/jcOxTBks","match_score":14.5},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-20 12:31:04.840702+00","updated_at":"2026-10-20 12:31:04.840702+00","public_url":"https://eternalsearch.net/journal/5GxlqHyb","api_url":"https://eternalsearch.net/api/v1/content/journal/5GxlqHyb"},{"public_id":"0mAMeE9A","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-19","title":"IL-1Ra Expression One Year After Joint Delivery","summary":"A phase 1 excerpt reports elevated IL-1Ra expression in joint fluid after one year, while patient benefit and Paul Robbins’s involvement remain unestablished.","cta_url":"https://eternalsearch.net/heroes/paul-d-robbins","source_refs":{"dossier":"THE EDGE: Paul D. Robbins (hero) —[person_holds_term, confidence 0.99]→ Gene Therapy (term)\n\nStored evidence excerpt: AAV-mediated intra-articular IL-1Ra expression remained elevated in synovial fluid after 1 year in a phase 1 trial.\n\nFROM ENDPOINT —\nPERSON (hero): Paul D. Robbins\nBio: Professor at the University of Minnesota and associate director of its aging institute whose laboratory develops senotherapeutics and other approaches targeting hallmarks of aging.\nImpact score: 35.6\n\nTO ENDPOINT —\nTERM: Gene Therapy (category: intervention_class)\nDefinition: Gene Therapy comprises medical interventions that produce a therapeutic effect by introducing, replacing, silencing, editing, or transiently delivering genetic material, or by genetically altering living cells. In this source, telomerase gene therapy prevented age-associated profibrotic lung pathology in wild-type and telomerase-deficient mice, supporting a preclinical strategy for disease associated with short telomeres.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Senomorphics (term)\n- person_holds_term: Senolytics (term)\n- person_holds_term: Quercetin (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: Navitoclax (term)\n- person_holds_term: Dasatinib (term)\n- person_holds_term: Wnt Signaling (term)\n- person_holds_term: Cell Therapy (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: George Church (hero)\n- article_references_term: Clinical Research Trial Listing ( Primary Mitochondrial Diseases ... (publication)\n- article_references_term: Biotechnology - Wikipedia (publication)\n- article_references_term: Secreted splicing variant of klotho for extending lifespan (publication)\n- article_references_term: Gene therapy - Wikipedia (publication)\n- article_references_term: General 4 - Rejuvenate Bio (publication)\n- article_references_term: Noah Davidsohn - BioFuture (publication)\n- article_references_term: Most biotech startups spend years chasing VCs. Rejuvenate Bio just ... (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier links Paul D. Robbins to gene therapy through an excerpt reporting that AAV-mediated delivery into a joint sustained IL-1Ra expression in synovial fluid for one year in a phase 1 trial. This is a concrete observation about sustained expression, but the dossier does not establish clinical benefit or Robbins’s role in the trial. The telomerase mouse study in the term definition is separate evidence and cannot explain this particular connection.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The writer could explore sustained local production of a therapeutic molecule as the interesting feature of this gene-therapy approach, provided the trial and its results can be identified.\n- The connection may reflect a broader research portfolio alongside Robbins’s senotherapeutics work, but it does not establish that this trial targeted aging.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The trial’s identity, indication, participant count, dose, safety findings, and clinical outcomes are unavailable.\n- Robbins’s involvement is unspecified: the excerpt does not establish whether he conducted, coauthored, advised on, or merely discussed the trial.\n- The excerpt does not identify the comparison underlying 'remained elevated' or establish therapeutic activity from the measured expression.\n- No compatible retrieval is available: the evidence uses hero_text, whereas fuller_evidence accepts project_publication or external_article; endpoint IDs and term slugs are not supplied.","endpoints":{"to":{"id":"gene_therapy","name":"Gene Therapy","type":"term","route":"/glossary/gene_therapy","isPublic":true},"from":{"id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","name":"Paul D. Robbins","type":"hero","route":"/heroes/paul-d-robbins","isPublic":true}},"connection":{"id":"3e32130c-e122-43c7-ab85-2fd3d8033434","kind":"person_holds_term","to_id":"gene_therapy","from_id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:50:45.05354+00","evidence_excerpt":"AAV-mediated intra-articular IL-1Ra expression remained elevated in synovial fluid after 1 year in a phase 1 trial.","evidence_source_id":"4456647d-512b-417a-b3e3-9c6a0fdf0274","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The writer could explore sustained local production of a therapeutic molecule as the interesting feature of this gene-therapy approach, provided the trial and its results can be identified.","The connection may reflect a broader research portfolio alongside Robbins’s senotherapeutics work, but it does not establish that this trial targeted aging."],"unresolved":["The trial’s identity, indication, participant count, dose, safety findings, and clinical outcomes are unavailable.","Robbins’s involvement is unspecified: the excerpt does not establish whether he conducted, coauthored, advised on, or merely discussed the trial.","The excerpt does not identify the comparison underlying 'remained elevated' or establish therapeutic activity from the measured expression.","No compatible retrieval is available: the evidence uses hero_text, whereas fuller_evidence accepts project_publication or external_article; endpoint IDs and term slugs are not supplied."],"understanding":"The dossier links Paul D. Robbins to gene therapy through an excerpt reporting that AAV-mediated delivery into a joint sustained IL-1Ra expression in synovial fluid for one year in a phase 1 trial. This is a concrete observation about sustained expression, but the dossier does not establish clinical benefit or Robbins’s role in the trial. The telomerase mouse study in the term definition is separate evidence and cannot explain this particular connection.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-19 15:18:56.033314+00","updated_at":"2026-10-19 15:18:56.033314+00","public_url":"https://eternalsearch.net/journal/0mAMeE9A","api_url":"https://eternalsearch.net/api/v1/content/journal/0mAMeE9A"},{"public_id":"A2WpU7L3","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-19","title":"A mathematics audit flags serious errors in 39 papers","summary":"A GPT-6.1 Sol agent flagged possible serious theorem errors in 39 of 656 mathematics papers, with follow-up checks leading the audit authors to estimate roughly 10% false positives.","cta_url":"https://eternalsearch.net/investors/cwSmDIBo","source_refs":{"ukhvat_news":{"id":"bba0df0b-15b3-4fa6-962b-95f2d88e1564","api_slug":"matharena-gpt61-sol-arxiv-math-errors-audit","keywords":["gpt-6-1-sol","mathematics","theorem-verification","counterexamples","arxiv","matharena"],"title_en":"A GPT-6.1 Sol agent flagged 39 of 656 mathematics papers on arXiv as containing a serious error in the main theorem","short_slug":"261019001","api_title_ru":"Агент GPT-6.1 Sol пометил 39 из 656 математических работ в онлайн-архиве arXiv как содержащие серьёзную ошибку в главной теореме","published_at":"2026-10-19 00:00:00+00","category_slugs":["scientific-computing","science-research"]},"linked_entity":{"url":"https://eternalsearch.net/investors/cwSmDIBo","name":"August Lin","type":"investor","route":"/investors/cwSmDIBo","match_score":5},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-19 11:14:57.677334+00","updated_at":"2026-10-19 11:14:57.677334+00","public_url":"https://eternalsearch.net/journal/A2WpU7L3","api_url":"https://eternalsearch.net/api/v1/content/journal/A2WpU7L3"},{"public_id":"LwLVm0E6","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-18","title":"A 2.5-Year Reduction in Estimated Biological Age","summary":"Exploratory analyses reported a median 2.5-year reduction in estimated biological age after three fasting-mimicking diet cycles, but the available material does not identify the estimation method or establish lasting health benefits.","cta_url":"https://eternalsearch.net/heroes/morgan-levine","source_refs":{"dossier":"THE EDGE: Morgan Levine (hero) —[person_holds_term, confidence 0.99]→ Fasting-Mimicking Diet (term)\n\nStored evidence excerpt: “Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk.”\n\nFROM ENDPOINT —\nPERSON (hero): Morgan Levine\nBio: Vice President of Computation at Altos Labs and former Yale professor whose research develops computational and epigenetic methods to quantify biological aging and cellular-state change.\nImpact score: 35.2\n\nTO ENDPOINT —\nTERM: Fasting-Mimicking Diet (category: intervention_class)\nDefinition: A fasting-mimicking diet is a limited-nutrient dietary intervention designed to reproduce fasting-associated metabolic signals while providing food. In this source, 5-day monthly cycles improved glycaemic management in a 12-month type 2 diabetes trial, and three cycles were associated with lower hepatic fat, reduced insulin resistance, a higher lymphoid-to-myeloid ratio, and a 2.5-year median reduction in biological age in exploratory clinical analyses. FMD also showed antitumor activity in preclinical models, including enhanced effects with chemotherapy, though clinical cancer efficacy still requires larger trials.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Caloric Restriction (term)\n- person_holds_term: Network Theory of Aging (term)\n- person_holds_term: Epigenetic Rejuvenation (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Valter Longo (hero)\n- article_references_term: Longevity Show announces first partners for 2026 (publication)\n- project_investigates_term: DTL (project)\n- project_investigates_term: Frontier Bio (project)\n- article_references_term: Longevity biotechnology: bridging AI, biomarkers, geroscience and ... (publication)\n- term_related_to_term: Insulin/IGF-1 Signaling (term)\n- term_related_to_term: Caloric Restriction (term)\n- article_references_term: Methods for inducing intermittent fasting and modulating autophagy (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier links Morgan Levine, whose research measures biological aging, to fasting-mimicking diets through an excerpt reporting changes in hepatic and blood markers. The term definition describes exploratory clinical analyses with a median 2.5-year reduction in estimated biological age, but the available evidence does not establish Levine’s specific role or demonstrate longer lifespan.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- Levine’s connection may concern the measurement or interpretation of biological-age changes following dietary intervention; her specific contribution remains unverified.\n- A useful angle could examine what changes in biological-age estimates reveal about an intervention, and what remains unknown about lasting health benefits.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Whether Levine authored the referenced research, developed a measure used in it, or merely discussed its findings.\n- Which study produced the quoted finding, including its population, sample size, controls, biological-age estimator, and follow-up duration.\n- Whether the reported biological-age changes persisted or predicted subsequent clinical outcomes.\n- The source is identified as hero_text, which fuller_evidence does not support; no eligible endpoint IDs or term slugs are supplied for further retrieval.","endpoints":{"to":{"id":"fasting_mimicking_diet","name":"Fasting-Mimicking Diet","type":"term","route":"/glossary/fasting_mimicking_diet","isPublic":true},"from":{"id":"5293bfe7-e09c-40f5-a3c8-41426dc2833a","name":"Morgan Levine","type":"hero","route":"/heroes/morgan-levine","isPublic":true}},"connection":{"id":"80722706-01d3-4f48-b6e4-50920a9f35de","kind":"person_holds_term","to_id":"fasting_mimicking_diet","from_id":"5293bfe7-e09c-40f5-a3c8-41426dc2833a","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 17:52:44.003225+00","evidence_excerpt":"“Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk.”","evidence_source_id":"5293bfe7-e09c-40f5-a3c8-41426dc2833a","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["Levine’s connection may concern the measurement or interpretation of biological-age changes following dietary intervention; her specific contribution remains unverified.","A useful angle could examine what changes in biological-age estimates reveal about an intervention, and what remains unknown about lasting health benefits."],"unresolved":["Whether Levine authored the referenced research, developed a measure used in it, or merely discussed its findings.","Which study produced the quoted finding, including its population, sample size, controls, biological-age estimator, and follow-up duration.","Whether the reported biological-age changes persisted or predicted subsequent clinical outcomes.","The source is identified as hero_text, which fuller_evidence does not support; no eligible endpoint IDs or term slugs are supplied for further retrieval."],"understanding":"The dossier links Morgan Levine, whose research measures biological aging, to fasting-mimicking diets through an excerpt reporting changes in hepatic and blood markers. The term definition describes exploratory clinical analyses with a median 2.5-year reduction in estimated biological age, but the available evidence does not establish Levine’s specific role or demonstrate longer lifespan.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-18 15:14:10.237596+00","updated_at":"2026-10-18 15:14:10.237596+00","public_url":"https://eternalsearch.net/journal/LwLVm0E6","api_url":"https://eternalsearch.net/api/v1/content/journal/LwLVm0E6"},{"public_id":"jivLUwuA","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-18","title":"Stimulating about 20 neurons sometimes triggered a learned movement in mice","summary":"Stimulating about 20 motor cortex neurons sometimes triggered a learned lever press in mice, with movement similarity depending on the selected cells and cortical activity before stimulation.","cta_url":"https://eternalsearch.net/organizations/FAnZddlr","source_refs":{"ukhvat_news":{"id":"f900b5d0-2c96-4b22-9aa0-15929c2bfd17","api_slug":"nature-motor-cortex-ensemble-holographic-stimulation-learned-movement","keywords":["motor-cortex","optogenetics","neural-activity","learned-movement","mice"],"title_en":"Light stimulation of about 20 motor cortex cells triggered a learned movement in mice","short_slug":"261018002","api_title_ru":"Свет на около 20 клеток двигательной коры запускал у мыши выученное движение","published_at":"2026-10-18 10:00:00+00","category_slugs":["neurotechnology","science-research"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/FAnZddlr","name":"Experiment","type":"organization","route":"/organizations/FAnZddlr","match_score":9},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-18 11:17:31.891494+00","updated_at":"2026-10-18 11:17:31.891494+00","public_url":"https://eternalsearch.net/journal/jivLUwuA","api_url":"https://eternalsearch.net/api/v1/content/journal/jivLUwuA"},{"public_id":"rYzrDdmC","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-17","title":"Caloric Restriction and Measuring Aging","summary":"Daniel Belsky studies biological aging measures, but the supplied material leaves his role in CALERIE, the measures assessed, and the trial results unspecified.","cta_url":"https://eternalsearch.net/heroes/daniel-belsky","source_refs":{"dossier":"THE EDGE: Daniel Belsky (hero) —[person_holds_term, confidence 0.99]→ Caloric Restriction (term)\n\nStored evidence excerpt: CALERIE Phase 2 tested 25% calorie restriction for 2 years.\n\nFROM ENDPOINT —\nPERSON (hero): Daniel Belsky\nBio: Associate Professor of Epidemiology at Columbia University whose research develops and validates measures of biological aging and studies how genes, environments, and interventions shape aging trajectories.\nImpact score: 30.3\n\nTO ENDPOINT —\nTERM: Caloric Restriction (category: intervention_class)\nDefinition: Caloric Restriction is reduced calorie intake relative to ad libitum feeding while maintaining adequate nutrition. In an 18-week randomized trial of 58 middle-aged and older adults with obesity and prediabetes, caloric restriction produced mean weight loss of 10.8 kg and altered composite circulating SASP factors. In middle-aged nonhuman primates, a 10% caloric restriction intervention improved body composition and immune-cell profiles.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Insulin/IGF-1 Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Gregory Fahy (hero)\n- person_holds_term: Steven Austad (hero)\n- person_holds_term: Luigi Ferrucci (hero)\n- article_references_term: Timeline of aging research - Wikipedia (publication)\n- article_references_term: Kalorienrestriktion - Wikipedia (publication)\n- article_references_term: Method for altering the lifespan of eukaryotic organisms (publication)\n- article_references_term: Kalorienrestriktion - Wikipedia (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nDaniel Belsky studies measures of biological aging and how interventions affect aging trajectories. The connection to caloric restriction is supported by an excerpt stating that CALERIE Phase 2 tested 25% calorie restriction for two years, but the supplied evidence does not establish Belsky’s role, trial results, or participants’ achieved calorie reduction.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The connection may concern using biological aging measures to evaluate caloric restriction, given Belsky’s stated research focus; the dossier does not confirm this.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- What role did Belsky have in CALERIE or its subsequent analyses?\n- Which aging measures were assessed, and what results and limitations were reported?\n- Was 25% the prescribed reduction or the reduction participants actually achieved?\n- The evidence source is hero_text, which fuller_evidence does not support. No endpoint IDs or term slugs are supplied for other valid retrieval requests.","endpoints":{"to":{"id":"caloric_restriction","name":"Caloric Restriction","type":"term","route":"/glossary/caloric_restriction","isPublic":true},"from":{"id":"3c2997e5-3f87-4471-8431-90dc3c466f63","name":"Daniel Belsky","type":"hero","route":"/heroes/daniel-belsky","isPublic":true}},"connection":{"id":"ad6cd95a-0945-4101-921a-40e2676e5975","kind":"person_holds_term","to_id":"caloric_restriction","from_id":"3c2997e5-3f87-4471-8431-90dc3c466f63","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 18:10:26.835976+00","evidence_excerpt":"CALERIE Phase 2 tested 25% calorie restriction for 2 years.","evidence_source_id":"3c2997e5-3f87-4471-8431-90dc3c466f63","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The connection may concern using biological aging measures to evaluate caloric restriction, given Belsky’s stated research focus; the dossier does not confirm this."],"unresolved":["What role did Belsky have in CALERIE or its subsequent analyses?","Which aging measures were assessed, and what results and limitations were reported?","Was 25% the prescribed reduction or the reduction participants actually achieved?","The evidence source is hero_text, which fuller_evidence does not support. No endpoint IDs or term slugs are supplied for other valid retrieval requests."],"understanding":"Daniel Belsky studies measures of biological aging and how interventions affect aging trajectories. The connection to caloric restriction is supported by an excerpt stating that CALERIE Phase 2 tested 25% calorie restriction for two years, but the supplied evidence does not establish Belsky’s role, trial results, or participants’ achieved calorie reduction.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-17 15:14:01.522108+00","updated_at":"2026-10-17 15:14:01.522108+00","public_url":"https://eternalsearch.net/journal/rYzrDdmC","api_url":"https://eternalsearch.net/api/v1/content/journal/rYzrDdmC"},{"public_id":"OCmTbxLr","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-17","title":"Sustaining longevity policy through research setbacks","summary":"Stolyarov proposes a lasting volunteer-supported political organization to pursue experimental treatment access and longevity research funding, but the source reports no enacted reform or allocated budget.","cta_url":"https://eternalsearch.net/organizations/FAnZddlr","source_refs":{"ukhvat_news":{"id":"51618be8-ac52-4ba4-9382-a4985dae87b2","api_slug":"stolyarov-uspt-transhumanist-politics-translational-longevity-summit","keywords":["radical-life-extension","right-to-try","drug-approval","aging-policy","research-funding"],"title_en":"The U.S. Transhumanist Party proposes sustaining a political agenda for radical life extension through company failures and unsuccessful trials","short_slug":"261017002","api_title_ru":"Партия трансгуманистов США предлагает сохранить политическую программу радикального продления жизни после неудач компаний и испытаний","published_at":"2026-10-17 12:00:00+00","category_slugs":["industry-policy","ecosystem","clinical-trials"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/FAnZddlr","name":"Experiment","type":"organization","route":"/organizations/FAnZddlr","match_score":9},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-17 12:16:10.183545+00","updated_at":"2026-10-17 12:16:10.183545+00","public_url":"https://eternalsearch.net/journal/OCmTbxLr","api_url":"https://eternalsearch.net/api/v1/content/journal/OCmTbxLr"},{"public_id":"UcKoH9TC","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-16","title":"Vera Gorbunova and Senolytics","summary":"Eternal Search links Vera Gorbunova to the topic of senolytics, but the available excerpt does not establish her scientific contribution to this intervention class.","cta_url":"https://eternalsearch.net/heroes/vera-gorbunova","source_refs":{"dossier":"THE EDGE: Vera Gorbunova (hero) —[person_holds_term, confidence 0.99]→ Senolytics (term)\n\nStored evidence excerpt: “senolytics which specifically induce lysis of SnCs”\n\nFROM ENDPOINT —\nPERSON (hero): Vera Gorbunova\nBio: Professor at the University of Rochester whose comparative biology research studies exceptionally long-lived mammals to uncover mechanisms of genome stability, cancer resistance, and longevity.\nImpact score: 39.7\n\nTO ENDPOINT —\nTERM: Senolytics (category: intervention_class)\nDefinition: Senolytics are interventions intended to selectively eliminate senescent cells while sparing non-senescent cells. In a middle-aged nonhuman-primate trial, monthly dasatinib plus quercetin for 6 months reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9, with anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. The study reported safety over that exposure period and called for larger controlled trials in older patients.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Senomorphics (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: Cell Therapy (term)\n- person_holds_term: Wnt Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Jamie Justice (hero)\n- person_holds_term: Marco Demaria (hero)\n- person_holds_term: Peter de Keizer (hero)\n- person_holds_term: Manuel Serrano (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: James L. Kirkland (hero)\n- person_holds_term: João Pedro de Magalhães (hero)\n- article_references_term: WO2018215795A2 - Senolytic compounds - Google Patents (publication)\n\nANALYST READING (orientation — the post still asserts only facts above):\nVera Gorbunova studies genome stability, cancer resistance, and longevity through comparative biology of long-lived mammals. Senolytics aim to selectively eliminate senescent cells, but the stored excerpt merely describes their action; it does not establish Gorbunova’s contribution to, use of, or endorsement of these interventions. The primate-trial findings in the term definition are not explicitly connected to her.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- The source may discuss senolytics as background within a broader account of aging interventions rather than describe Gorbunova’s own research.\n- The neighbouring Senomorphics link may reflect a discussion comparing approaches to targeting cellular senescence.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- Whether Gorbunova authored the underlying text, was quoted in it, or was merely associated with it.\n- Whether she conducted a specific senolytic study or made an identifiable contribution to this intervention class.\n- The context of the excerpt cannot be retrieved with the supplied menu: its source is hero_text, whereas fuller_evidence supports only project_publication and external_article.\n- No endpoint IDs or term slugs are supplied for valid additional retrieval requests.","endpoints":{"to":{"id":"senolytics","name":"Senolytics","type":"term","route":"/glossary/senolytics","isPublic":true},"from":{"id":"76b22dea-8d76-4ad9-8634-cac4e891741c","name":"Vera Gorbunova","type":"hero","route":"/heroes/vera-gorbunova","isPublic":true}},"connection":{"id":"f0768171-7c2b-4c00-940a-e6cc600899c3","kind":"person_holds_term","to_id":"senolytics","from_id":"76b22dea-8d76-4ad9-8634-cac4e891741c","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 18:11:22.095924+00","evidence_excerpt":"“senolytics which specifically induce lysis of SnCs”","evidence_source_id":"76b22dea-8d76-4ad9-8634-cac4e891741c","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["The source may discuss senolytics as background within a broader account of aging interventions rather than describe Gorbunova’s own research.","The neighbouring Senomorphics link may reflect a discussion comparing approaches to targeting cellular senescence."],"unresolved":["Whether Gorbunova authored the underlying text, was quoted in it, or was merely associated with it.","Whether she conducted a specific senolytic study or made an identifiable contribution to this intervention class.","The context of the excerpt cannot be retrieved with the supplied menu: its source is hero_text, whereas fuller_evidence supports only project_publication and external_article.","No endpoint IDs or term slugs are supplied for valid additional retrieval requests."],"understanding":"Vera Gorbunova studies genome stability, cancer resistance, and longevity through comparative biology of long-lived mammals. Senolytics aim to selectively eliminate senescent cells, but the stored excerpt merely describes their action; it does not establish Gorbunova’s contribution to, use of, or endorsement of these interventions. The primate-trial findings in the term definition are not explicitly connected to her.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-16 15:15:42.832468+00","updated_at":"2026-10-16 15:15:42.832468+00","public_url":"https://eternalsearch.net/journal/UcKoH9TC","api_url":"https://eternalsearch.net/api/v1/content/journal/UcKoH9TC"},{"public_id":"eZU8bqEu","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-16","title":"Engineered T cells recruit a second wave in culture","summary":"An engineered signal-receptor pair directed T cells to signal-producing tumors in mice and supported self-amplifying recruitment in cell culture, with therapeutic benefit still unestablished.","cta_url":"https://eternalsearch.net/organizations/vcvirbR7","source_refs":{"ukhvat_news":{"id":"fce2c79f-637f-480f-8db0-bda08968027f","api_slug":"biorxiv-lim-orthogonal-chemokine-receptor-pairs-t-cell-swarming","keywords":["engineered-t-cells","chemokine-receptors","cell-therapy","tumor-targeting","synthetic-biology","synnotch"],"title_en":"An engineered signaling protein and receptor pair with little cross-talk with natural signals directed T-cells to tumors producing the protein in mice and helped them form a “swarm” in cell culture","short_slug":"261016003","api_title_ru":"Искусственная пара «сигнальный белок — рецептор», почти не пересекающаяся с природными сигналами, привела Т-клетки у мышей в опухоль с этим белком, а в клеточной культуре помогла им собраться в «рой»","published_at":"2026-10-16 06:00:00+00","category_slugs":["therapeutics","science-research"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/vcvirbR7","name":"University of California, San Francisco","type":"organization","route":"/organizations/vcvirbR7","match_score":16.9},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-16 11:16:56.151551+00","updated_at":"2026-10-16 11:16:56.151551+00","public_url":"https://eternalsearch.net/journal/eZU8bqEu","api_url":"https://eternalsearch.net/api/v1/content/journal/eZU8bqEu"},{"public_id":"U3ubZKsk","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-14","title":"The Unconfirmed Autophagy Peak After 48 to 72 Hours","summary":"A review covering 20 human studies finds no established timing for autophagy activation during fasting, leaving Mindy Pelz's claimed peak after 48 to 72 hours unconfirmed.","cta_url":"https://eternalsearch.net/investors/8ZzwPnPm","source_refs":{"ukhvat_news":{"id":"cd4dafb5-39a6-4088-b4a5-25b2d5b20bbd","api_slug":"autophagy-fasting-diet-human-evidence-review-biochem-soc-trans","keywords":["autophagy","fasting","autophagic-flux","lc3b-ii","fgf21"],"title_en":"The timing of autophagy activation in humans during fasting remains unknown, and the widely cited “24–72 hours” likely comes from mouse experiments, review authors write","short_slug":"261014003","api_title_ru":"Через сколько часов голода у человека включается аутофагия (разборка клеткой изношенных частей), не установлено, а расхожее «24–72 часа», вероятно, восходит к опытам на мышах — пишут авторы обзора","published_at":"2026-10-14 12:00:00+00","category_slugs":["longevity-research"]},"linked_entity":{"url":"https://eternalsearch.net/investors/8ZzwPnPm","name":"Mindy Pelz","type":"investor","route":"/investors/8ZzwPnPm","match_score":14},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-14 13:16:25.43961+00","updated_at":"2026-10-14 13:16:25.43961+00","public_url":"https://eternalsearch.net/journal/U3ubZKsk","api_url":"https://eternalsearch.net/api/v1/content/journal/U3ubZKsk"},{"public_id":"KSgIZ3hW","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-12","title":"The cellular energy cost of chronic stress","summary":"Chronic cortisol exposure raised energy use by 60% in cultured skin cells and accelerated their aging, while observations of hair regaining pigment leave the cause and extent of recovery unresolved.","cta_url":"https://eternalsearch.net/organizations/Smh573UV","source_refs":{"ukhvat_news":{"id":"b960e67e-caec-4cb0-b827-7e3b82910959","api_slug":"picard-allostatic-load-mitochondrial-energy-aging","keywords":["cortisol","cellular-aging","mitochondria","allostatic-load","hair-graying","stress-recovery"],"title_en":"Chronic exposure to cortisol (the stress hormone) increases cellular energy expenditure by 60% in the laboratory and accelerates cellular aging, but hair that turns gray under stress regains its color when stress subsides, suggesting that part of this process is reversible","short_slug":"261012005","api_title_ru":"Хронический кортизол (гормон стресса) повышает расход энергии клетки на 60% в лаборатории и ускоряет её старение, но поседевшие от стресса волосы снова темнеют, когда стресс проходит — часть этого процесса обратима","published_at":"2026-10-12 12:00:00+00","category_slugs":["longevity-research"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/Smh573UV","name":"Columbia University","type":"organization","route":"/organizations/Smh573UV","match_score":14.9},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-12 14:31:40.094549+00","updated_at":"2026-10-12 14:31:40.094549+00","public_url":"https://eternalsearch.net/journal/KSgIZ3hW","api_url":"https://eternalsearch.net/api/v1/content/journal/KSgIZ3hW"},{"public_id":"bj5nZvmJ","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-11","title":"What an AI cancer drug trial would establish","summary":"Prasad points to medicine's use of drugs with partly understood mechanisms, while Tao asks whether an AI-designed treatment could pass a trial by exploiting a flaw in its testing procedure.","cta_url":"https://eternalsearch.net/organizations/vcvirbR7","source_refs":{"ukhvat_news":{"id":"ceeb16c1-3631-462a-a983-2b36006a2692","api_slug":"tao-math2-ai-cancer-cure-interpretability-debate","keywords":["ai-drug-discovery","cancer-drugs","phase-iii","mechanism-of-action","trial-design","ai-safety"],"title_en":"Terence Tao posed a thought experiment about whether people would accept an AI-designed cancer drug that had passed clinical trials even though no one understood how it worked. The debate divided social media, and an oncologist reminded him that medicine has used drugs with poorly understood mechanisms for years","short_slug":"261011005","api_title_ru":"Терренс Тао показал мысленный эксперимент: ИИ нашёл лекарство от рака, прошедшее испытания без понятного механизма — приняли бы вы его? Спор об этом разделил соцсети, и онколог напомнил математику, что медицина и так годами лечит непонятными препаратами","published_at":"2026-10-11 09:00:00+00","category_slugs":["ai-and-medicine","clinical-trials","therapeutics"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/vcvirbR7","name":"University of California, San Francisco","type":"organization","route":"/organizations/vcvirbR7","match_score":16.9},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-11 11:17:49.406387+00","updated_at":"2026-10-11 11:17:49.406387+00","public_url":"https://eternalsearch.net/journal/bj5nZvmJ","api_url":"https://eternalsearch.net/api/v1/content/journal/bj5nZvmJ"},{"public_id":"7PcJgBUI","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-10","title":"GSK tests Chai-designed protein binders","summary":"GSK found protein binders for every target tested among candidates proposed by Chai Discovery models, then expanded the work into a collaboration.","cta_url":"https://eternalsearch.net/organizations/EV17x2oE","source_refs":{"ukhvat_news":{"id":"73974540-c6f0-426f-92ca-eca05b946cfa","api_slug":"chai-gsk-ai-biologics-collaboration","keywords":["protein-design","protein-binders","chai-discovery","gsk","wet-lab-validation"],"title_en":"GSK tested protein candidates generated by Chai Discovery models and is gaining access to the models for drug discovery","short_slug":"261010002","api_title_ru":"GSK проверила белковые варианты, созданные моделями Chai Discovery, и получает доступ к ним для поиска лекарств","published_at":"2026-10-10 07:00:00+00","category_slugs":["ai-and-medicine","therapeutics"]},"linked_entity":{"url":"https://eternalsearch.net/organizations/EV17x2oE","name":"Chai Discovery","type":"organization","route":"/organizations/EV17x2oE","match_score":14.4},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-10 11:22:13.248392+00","updated_at":"2026-10-10 11:22:13.248392+00","public_url":"https://eternalsearch.net/journal/7PcJgBUI","api_url":"https://eternalsearch.net/api/v1/content/journal/7PcJgBUI"},{"public_id":"YoNuBaKC","type_slug":"connection","type_name":"Connection","dispatch_date":"2026-10-09","title":"Vera Gorbunova and Senomorphics","summary":"Eternal Search links Vera Gorbunova to senomorphics, which suppress harmful features of cellular senescence, but the supporting excerpt does not establish her research role.","cta_url":"https://eternalsearch.net/heroes/vera-gorbunova","source_refs":{"dossier":"THE EDGE: Vera Gorbunova (hero) —[person_holds_term, confidence 0.99]→ Senomorphics (term)\n\nStored evidence excerpt: “senomorphics, which suppress the senescence phenotype”\n\nFROM ENDPOINT —\nPERSON (hero): Vera Gorbunova\nBio: Professor at the University of Rochester whose comparative biology research studies exceptionally long-lived mammals to uncover mechanisms of genome stability, cancer resistance, and longevity.\nImpact score: 39.7\n\nTO ENDPOINT —\nTERM: Senomorphics (category: intervention_class)\nDefinition: Senomorphics are interventions that suppress harmful senescent-cell phenotypes without necessarily eliminating senescent cells, including inflammatory and secretory programs. In this source, fucoidan from Fucus vesiculosus reduced senescence across several senescent-cell types and tissues in aged mice, while increasing SIRT6 activity and DNA-repair-associated gene expression.\n\nNEIGHBOURS of this hero (other public links it participates in):\n- person_holds_term: Senolytics (term)\n- person_holds_term: Sirtuin Signaling (term)\n- person_holds_term: Cell Therapy (term)\n- person_holds_term: Wnt Signaling (term)\n\nNEIGHBOURS of this term (other public links it participates in):\n- person_holds_term: Andrei Seluanov (hero)\n- person_holds_term: Paul D. Robbins (hero)\n- person_holds_term: Alex Zhavoronkov (hero)\n- article_references_term: Life extension - Wikipedia (publication)\n- project_investigates_term: Omega-Point (project)\n- project_investigates_term: Frontier Bio (project)\n- term_related_to_term: Senescence-Associated Secretory Phenotype (term)\n- term_related_to_term: Senolytics (term)\n\nANALYST READING (orientation — the post still asserts only facts above):\nThe dossier links Vera Gorbunova to senomorphics through an excerpt defining them as interventions that suppress the senescence phenotype. The term definition describes fucoidan-associated reductions in senescence in aged mice alongside increased SIRT6 activity and DNA-repair-associated gene expression, but the excerpt does not establish Gorbunova's role in that research. The concrete scientific angle is suppressing harmful senescent-cell behavior without necessarily eliminating the cells.\n\nHYPOTHESES (clearly speculative — label as such if used):\n- A writer could explore whether Gorbunova's research on genome stability connects to the SIRT6 and DNA-repair findings described in the term definition; the dossier does not establish that connection.\n- The linked concepts of senomorphics, senolytics, and the senescence-associated secretory phenotype could support an explanation of how suppressing harmful cell behavior differs from eliminating senescent cells.\n\nNOT ESTABLISHED FROM AVAILABLE DATA (the post may say these are unknown — never fill the gap):\n- The underlying study, its authors, and Gorbunova's specific involvement are not identified.\n- The experimental doses, effect sizes, safety findings, and any human evidence are unavailable.\n- The dossier does not establish whether increased SIRT6 activity caused the reported reductions in senescence.\n- Further retrieval is unavailable with valid menu arguments: neighbour IDs and term slugs are absent, and the evidence source is hero_text, which fuller_evidence does not support.","endpoints":{"to":{"id":"senomorphics","name":"Senomorphics","type":"term","route":"/glossary/senomorphics","isPublic":true},"from":{"id":"76b22dea-8d76-4ad9-8634-cac4e891741c","name":"Vera Gorbunova","type":"hero","route":"/heroes/vera-gorbunova","isPublic":true}},"connection":{"id":"cf1215ef-1f51-4361-9fcc-b74115494473","kind":"person_holds_term","to_id":"senomorphics","from_id":"76b22dea-8d76-4ad9-8634-cac4e891741c","to_type":"term","from_type":"hero","confidence":0.99,"created_at":"2026-09-03 18:11:22.095924+00","evidence_excerpt":"“senomorphics, which suppress the senescence phenotype”","evidence_source_id":"76b22dea-8d76-4ad9-8634-cac4e891741c","evidence_source_kind":"hero_text"},"analyst_verdict":{"hollow":false,"rounds":1,"degraded":false,"hypotheses":["A writer could explore whether Gorbunova's research on genome stability connects to the SIRT6 and DNA-repair findings described in the term definition; the dossier does not establish that connection.","The linked concepts of senomorphics, senolytics, and the senescence-associated secretory phenotype could support an explanation of how suppressing harmful cell behavior differs from eliminating senescent cells."],"unresolved":["The underlying study, its authors, and Gorbunova's specific involvement are not identified.","The experimental doses, effect sizes, safety findings, and any human evidence are unavailable.","The dossier does not establish whether increased SIRT6 activity caused the reported reductions in senescence.","Further retrieval is unavailable with valid menu arguments: neighbour IDs and term slugs are absent, and the evidence source is hero_text, which fuller_evidence does not support."],"understanding":"The dossier links Vera Gorbunova to senomorphics through an excerpt defining them as interventions that suppress the senescence phenotype. The term definition describes fucoidan-associated reductions in senescence in aged mice alongside increased SIRT6 activity and DNA-repair-associated gene expression, but the excerpt does not establish Gorbunova's role in that research. The concrete scientific angle is suppressing harmful senescent-cell behavior without necessarily eliminating the cells.","instrument_calls":[]},"telegram_warnings":[],"published_languages":["ru","en"]},"published_at":"2026-10-09 15:14:09.007562+00","updated_at":"2026-10-09 15:14:09.007562+00","public_url":"https://eternalsearch.net/journal/YoNuBaKC","api_url":"https://eternalsearch.net/api/v1/content/journal/YoNuBaKC"},{"public_id":"YbIm0dLx","type_slug":"news_ukhvat","type_name":"Ukhvat News Take","dispatch_date":"2026-10-09","title":"MUVON cell therapy benefit persisted at one year in 12 women","summary":"All 12 six-month responders among 13 women assessed maintained improvement at one year in MUVON's phase two trial, but follow-up remains incomplete and the reported comparison between doses cannot establish how much improvement the treatment caused.","cta_url":"https://eternalsearch.net/glossary/cell_therapy","source_refs":{"ukhvat_news":{"id":"6874e13e-98a5-47a9-916a-c4a1dea1c0b8","api_slug":"muvon-muscle-precursor-cell-therapy-sui-12-month-durability","keywords":["stress-urinary-incontinence","cell-therapy","muscle-progenitor-cells","urethral-sphincter","phase-2","muvon"],"title_en":"Cell therapy for incontinence maintained its effect at one year in 12 of 13 women in a phase two trial","short_slug":"261009001","api_title_ru":"Во второй фазе клинических испытаний клеточная терапия недержания сохранила эффект у 12 из 13 женщин через год","published_at":"2026-10-09 00:00:00+00","category_slugs":["clinical-trials","therapeutics"]},"linked_entity":{"url":"https://eternalsearch.net/glossary/cell_therapy","name":"Cell Therapy","type":"term","route":"/glossary/cell_therapy","match_score":14.2},"telegram_warnings":[],"published_languages":["ru","en"],"skipped_without_public_entity":0},"published_at":"2026-10-09 11:17:46.927064+00","updated_at":"2026-10-09 11:17:46.927064+00","public_url":"https://eternalsearch.net/journal/YbIm0dLx","api_url":"https://eternalsearch.net/api/v1/content/journal/YbIm0dLx"}],"pagination":{"limit":50,"offset":0,"total":228,"has_more":true},"access_level":"public","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"Eternal Search (eternalsearch.net), powered by Open Longevity","scope":"Applies to data produced by Eternal Search (scores, rationale, extracted structures, summaries, graph). Third-party texts keep their own rights; see text_policy on each record."},"generated_at":"2026-11-15T09:22:49.938Z","family":"journal","index_url":"https://eternalsearch.net/journal"}